

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/004432

International filing date: 14 February 2005 (14.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/545,446  
Filing date: 18 February 2004 (18.02.2004)

Date of receipt at the International Bureau: 17 March 2005 (17.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1294320

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*March 09, 2005*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/545,446**

**FILING DATE: February 18, 2004**

**RELATED PCT APPLICATION NUMBER: PCT/US05/04432**



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

# PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a **PROVISIONAL APPLICATION FOR PATENT** under 37 CFR 1.53 (c).

021804  
17264 U.S. PTO

22154 U.S. PTO  
60/545446  
021804

DOCKET NUMBER						21314PV	
INVENTOR(S)							
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)			
VICTOR N. THOMAS M.		UEBELE CONNOLLY		RAHWAY, NEW JERSEY 07065 RAHWAY, NEW JERSEY 07065			
<input type="checkbox"/> Additional inventors are being named on the separately numbered sheets attached hereto							
TITLE OF THE INVENTION (500 characters max)							
NUCLEIC ACID MOLECULES ENCODING NOVEL MURINE LOW-VOLTAGE ACTIVATED CALCIUM CHANNEL PROTEINS, DESIGNATED - $\alpha$ 1H, ENCODED PROTEINS AND METHODS OF USE THEREOF							
CORRESPONDENCE ADDRESS							
Direct all Correspondence to: Merck & Co., Inc. Patent Department - RY60-30 P.O. Box 2000 Rahway							
STATE		New Jersey		ZIP CODE		07065	
COUNTRY		U.S.A.					
ENCLOSED APPLICATION PARTS (check all that apply)							
<input checked="" type="checkbox"/> Specification		Number of Pages		51		<input type="checkbox"/> CD(s), Number	
<input checked="" type="checkbox"/> Drawing(s)		Number of Sheets		1		<input checked="" type="checkbox"/> Other (specify)	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		Sequence Listing - Sequence Nos. 1-6					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)							
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees						FILING FEE AMOUNT (\$)	
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 13-2755						\$160.00	

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.

☐ Yes, the name of the U.S. Government agency and the Government contract number are: \_\_\_\_\_

Respectfully submitted,

SIGNATURE

*Vincent Kohli*

Date 02/18/2004

TYPED or PRINTED NAME Vincent Kohli

REGISTRATION NO. 37,003

TELEPHONE 732-594-3889

(if appropriate)

NOTE: Mail to Mail Stop Provisional Application

EXPRESS MAIL CERTIFICATE	
DATE OF DEPOSIT	February 18, 2004
EXPRESS MAIL NO.	EV321985965US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.	
MAILED BY	DATE
<i>Lou Schepisi</i>	2/18/04

In Duplicate

## TITLE OF THE INVENTION

NUCLEIC ACID MOLECULES ENCODING NOVEL MURINE LOW-VOLTAGE ACTIVATED CALCIUM CHANNEL PROTEINS, DESIGNATED -  $\alpha_{1H}$ , ENCODED PROTEINS AND METHODS OF USE THEREOF.

## BACKGROUND OF THE INVENTION

The present invention relates to novel nucleic acid molecules, encoded proteins, vectors, host cells transformed therewith, antibodies reactive with said proteins, as well as pharmaceutical compositions. Methods of using any of the foregoing, e.g., methods for screening for candidate agonists or antagonists utilizing the novel protein isoforms are also contemplated by the present invention.

Calcium is an essential signaling molecule for many normal physiological functions in the human body. These include all electrical signaling in the nervous system, as well as controlling heart and smooth muscle contraction, and hormone release. The entry of calcium into cells is regulated by a diverse set of proteins called calcium channels.

Calcium channels were discovered in 1958 by Fatt and Ginsborg when they explored the ionic basis of a  $\text{Na}^+$  -independent action potential in crab muscle. The most unique and crucial role of  $\text{Ca}^{2+}$  channels is to translate the electrical signal on the surface membrane into a chemical signal within the cytoplasm, which, in general, increases the intracellular second messenger  $\text{Ca}^{2+}$ , which, in turn, activates many crucial intracellular processes including contraction, secretion, neurotransmission and regulation of enzymatic activities and gene expression. Tsien et al., (1988), Trends Neurosci., vol. 11, pp. 431-438. As might be expected from their central role in signal transduction,  $\text{Ca}^{2+}$  channels are tightly regulated by a range of signal transduction pathways in addition to regulation by their intrinsic, voltage-dependent gating processes.

Continuing studies have revealed that there are multiple types of  $\text{Ca}^{2+}$  currents as defined by physiological and pharmacological criteria. See, e.g., Catterall, W.A., (2000) Annu. Rev. Cell Dev. Biol., 16:521-55; Llinas et al, (1992) Trends Neurosci, 15:351-55; Hess, P. (1990) Ann. Rev. Neurosci. 56:337; Bean, B. P. (1989) Ann. Rev. Physiol. 51:367-384; and Tsien et al. (1988) Trends Neurosci. 11:431-38. In addition to exhibiting distinct kinetic properties, different  $\text{Ca}^{2+}$  channel types can be localized on different regions of a cell with complex morphology. Finally,  $\text{Ca}^{2+}$  channels in different tissues display different pharmacological profiles, suggesting the possibility of drugs selective for particular organs.

The calcium in nerve cells plays an important role in delivering signals between nerve cells. Calcium has many different delivery paths, however, when delivering peripheral

stimuli, the voltage-activated calcium channel is crucial. Voltage activated channels play important roles including neuroexcitation, neurotransmitter and hormone secretion, and regulation of gene transcription through Ca-dependent transcription factors. Their functions depend in part on their cellular localization and their gating properties (characteristics of their opening, inactivation, deactivation, and recovery from inactivation). Five general classes of voltage activated calcium channels have been observed in various neuronal and non-neuronal tissues. The complement of calcium subunits and the subcellular localization of the expressed voltage activated calcium channels determine the functional cellular properties.

Native calcium channels have been classified by their electrophysiological and pharmacological properties as T, L, N, P and Q types (for views see McCleskey, E. W. et al. *Curr Topics Membr* (1991) 39:295-326, and Dunlap, K. et al. *Trends Neurosci* (1995) 18:89-98). Voltage-gated calcium channels can be divided into Low Voltage Activated calcium channel (LVA) that is activated at a lower voltage and High Voltage Activated (HVA) calcium channel that is activated at a higher voltage than the resting membrane potential. HVA channels are currently known to comprise at least three groups of channels, known as L-, N- and P/Q-type channels. These channels have been distinguished from one another electrophysiologically as well as biochemically on the basis of their pharmacology and ligand binding properties. The L, N, P and Q-type channels activate at more positive potentials (high voltage activated) and display diverse kinetics and voltage-dependent properties. A fourth type of high voltage-activated calcium channel (Q-type) has been described, although whether the Q- and P-type channels are distinct molecular entities is controversial (Sather, W. A et al. *Neuron* (1995) 11:291-303; Stea, A. et al. *Proc Natl Acad Sci USA* (1994) 91:10576-10580; Bourinet, E. et al. *Nature Neuroscience* (1999) 2:407-415).

To date, only one type of low-threshold calcium channel is known, the T-type calcium channel. These channels are so called because they carry a transient current with a low voltage of activation and rapid inactivation. (Ertel and Ertel (1997) *Trends Pharmacol. Sci.* 18:37-42.) In general, T-type calcium channels are involved in the generation of low threshold spikes to produce burst firing (Huguenard, 1996). The main factor which defines the different calcium currents is which  $\alpha_1$  subtype is included in the channel complex. The subfamily of  $\alpha_{1G}$ ,  $\alpha_{1H}$  and  $\alpha_{1I}$  subunits display the low-voltage activation characteristic of T-type channels.

One low -T type and five high VGCC types (L, N, P, Q, R) have been studied through pharmacological and electrophysiological studies. Three genes have been identified for the  $\alpha_1$  subunits of LVA channels, reviewed in Hofmann et al., (1999), *Rev. Physiol. Biochem. Pharmacol.* 139:33-87; Lacinova et al., (2000) *Gen. Physiol. Biophys.*, 19: 121-36).

Although only the pore-forming subunits of three members of T-type calcium channels have been cloned until now (Perez-Reyes, 1998; Perez-Reyes *et al.*, 1998; Lee *et al.*, 1999; Lacinova *et al.*, 2000; Lory *et al.*, 2000; McRory *et al.*, 2001), the L-type subfamily has been characterized extensively by biochemical approaches. These studies have revealed that the L-type calcium channel complex is a heteropentamer consisting of  $\alpha_1$ ,  $\beta$ ,  $\alpha/\delta$  and  $\gamma$  subunits. The predicted structure of the  $\alpha_1$  subunit consists of four repeating motifs (MI–MIV), each motif comprising six hydrophobic segments (S1–S6). A highly conserved segment connecting the S5 and S6 transmembrane domains in each motif, termed the P loop or ‘SS1-SS2’ region, is responsible for calcium selectivity in the pore region (Figure 1B) (Catterall, 1988; Varadi *et al.*, 1999).

For calcium channels to be effective,  $\text{Ca}^{2+}$  ions must enter selectively through the pore of the  $\alpha_1$  subunit, bypassing competition with other extracellular ions (Catterall, 1988; Imoto, 1993; Varadi *et al.*, 1995, 1999; Randall and Benham, 1999). The molecular “pores” that flood the surface of voltage gated calcium channels “open” in response to the depolarization of the membrane voltage, which allows for the selective influx of  $\text{Ca}^{2+}$  ions from an extracellular environment into the interior of a cell. The “opening” of the pores essentially requires a depolarization to a certain level of the potential difference between the inside of the cell bearing the channel and the extracellular medium bathing the cell. The rate of influx of  $\text{Ca}^{2+}$  into the cell depends on this potential difference. When the accumulating  $\text{Ca}^{2+}$  reaches a sufficient concentration, it can activate ion channels such as  $\text{Ca}^{2+}$ -activated  $\text{K}^+$  channels that allow positive charge out the cell and thereby repolarize the membrane. It can be seen how calcium channels serve as elements that can sense, amplify, and terminate electrical signals.

T-type channels are located in cardiac & vascular smooth muscle; and in the nervous system. Perez-Reyes *et al.* discuss the molecular characterization of a neuronal low-voltage-activated T-type calcium channel (*Nature* 391, 896-900, 1998). Generally, T-type channels are thought to be involved in pacemaker activity, low-threshold calcium spikes, neuronal oscillations and resonance, and rebound burst firing. See F.R. Buhler, J. Hypertension supplement 15(5):s3-7, 1997; B. Cremers *et al.*, J. Cardiovascular Pharmacology, vol. 29(5), pp. 692-6, 1997. The functional roles for T-type calcium channels in neurons include, *inter alia*, membrane depolarization, calcium entry and burst firing. (White *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:6802-6806.) The LVA channels differ from HVA channels in a number of ways, i.e., length of I-II intracellular linker etc and the  $\beta$  subunit does not appear to be associated with  $\alpha_1$  in the LVA class. As well, they lack the canonical sequence that is known to be crucial for beta subunit binding. See Lambert *et al.*, J. Neurosci., 17; 6621-6628, 1997; Leuranguer *et al.*, Neuropharmacology, 37: 701-708, 1998.

Functionally unique Ca channels allow for temporal and spatial control of intracellular calcium ( $[Ca]_i$ ) and support regulation of cellular activity. T-type calcium channels have more negative activation ranges and inactivate more rapidly than other calcium channels. When the range of membrane potentials for activation and inactivation overlap, these channels can undergo rapid cycling between open, inactivated, and closed states, giving rise to continuous calcium influx in a range of negative membrane potentials where HVA channels are not normally activated. The membrane depolarizing influence of T-type calcium channel activation can become regenerative and produce calcium action potentials and oscillations.

Increases in  $[Ca]_i$ , occurring in part via activation of voltage-dependent T-type calcium channels, are important for the orderly progression of the cell cycle and may contribute to the regulation of cell proliferation and growth (Berridge et al. 1998; Ciapa et al. 1994; Guo et al. 1998). Alterations in the density of T-type calcium channel currents and oscillations in  $[Ca]_i$  have been described in a variety of organisms (Day et al. 1998; Kono et al. 1996; Kuga et al. 1996; Mitani 1985).

In addition to the variety of normal physiological functions mediated by calcium channels, they are also implicated in a number of human disorders. For example, changes to calcium influx into neuronal cells may be implicated in conditions such as epilepsy, stroke, brain trauma, Alzheimer's disease, multiinfarct dementia, other classes of dementia, Korsakoff's disease, neuropathy caused by a viral infection of the brain or spinal cord (e.g., human immunodeficiency viruses, etc.), amyotrophic lateral sclerosis, convulsions, seizures, Huntington's disease, amnesia, pain transmission, cardiac pacemaker activity or damage to the nervous system resulting from reduced oxygen supply, poison or other toxic substances (See e.g., Goldin et al., U.S. Pat. No. 5,312,928). Other pathological conditions associated with elevated intracellular free calcium levels include muscular dystrophy and hypertension (Steinhardt et al., U.S. Pat. No. 5,559,004).

Recently, mutations identified in human and mouse calcium channel genes have been found to account for several disorders including, familial hemiplegic migraine, episodic ataxia type 2, cerebellar ataxia, absence epilepsy and seizures. Fletcher, et al. (1996) "Absence epilepsy in tottering mutant mice is associated with calcium channel defects." *Cell* 87:607-617; Burgess, et al. (1997) "Mutation of the  $Ca^{2+}$  channel P subunit gene *Cchb4* is associated with ataxia and seizures in the lethargic (1h) mouse." *Cell* 88:385-392; Ophoff, et al. (1996) "Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the  $Ca^{2+}$  channel gene *CACNL1A4*." *Cell* 87:543-552; Zhuchenko, O. et al. (1997) "Autosomal dominant cerebellar ataxia (SCA6) associated with the small polyglutamine expansions in the UIA-Voltage-dependent calcium channel." *Nature Genetics* 15:62-69. The clinical treatment of some

disorders has been aided by the development of therapeutic calcium channel antagonists. Janis, et al. (1991) in *Calcium Channels: Their Properties, Functions, Regulation and Clinical Relevance*. CRC Press, London.

Significantly, changes to calcium influx into cardiovascular cells are implicated in conditions such as cardiac arrhythmia, angina pectoris, hypoxic damage to the cardiovascular system, ischemic damage to the cardiovascular system, myocardial infarction, and congestive heart failure (Goldin et al., supra). More, T-type calcium channels have been implicated in cellular growth and proliferation, particularly in the cardiovascular system (Katz, A.M, Eur. Heart J. Suppl., H18-H23, 999; Lijnen and Petrov, Exp. Clin. Pharmacol., 21: 253-259, 1999; Richard and Nargeot, Electrophysiol. Meet., 123-132, 1998; Wang et al., Am. J. Physiol. 265: C1239-C1246, 1993. Of equal import is the observation that there is limited knowledge in the art of the role of calcium channel types in cell growth control and abnormalities of calcium channels leading to cancer development.

The low threshold spikes and rebound burst firing characteristic of T-type calcium currents is prominent in neurons from inferior olive, thalamus, hippocampus, lateral habenular cells, dorsal horn neurons, sensory neurons (DRG, no dose), cholinergic forebrain neurons, hippocampal interneurons, CA1, CA3 dentate gyrus pyramidal cells, basal forebrain neurons, amygdaloid neurons (Talley et al., J. Neurosci., 19: 1895-1911, 1999) and neurons in the thalamus. (Suzuki and Rogawski, Proc. Natl. Acad. Sci. USA 86:7228-7232, 1998). As well, T-type channels are prominent in the soma and dendrites of neurons that reveal robust Ca-dependent burst firing behaviors such as the thalamic relay neurons and cerebellar Purkinje cells (Huguenard, J.R., Annu. Rev. Physiol., 329-348, 1996. Consequently, improper functioning of these LVA channels has been implicated in arrhythmias, chronic peripheral pain, improper pain transmission in the central nervous system to name a few.

For example, the data show that T-type channels promote oscillatory behavior which has important consequences for epilepsy. The ability of a cell to fire low threshold spikes is critical in the genesis of oscillatory behavior and increased burst firing (groups of action potentials separated by about 50-100 ms). T-type calcium channels are believed to play a vital role in absence epilepsy, a type of generalized non-convulsive seizure. The evidence that voltage-gated calcium currents contribute to the epileptogenic discharge, including seizure maintenance and propagation includes 1) a specific enhancement of T-type currents in the reticular thalamic (nRT) neurons which are hypothesized to be involved in the genesis of epileptic seizures in a rat genetic model (GAERS) for absence epilepsy (Tsakiridou et al., J. Neurosci., 15: 3110-3117, 1995); 2) antiepileptics against absence petit mal epilepsy (ethosuximide and dimethadione) have been shown at physiologically relevant doses to partially



depress T-type currents in thalamic (ventrobasal complex) neurons (Coulter et al., *Ann. Neurol.*, 25:582-93, 1989; U.S. 6,358,706 and references cited therein); and 3) T-type calcium channels underlie the intrinsic bursting properties of particular neurons that are hypothesized to be involved in epilepsy (nRT, thalamic relay and hippocampal pyramidal cells) (Huguenard, *supra*). The rat  $\alpha_1G$  is highly expressed in thalamocortical relay cells (TCs) which are capable of generating prominent  $Ca^{2+}$ -dependent low-threshold spikes (Talley et al., *J. Neurosci.*, 19: 1895-1911, 1999).

The T-type calcium channels have also been implicated in thalamic oscillations and cortical synchrony, and their involvement has been directly implicated in the generation of cortical spike waves that are thought to underlie absence epilepsy and the onset of sleep (McCormick and Bal, *Annu. Rev. Neurosci.*, 20: 185-215, 1997). Oscillations of neural networks are critical in normal brain function such during sleep-wave cycles. It is widely recognized that the thalamus is intimately involved in cortical rhythmogenesis. Thalamic neurons most frequently exhibit tonic firing (regularly spaced spontaneous firing) in awake animals, whereas phasic burst firing is typical of slow-wave sleep and may account for the accompanying spindling in the cortical EEG. The shift to burst firing occurs as a result of activation of a low threshold  $Ca^{2+}$  spike which is stimulated by synaptically mediated inhibition (i.e., activated upon hyperpolarization of the RP). The reciprocal connections between pyramidal neurons in deeper layers of the neocortex, cortical relay neurons in the thalamus, and their respective inhibitory interneurons are believed to form the elementary pacemaking circuit. That anti-epileptic drugs cause a reduction of the low-threshold calcium current (LTCC or T-type  $Ca^{2+}$  current) in thalamic neurons is evident from the prior art. See Coulter et al. (1989) *Ann. Neurol.* 25:582-593.) For example, ethosuximide, an anti-epileptic drug has been shown to fully block T-type  $Ca^{2+}$  current in freshly dissected neurons from dorsal root ganglia (DRG neurons) of adult rats (Todorovic and Lingle, *J. Neurophysiol.* 79:240-252, 1998), and may have limited efficacy in the treatment of abnormal, chronic pain syndromes that follow peripheral nerve damage.

T-type channels have also been implicated in contributing to spontaneous fluctuations in intracellular calcium concentrations  $[Ca]_i$ . Changes to calcium influx into cardiovascular cells, in turn, may be implicated in conditions such as cardiac arrhythmia, angina pectoris, hypoxic damage to the cardiovascular system, ischemic damage to the cardiovascular system, myocardial infarction, and congestive heart failure (Goldin et al., *supra*).

Other pathological disease states associated with dysfunctional calcium channels, e.g., elevated intracellular free calcium levels include muscular dystrophy and hypertension (Steinhardt et al., U.S. Pat. No. 5,559,004). Consequently, T-type calcium channels are

important in pacemaker activity and therefore heart rate in the heart, and in vesicle release from non-excitabile cells (Ertel et al., *In cardiovasc. Drugs Ther.*, 723-739, 1997). It is believed that therapeutic moieties capable of blocking the T-type channel in specific conformational states will find use in the treatment of tachycardia (by decreasing the heart rate) while having little effect on the inotropic properties of the normal heart. See Rousseau et al., *J. Am. Coll. Cardiol.*, 28: 972-979, 1996. According to Sen and Smith, *Circ. Res.*, 75: 149-55, 1994, in a particular cardiomyopathic disease (genetic Syrian hamster model), the disease status results from calcium overload due to an increased expression of T-type calcium channels in ventricular myocytes.

Likewise, researchers have shown that there are increased T-type currents in atrial myocytes from adult rats with growth hormone-secreting tumors. See also Xu and Best, *Proc. Natl. Acad. Sci. U.S.A.*, 87: 4655-4659, 1990; U.S. Patent No. 6,358,706 and references cited therein. Consequently, a specific T-type calcium channel blocker would find use as a cardioprotectant in these cases.

It is well documented that cortisol is the precursor for glucocorticoids and prolonged exposure to glucocorticoids causes breakdown of peripheral tissue protein, increased glucose production by the liver and mobilization of lipid from the fat depots. Furthermore, individuals suffering from anxiety and stress produce abnormally high levels of glucocorticoids. Consequently, drugs that would regulate these levels would aid in the treatment of stress disorders, e.g., antagonists to CRF. In this regard, the observations of Enyeart et al., *Mol. Endocrinol.*, 7:1031-1040, 1993, that T-type channels in adrenal zona fasciculata cells of the adrenal cortex modulate cortisol secretion will greatly aid in the identification of such a therapeutic candidate.

T-type calcium channels may also be involved in release of nutrients from testis Sertoli cells. Sertoli cells are testicular cells that are thought to play a major role in sperm production. Sertoli cells secrete a number of proteins including transport proteins, hormones and growth factors, enzymes which regulate germinal cell development and other biological processes related to reproduction (Griswold, *Int. Rev. Cytol.*, 133-156, 1988). They secrete the peptide hormone inhibin B, an important negative feedback signal to the anterior pituitary. They assist in spermiation (the final detachment of the mature spermatozoa from the Sertoli cell into the lumen) by releasing plasminogen activator which produces proteolytic enzymes. The data show that T-type calcium channels are expressed on immature rat Sertoli cells according to Lalevee et al., 1997. The intimate juxtaposition of the developing germ cells with the Sertoli cells suggests that the Sertoli cells may indeed play a role in supporting and nurturing the gametes. While the role of T-type calcium channels is not well documented, it is believed that they may be important in the release of nutrients, inhibin B, and/or plasminogen activator and

thus may impact sperm production. According to researchers, the inhibition of T-type calcium channels in sperm during gamete interaction inhibits zona pellucida-dependent  $\text{Ca}^{2+}$  elevations and inhibits acrosome reactions, thus directly linking sperm T- type calcium channels to fertilization. See Arnoult et al., 1996.

Likewise, tremor can be controlled through the basal ganglia and the thalamus, regions in which T type calcium channels are strongly expressed (Talley et al., *supra*). T-type calcium channels have been implicated in the pathophysiology of tremor since the anti-epileptic drug ethosuximide is used for treating tremor, in particular, tremor associated with Parkinson's disease, essential tremor, or cerebellar disease (U.S. Pat. No. 4,981,867; D. A. Prince).

T-type calcium channels also facilitate insulin secretion by enhancing the general excitability of these cells. Therefore, T-type calcium channels may be therapeutic targets in hypo- and hyperinsulinemia (A. Bhattacharjee et al., *Endocrinology*, vol. 138(9), pp. 3735-40, 1997). A direct link between T-type calcium channel activity and steroidogenesis has been suggested (M.F. Rossier et al., 1996).

Cellular calcium homeostasis plays an essential part in the physiology of nerve cells. The intracellular calcium concentration is about 0.1  $\mu\text{M}$  compared with 1 mM outside the nerve cell. This steep concentration gradient ( $\times 10,000$ ) is regulated primarily by voltage-gated calcium channels. Several pathologies of the central nervous system involve damage to or inappropriate function of voltage-gated calcium channels. In cerebral ischaemia (stroke) the channels of neurons are kept in the open state by prolonged membrane depolarization, producing a massive influx of calcium ions. This, in turn activates various calcium/calmodulin dependent cellular enzyme systems, e.g. kinases, proteases and phospholipases. Such prolonged activation leads to irreversible damage to nerve cells.

Certain diseases, such as Lambert-Eaton Syndrome, involve autoimmune interactions with calcium channels. The availability of the calcium channel subunits makes possible immunoassays for the diagnosis of such diseases. An understanding of them at the molecular level will lead to effective methods of treatment.

As well, there is a need for a better understanding of the structure and function of calcium channels, which, in turn would permit identification of substances that, in some manner, modulate the activity of calcium channels and that have potential for use in treating such disorders. That mutations of several channel proteins have been shown to be a causative factor in neurological disorders, is well known, thereby making the calcium channel subunits target for therapeutic interventions. See, e.g., Marais, *supra* and Burgess and Noebels, (1999) *Epilepsy Res.*, 36:111-122.

An understanding of the pharmacology of compounds that interact with calcium channels in other organ systems, such as the central nervous system ("CNS"), will greatly aid in the rational design of compounds that specifically interact with the specific subtypes of human calcium channels to have desired therapeutic effects, such as in the treatment of neurodegenerative and cardiovascular disorders. Such an understanding together with the ability to rationally design therapeutically effective compounds have been hampered by an inability to independently determine the types of human calcium channels and the molecular nature of individual subtypes, particularly in the CNS, and by the unavailability of pure preparations of specific channel subtypes to use for evaluation of the specificity of calcium channel-affecting compounds. Thus, the identification of nucleic acid molecules encoding human calcium channel subunits coupled with the use of such molecules for expression of the encoded calcium channel subunits subsequent use in of the functional calcium channels would aid in screening and design of therapeutically effective compounds.

A number of compounds useful in treating various diseases in animals, including humans, are thought to exert their beneficial effects by modulating functions of voltage-gated calcium channels. Many of these compounds bind to calcium channels and block, or reduce the rate of influx of calcium into cells in response to depolarization of the inside and outside of the cells. An understanding of the pharmacology of compounds that interact with calcium channels, and the ability to rationally design compounds that will interact with calcium channels to have desired therapeutic effects, depends upon the understanding of the structure of calcium subunits and the genes that encode them. The identification and study of tissue specific subunits allows for the development of therapeutic compounds specific for pathologies of those tissues.

However, there is a paucity of understanding of the pharmacology of compounds which interact with calcium channels. This paucity of understanding, together with the limited knowledge in the art of the human calcium channel types, the molecular nature of the human calcium channel subtypes, and the limited availability of pure preparations of specific calcium channel subtypes to use for evaluating the efficacy of calcium channel-modulating compounds has hampered the rational testing and screening of compounds that interact with the specific subtypes of human calcium channels to have desired therapeutic effects.

While a number of pharmacological blockers have differential effects on T type calcium currents expressed in different cell types as noted *supra*, there are no known specific blockers of the T-type class of calcium channel. It is believed that the differential sensitivity of T-type currents to antagonists may be due to different subunit structure (Perez-Reyes, 1998) as well as cellular environments. T-type calcium channel alpha subunit genes, like the genes for HVA channels, reveal alternative splicing (Lee et al., 1999 Biophys J 76:A408). Extracellular

and intracellular loops of individual T-type calcium channel clones also show marked diversity amongst themselves and even less homology to HVA channels.

Examples of conventional putative calcium channel blockers include dihydropyridines such as nifedipine, nitrendipine, nicardipine, nimodipine, niludipine, riodipine (ryosidine) felodipine, darodipine, isradipine, (+)Bay K 8644, (-)202-791, (+)H 160/SI, PN 200-110 and nisoldipine. Other examples of the calcium channel blocker include Kurtoxin, benzothiazepine, such as diltiazem (dilizem) and TA 3090 and phenylalkylamine, such as verapamil (isoptin), desmethoxyverapamil, methoxy verapamil (D-600, gallopamil or (-)D-888), prenylamine, fendiline, terodiline, caroverine, perhexiline.

In view of the above, pharmacological modulation of T-type calcium channels' function is very important and therapeutic moieties capable of modulating T-type currents will find tremendous use in the practice of medicine, i.e., calcium channel blockers for the treatment of epilepsy, hypertension, and angina pectoris etc. Unfortunately, as noted above, conventional medicine and its use of conventional calcium channels blockers for the treatment of a wide variety of calcium channels mediated diseases is not very effective. Importantly, such intervention is not yet available for calcium channels in electrically non-excitable cells. This deficiency likely reflects the fact that the mechanism by which calcium entry occurs has not been clearly identified.

Recent studies that demonstrated the association of mutations in calcium channel genes ( $\alpha_1$  and  $\beta$  genes) with inherited and acquired diseases further underlined the importance of calcium channels and have created a new field of research aimed at understanding and controlling these "channelopathies" (Miller, *supra*).

Various efforts have been made to obtain sequences of calcium channel subunit genes, such as the human ( $\alpha_2$ )-subunit gene (Ellis et al., *Science* 241(4873):1661-[1988]; Williams et al., *Neuron*, 8(1):71-84 [1992]; Ellis et al. U.S. Pat. No. 5,686,241; and Harpold et al., U.S. Pat. No. 5,792,846), and its murine (GenBank Accession ## U73483-U73487), rat (GenBank Accession # M86621), porcine (GenBank Accession # M21948), and rabbit orthologs (GenBank Accession # AF077665).

Significantly, the development of new therapeutic strategies against, and the creation of new analytical tools for a better understanding of diseases characterized by aberrant voltage regulated calcium influx are greatly desired.

Because T-type channels appear to be associated with a variety of key functions, cells that express T-channels and assays using such cells will have utility in the identification of compounds effective in modulating a T-type channel, and thus will find use in the treatment of a variety of disorders, disease and conditions effecting both humans and animals. Compounds

identified thereby will be candidates for use in the treatment of disorders and conditions associated with T-channel activity in humans and animals. Such activities include, but are not limited to, those involving a role in muscle excitability, secretion and pacemaker activity,  $\text{Ca}^{2+}$  dependent burst firing, neuronal oscillations, and potentiation of synaptic signals, for improving arterial compliance in systolic hypertension, or improving vascular tone, such as by decreasing vascular welling, in peripheral circulatory disease, and others. Other disorders include, but are not limited to hypertension, cardiovascular disorders, including but not limited to: myocardial infarct, cardiac arrhythmia, heart failure and angina pectoris; neurological disorders, such as schizophrenia, epilepsy and depression, peripheral muscle disorders, respiratory disorders and endocrine disorders.

Consequently, the discovery of the herein disclosed sequences of murine  $\alpha_{1H}$  subunits will allow for the development of therapeutic compounds specific for the pathologies noted above thereby satisfying a long-sought need for such therapies and tools.

#### SUMMARY OF THE INVENTION

The present invention is based on the discovery of a novel low-voltage calcium channel  $\alpha_{1H}$  subunit ( $\text{Ca}_v 3.2$ ) from three strains of rats - Sprague-Dawley (S-D), Spontaneous Hypertensive (SHR) and Wistar-Kyoto (WKY). Importantly, the amino acid sequence encoded by each of the nucleic acid sequences derived from SHR and WKY are identical whereas the amino acid sequence encoded by the nucleic acid sequence derived from the S-D differs from that of the SHR and WKY at position 2188. These calcium channel subunits of the invention are the major pathway for regulating influx of  $\text{Ca}^{2+}$  into cells and play critical roles in diverse cellular processes such as electrical excitability and contraction, hormone secretion, enzyme activity, and gene expression.

The invention and its use is based, in part, on the fact that the murine calcium channel  $\alpha_{1H}$  subunit ( $\text{Ca}_v 3.2$ ) is closely related to a mammalian calcium channel  $\alpha_{1H}$  subunit ( $\text{Ca}_v 3.2$ ). It is also based on the tissue distribution of the exact matches, related sequences or variants of SEQ ID NOS:1-6 which may be found in heart, kidney, liver, brain and endocrine tissues.

The use of the herein disclosed calcium channel  $\alpha_{1H}$  subunit, and of the nucleic acid sequences which encode it, is also based on the amino acid and structural homologies between the herein disclosed  $\alpha_{1H}$  subunit and the other known T-type calcium channel subunits as well as on the known associations and functions of T-type calcium channels in general. The timing of and amount of expression of any one or more of the polypeptides of the invention, calcium channel  $\alpha_{1H}$  subunit of SEQ ID NOS:2, 4 and 6 is implicated in various diseases

characterized by a dysfunctional or aberrant expression/activity of a T-type calcium channel, in particular, an  $\alpha_1H$  subunit. Given the tissue distribution, the novel T-type calcium channel  $\alpha_1H$  subunit(s) in this application are likely involved in signal transduction pathways related to cardiac, renal, endocrine and neuronal cell activity.

An illustrative nucleic acid molecule containing a sequence that encodes the  $\alpha_1H$  polypeptide has the nucleotide sequence of SEQ ID NO:1 of 7426 nucleotides, of which the coding sequence encompasses nucleotides 50 to 7129. This sequence is designated herein as  $\alpha_1H$ -SHR. The coding sequence contained within SEQ ID NO:1 is 7080 nucleotides (nts). The encoded polypeptide has the amino acid sequence as set forth in SEQ ID NO:2.

Another illustrative nucleic acid molecule containing a sequence that encodes the  $\alpha_1H$  polypeptide has the nucleotide sequence of SEQ ID NO:3 of which the coding sequence encompasses nucleotides 56 to 7135. This sequence is designated herein as  $\alpha_1H$  - WKY. The coding sequence contained within SEQ ID NO:3 is 7080 nts. The encoded polypeptide has the amino acid sequence as set forth in SEQ ID NO:4. Thus, the  $\alpha_1H$  -WKY nucleotide sequence described herein encodes a polypeptide that is 2359 amino acids.

Yet another illustrative nucleic acid molecule containing a sequence that encodes the  $\alpha_1H$  polypeptide has the nucleotide sequence of SEQ ID NO:5 of 7277 nucleotides, of which the coding sequence encompasses nucleotides 50 to 7129. This sequence is designated herein as  $\alpha_1H$ -S-D. The coding sequence contained within SEQ ID NO:5 is 7080 nts. The encoded polypeptide has the amino acid sequence as set forth in SEQ ID NO:6.

In another aspect, the invention provides nucleic acid molecule(s) comprising a nucleotide sequence which is complementary to that of SEQ ID NOS:1, 3, or 5 or complementary to a sequence having at least 90% identity to said sequence or a fragment of said sequence. The complementary sequence may be a DNA sequence which hybridizes with, for example, SEQ ID NO:1 or hybridizes to a portion of that sequence having a length sufficient to inhibit the transcription of the complementary sequence. The complementary sequence may be a DNA sequence which can be transcribed into an mRNA being an antisense to the mRNA transcribed from SEQ ID NO:1 or into an mRNA which is an antisense to a fragment of the mRNA transcribed from SEQ ID NO:1 which has a length sufficient to hybridize with the mRNA transcribed from SEQ ID NO:1, so as to inhibit its translation. The complementary sequence may also be the mRNA or the fragment of the mRNA itself.

Considering the high degree (> 90%) of sequence homology in the primary sequence between the reference  $\alpha_1H$  sequence GenBank accession #AF211189 and the corresponding human  $\alpha_1H$  subunit (AF073931) and the novel sequences disclosed herein, it is believed that compositions comprising the novel sequences or biologically active fragments or

derivatives thereof may be administered to a subject to treat or prevent a pathological disorder characterized by a dysfunctional T-type calcium channel subunit. As such, the novel proteins of the invention may find use, *inter alia*, in treating a number of  $\alpha_1H$  subunit mediated pathologies including epilepsy, colorectal cancers, gastric cancers, acute myelogenous leukemias as well as lung and breast cancers. See, for example, McRory, et al., J. Biol. Chem., 276 (6), 3999-4011 (2001).

The present invention further provides nucleic acid molecule comprising a nucleotide sequence which encode the amino acid sequences of SEQ ID NOS:2, including fragments and homologues of the amino acid sequences. Due to the degenerative nature of the genetic code, a plurality of alternative nucleic acid sequences beyond those depicted in SEQ ID NO:1, can code for the amino acid sequences of the invention. Consequently, those alternative nucleic acid sequences which code for the same amino acid sequences coded by the sequence of SEQ ID NO:1 are also included in the scope of the present invention.

The present invention also relates, in part, to an expression vector and host cells comprising nucleic acids encoding an  $\alpha_1H$  subunit of the invention. Such transfected host cells are useful for the production and recovery of  $\alpha_1H$ . The present invention also encompasses purified  $\alpha_1H$ . The present invention still further provides pharmaceutical compositions comprising, as an active ingredient, nucleic acid molecules encoding a functional  $\alpha_1H$  protein/polypeptide or antibodies specific thereto, fragments or variants thereof or a therapeutic composition identified via use of the herein disclosed nucleic acid molecules e.g., inhibitors of a T-type calcium channel  $\alpha_1H$  subunit which can be used in the prevention or treatment of conditions or diseases noted below.

In another aspect, the invention provides a protein or polypeptide comprising an amino acid sequence encoded by any of the above nucleic acid sequences. In one embodiment, the polypeptide corresponding to  $\alpha_1H$  comprises the amino acid sequence of SEQ ID NO:2 ((SHR). In another embodiment the polypeptide corresponds to  $\alpha_1H$  (WKY) and comprises the amino acid sequence of SEQ ID NO:4. Yet another polypeptide corresponds to  $\alpha_1H$  (S-D) and comprises the amino acid sequence of SEQ ID NO:6. Fragments of the above amino acid sequences of sufficient length coded by the above fragments of the nucleic acid sequences, as well as homologues of the above amino acid sequences in which one or more of the amino acid residues has been substituted by conservative or non-conservative substitution) added, deleted, or chemically modified are also within the scope of the invention.

The deletions, insertions and modifications should be in regions, or adjacent to regions, wherein the novel isoforms differs from the reference sequence, but maintains its ability to regulate voltage gated calcium influx. Applicants appreciate that a skilled artisan will be able



to modify the novel isoforms or fragments thereof by addition, deletions or substitutions of amino acids (derivative product/polypeptide). Consequently, homologues of the  $\alpha_{1H}$  variants which are derivated from the reference  $\alpha_{1H}$  sequence e.g.,  $\alpha_{1H}$  (SEQ ID NO:1, 3 or 5) by changes (deletion, addition, substitution) are also a part of the present invention, wherein said derivatized sequence is functionally equivalent to the novel sequences detailed herein, i.e., ability to modulate voltage-gated calcium influx etc.

Medicaments for treating  $\alpha_{1H}$  subunit mediated disorders in human or animals identified via the use of the herein disclosed sequences, are also a part of the invention. Such medicaments will find use in the treatment of diseases and pathological conditions where a therapeutically beneficial effect may be achieved by correcting abnormal calcium influx. Typically, these are diseases wherein  $\alpha_{1H}$  or other auxiliary subunit proteins of the calcium channel plays a role in the etiology of the disease, i.e. aberrant (excessive or insufficient voltage regulated calcium influx) cause or are a result of the disease.

The invention further features a method for identifying a candidate pharmacological agent useful in the treatment of diseases associated with increased or decreased voltage regulated calcium influx mediated by a human T-type calcium channel  $\alpha_{1I}$  subunit isoform of the invention.

Compounds identified by any of the herein disclosed methods are also within the scope of the invention.

Thus, in accordance with an aspect of the invention, suitable host cells expressing functional LVA channels, such as an  $\alpha_{1H}$  subunit of the invention, preferably those encoding SEQ ID NOS:2, 4 or 6, will find use in identifying compounds that are candidates for treatment of disorders associated with a dysfunctional T-type calcium channel or normal functioning T-type channels impacting a disease state. Representative disorders amenable to treatment by compounds identified via use of the herein disclosed sequences include treatment of cardiovascular, such as angina, vascular, such as hypertension, and urologic, hepatic, reproductive, adjunctive therapies for reestablishing normal heart rate and cardiac output following traumatic injury, heart attack and other cardiac injuries; treatments of myocardial infarct (MI), post-MI and in an acute setting. Endocrinology diseases especially hyper aldosteronism and diseases of the central nervous system are also amenable to treatment by compounds identified using any one or more of the novel sequences disclosed herein.

Other compounds that interact with LVA, particularly T-type, calcium channels, may be effective for increasing cardiac contractile force, such as measured by left ventricular end diastolic pressure, and without changing blood pressure or heart rate. Alternatively, some

compounds may be effective to decrease formation of scar tissue, such as that measured by collagen deposition or septal thickness, and without cardiodepressant effects.

The herein disclosed assays may also be used to

- (a) identify compounds useful in regulating vascular smooth muscle tone, either vasodilating or vasoconstricting in:
  - (i) treatments for reestablishing blood pressure control, e.g., following traumatic injury, surgery or cardiopulmonary bypass, and in prophylactic treatments designed to minimize cardiovascular effects of anesthetic drugs;
  - (ii) treatments for improving vascular reflexes and blood pressure control by the autonomic nervous system;
- (b) identify compounds useful in treating urological disorders, e.g., treating and restoring renal function following surgery, traumatic injury, uremia and adverse drug reactions; treating bladder dysfunctions; and uremic neuronal toxicity and hypotension in patients on hemodialysis; reproductive disorders,
- (c) identify compounds useful in treating:
  - (i) disorders of sexual function including impotence;
  - (ii) alcoholic impotence (under autonomic control that may be subject to T-channel controls);
  - (iii) hepatic disorders for identifying compounds useful in treating and reducing neuronal toxicity and autonomic nervous system damage resulting from acute over-consumption of alcohol; neurologic disorders for identifying compounds useful in treating:
    - (a) epilepsy and diencephalic epilepsy;
    - (b) Parkinson's disease;
    - (c) aberrant temperature control, such as, abnormalities of shivering and sweat gland secretion and peripheral vascular blood supply;
    - (d) aberrant pituitary and hypothalamic functions including abnormal secretion of noradrenalin, dopamine and other hormones; for respiratory such as in treating abnormal respiration, e.g., post-surgical complications of anesthetics; and endocrine disorders, for identifying compounds useful in treating aberrant secretion of hormones including e.g., possible treatments for overproduction of insulin, thyroxin, adrenalin, and other hormonal imbalances.

In a broad aspect, the invention provides a method for screening for compounds which modulate the activity of T-type voltage-gated calcium channels. The method involves providing a cell transformed with a DNA expression vector comprising a cDNA sequence encoding a T-type  $\alpha_1H$  subunit of a voltage-gated calcium channel, e.g., a murine  $\alpha_1H$  subunit

of a voltage-gated calcium channel, the cell comprising additional calcium channel subunits necessary and sufficient for assembly of a functional low-voltage-gated calcium channel. The cell is contacted with a test compound and agonistic or antagonistic action of the test compound on the reconstituted calcium channels is determined.

Without intending to limit the type or source of host cell, in yet another preferred embodiment, the host cell is eukaryotic.

In another aspect, a method of the invention proposes that the eukaryotic cell that expresses a heterologous calcium channel is in a solution containing a test compound and a calcium channel selective ion, the cell membrane is depolarized, and current flowing into the cell is detected. If the test compound is one that modulates calcium channel activity, the current that is detected is different from that produced by depolarizing the same or a substantially identical cell in the presence of the same calcium channel-selective ion but in the absence of the compound (control cell). Preferably, prior to the depolarization step, the cell is maintained at a holding potential which substantially inactivates calcium channels which are endogenous to the cell. As well, in certain preferred embodiments, the cells are mammalian cells, most preferably HEK cells, or amphibian oocytes.

Thus, in accordance with the above, there is provided a method for screening test compounds for modulating calcium channel activity, comprising:

- a) providing:
  - i) the test compound;
  - ii) a calcium channel selective ion;
  - iii) a control cell; and
  - iv) a host cell expressing heterologous nucleic acid sequences encoding: a functional calcium channel  $\alpha_1H$  subunit; preferably one having the amino acid sequence as set forth in one of SEQ ID NOS: 2, 4 or 6 or a biologically equivalent/active fragment thereof;
- b) contacting the host cell with the test compound and with the molecule to produce a treated host cell;
- c) depolarizing the cell membrane of the treated host cell under conditions such that the molecule enters the cell through a functional calcium channel; and
- d) detecting a difference between current flowing into the treated host cell and current flowing into a control cell, thereby identifying the test compound as a compound capable of modulating calcium channel activity.

The method further comprises, prior to the depolarizing, maintaining the treated host cell at a holding potential that substantially inactivates endogenous calcium channels. In

another preferred embodiment, the method further comprises, prior to or simultaneously with the step of contacting the host cell with the test compound, contacting the host cell with a calcium channel agonist, wherein the test compound is tested for activity as an antagonist.

Alternative embodiments propose a transcription based assays for identifying compounds that modulate the activity of calcium channels (see, U.S. Patent Nos. 5,436,128 and 5,401,629), in particular calcium channels that contain an  $\alpha_1H$  subunit.

Other reporter based assays may include the use of a dye which coordinate  $Ca^{2+}$ . The method provides (i) incubating recombinant cells of the invention (those expressing a function calcium channel  $\alpha_1H$  subunit) with (1) a dye which has acid groups which can coordinate  $Ca^{2+}$  and which undergoes a spectral shift when coordinated to  $Ca^{2+}$  and (2) a compound with unknown effect; (ii) stimulating  $Ca^{2+}$  influx into the cell; and (iii) monitoring the spectral characteristics of the dye in the recombinant cells. These spectral characteristics will change as calcium is bound to the dye. Because calcium will bind to (be coordinated by) the dye in proportion to the concentration of calcium in the activated cell, the change in spectral characteristics of the dye will be a measure of the calcium concentration within the cell. If the compound is a T-type channel selective inhibitor then the absorbance or fluorescent emission of the uncoordinated dye (A) will be different than the absorbance or fluorescent emission of the  $Ca^{2+}$ -coordinated dye (A2) because the inhibitor will have suppressed calcium entry into the cell. In preferred embodiments, the DNA is one of SEQ ID NOS:1, 3 or 5.

Other assays formats, well known to one skilled in the art, for identifying calcium channel modulators, in particular T-type calcium channels may also be used.

The invention further provides diagnostic kits for the detection of naturally occurring  $\alpha_1H$  sequences and provides for the use of purified  $\alpha_1H$  as a positive control and to produce anti- $\alpha_1H$  antibodies. These antibodies may be used to monitor  $\alpha_1H$  expression conditions or diseases associated with aberrant expression or mutated  $\alpha_1H$ . Alternatively, the sequences of the invention may be used to detect mutations within a gene encoding a T-type  $\alpha_1H$  subunit.

Thus, an aspect of the invention provides antibodies specific for one or more of the novel proteins of the invention, which may be used in identifying corresponding genes in humans having a sequence of amino acids substantially similar to that one the sequence which was used to generate said antibody. Consequently, antibodies specific for a protein of the invention will find use for identifying corresponding proteins in humans, e.g. western blot etc. Thus, such antibodies may be useful for diagnostic purposes in humans. Methods for generating antibodies are well known.

The immunoglobulins that are produced using the calcium channel subunits or purified calcium channels as immunogens have, among other properties, the ability to specifically and preferentially bind to and/or cause the immunoprecipitation of a human calcium channel or a subunit thereof which may be present in a biological sample or a solution derived from such a biological sample. Such antibodies may also be used to selectively isolate cells that express calcium channels that contain the subunit for which the antibodies are specific.

The  $\alpha_1H$  polynucleotide sequence, oligonucleotides, fragments, portions or antisense molecules thereof, may be used in diagnostic assays to detect and quantify levels of  $\alpha_1H$  mRNA in cells and tissues. For example,  $\alpha_1H$  polynucleotides, or fragments thereof, may be used in hybridization assays of body fluids or biopsied tissues to detect the level of  $\alpha_1H$  expression.

Thus, an aspect of the invention features methods for (i) detecting the level of the transcript (mRNA) of said  $\alpha_1H$  subunit or a variant product (SEQ ID NO:1, 3 or 5, or fragments thereof) in a body fluid sample, or in a specific tissue sample, for example by use of probes comprising all or parts of the nucleotide sequences disclosed herein; (ii) detecting levels of expression of said subunit in tissue, e.g. by the use of antibodies capable of specifically reacting with the gene products of the nucleotide sequences of the invention or biologically equivalent fragments thereof. Detection of the level of the expression of a variant product(s) of the invention in particular as compared to that of the reference sequence from which it was varied or compared to other variant sequences all varied from the same reference sequence may be indicative of a plurality of physiological or pathological conditions. Quantifying normal levels of the target gene or its encoded gene product are well known to a skilled artisan.

The probes of the invention, in turn, may be used to detect and quantify the level of transcription of a corresponding human  $\alpha_1H$  channel subunit in a human for diagnostic and therapeutic purposes. The method, according to this latter aspect, for detecting a nucleic acid sequence which encodes a human T-type calcium channel  $\alpha_1H$  subunit isoforms in a biological sample, comprises the steps of:

- (a) providing a probe comprising at least one of the nucleic acid sequences disclosed herein;
- (b) contacting the biological sample with said probe under conditions allowing hybridization of nucleic acid sequences thereby enabling formation of hybridization complexes;
- (c) detecting hybridization complexes, wherein the presence of the complex indicates the presence of nucleic acid sequence encoding the  $\alpha_1H$  subunit or an isoform thereof in the biological sample.

The methods as described above are qualitative, i.e. indicate whether the transcript or gene product is present in or absent from the sample. The method can also be quantitative, by determining the level of hybridization complexes and/or protein/antibody complex and then calibrating said levels to determining levels of transcripts or antibody complexes of the desired variant in the sample. Both qualitative and quantitative determination methods can be used for diagnostic, prognostic and therapy planning purposes.

The nucleic acid sequence used in the above method may be a DNA sequence, an RNA sequence, etc; it may be a coding or a sequence or a sequence complementary thereto (for respective detection of RNA transcripts or coding-DNA sequences). By quantization of the level of hybridization complexes and calibrating the quantified results it is possible also to detect the level of the transcript in the sample.

Methods for modulating the activity of ion channels by contacting the calcium channels with an effective amount of the above-described antibodies are also provided.

Methods for treating subjects suffering from or at risk of being afflicted with a pathology/disease characterized by aberrant voltage regulated calcium influx using compounds identified by the methods of the present invention are also embraced by the invention. The disease status can be characterized as aberrant - excessive or insufficient voltage regulated calcium influx relative to normal.

Also included are methods for diagnosing LVA calcium channel-mediated, particularly T-type channel-mediated, disorders. Methods of diagnosis will involve detection of aberrant channel expression or function, such altered amino acid sequences, altered pharmacological profiles and altered electrophysiological profiles compared to normal or wild-type channels. Such methods typically can employ antibodies specific for the altered channel or nucleic acid probes to detect altered genes or transcripts.

In another aspect, the present invention relates to diagnostic screening techniques useful for the identification of mutations within the  $\alpha 1I$  encoding ( $Ca_v3.3$ ) gene that is involved in neuronal disorders. The proposed method will involve detection of a species of  $\alpha 1H$  sequence via a Northern. Southern or western blot using any one or more sequences of the invention.

Thus, initial identification of mutations responsible for such conditions can be made, for example, by producing cDNA from the mRNA of an individual suffering from a neuronal disorder (e.g., epilepsy). The sequence of nucleotides in the cDNA is then determined by conventional techniques. This determined sequence is then compared to the wild-type sequence available in the public database. Differences between the determined cDNA sequence, and that disclosed in the public database, GeneBank Accession # AF290213, are candidate deleterious mutations. Following identification and characterization, oligonucleotides can be

designed for the detection of specific mutants. Alternatively, a  $\alpha_1H$  gene can be isolated from the genome of a patient and directly examined for mutations by such techniques as restriction mapping or sequencing.

To determine whether such mutations are responsible for the diseased phenotype, experiments can be designed in which the defective gene carrying the identified mutation is introduced into a cell system expressing a complement of components sufficient for the production of functional neuronal low-voltage-gated calcium channels. The ability of the mutant  $\alpha_1H$  sequence to function as a calcium channel can be assessed using conventional techniques, such as the ones described above.

Other aspects of the present invention are presented in the accompanying claims and in the following description and drawings. These aspects are presented under separate section headings. However, it is to be understood that the teachings under each section are not necessarily limited to that particular section heading.

#### BRIEF DESCRIPTION OF THE DRAWINGS:

In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which: Figure 1 details the intracellular recording or patch-clamp recording used to quantitate changes in electrophysiology of cells for the SHR channels.

#### DETAILED DESCRIPTION OF THE INVENTION:

Before the present proteins, nucleotide sequences, and methods are described, it is to be understood that the present invention is not limited to the particular methodologies, protocols, cell lines, vectors, and reagents described, as these may vary. It is also understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not to limit the scope of the present invention.

The singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise.

All technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention pertains. The practice of the present invention will employ, unless otherwise indicated, conventional techniques of protein chemistry and biochemistry, molecular biology, microbiology and recombinant DNA technology, which are within the skill of the art. Such techniques are explained fully in the literature.

Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials, and methods are now described. All patents, patent applications, and publications mentioned herein, whether supra or infra, are each incorporated by reference in its entirety.

While the description details various embodiments encompassing the nucleic acid molecule of SEQ ID NO:1 and the encoded protein of SEQ ID NO:2, including variants and fragments thereof, the same description applies equally to the nucleic acid molecules of SEQ ID NOS:3 and 5, and the encoded proteins of SEQ ID NOS:4 and 6, including various fragments, and variants thereof. For example, just as the rat T-type calcium channel  $\alpha_1H$  subunit encoding nucleic acid of SEQ ID NO:1 is "isolated", so is the rat T-type calcium channel  $\alpha_1H$  subunit encoding nucleic acid molecule of SEQ ID NOS:3 and 5 etc.

## Glossary

In the following description and claims use will be made, at times, with a variety of terms, and the meaning of such terms as they should be construed in accordance with the invention is as follows:

In the following commentary, a "gene" refers to a nucleic acid molecule whose nucleotide sequence codes for a polypeptide molecule. Genes may be uninterrupted sequences of nucleotides or they may include such intervening segments as introns, promoter regions, splicing sites and repetitive sequences. A gene can be either RNA or DNA. A preferred gene is one that encodes the invention protein.

The present invention relates to various novel murine T-type calcium channel subunits, and to the use of the nucleic acid and amino acid sequences in the study, diagnosis, prevention and treatment of diseases mediated by a dysfunctional calcium channel  $\alpha_1H$  subunit.

The polynucleotide sequence encoding one or more of the herein disclosed  $\alpha_1H$  subunit were identified as outlined in the Examples *infra*.

The present invention and the use of the  $\alpha_1H$  subunit sequences identified herein, and of the nucleic acid sequences which encode it, is based, in part, on the amino acid homology between the murine  $\alpha_1H$  subunit and the corresponding human protein. It is also based on the tissue distribution of variants, closely related or exact cDNA sequences in (describe tissue distribution, if known).

The murine  $\alpha_1H$  SHR subunit polynucleotide sequence, oligonucleotides, fragments, portions or antisense thereof, may be used in diagnostic assays to detect and quantify levels of  $\alpha_1H$  SHR subunit mRNA in cells and tissues, genomic as well as mutated sequences. For example,  $\alpha_1H$  SHR subunit polynucleotides, or fragments thereof, may be used in



hybridization assays of body fluids or biopsied tissues to detect the level of  $\alpha_1H$  SHR subunit expression. The invention further provides for the use of purified  $\alpha_1H$  SHR subunit as a positive control and to produce anti- $\alpha_1H$  SHR subunit antibodies. These antibodies may be used to monitor  $\alpha_1H$  SHR subunit expression in conditions or diseases associated with dysfunctional or aberrant levels of calcium ions.

The present invention also relates, in part, to an expression vector and host cells comprising nucleic acids encoding  $\alpha_1H$  SHR subunit. Such transfected host cells are useful for the production and recovery of  $\alpha_1H$  SHR subunit. The present invention also encompasses purified  $\alpha_1H$  SHR subunit.

The invention further provides for methods for treatment of conditions or diseases associated with over-expression of  $\alpha_1H$  subunit by the delivery of effective amounts of antisense molecules, including peptide nucleic acids, or inhibitors of  $\alpha_1H$  subunit for the purpose of diminishing or correcting aberrant calcium channel activity.

The invention also provides pharmaceutical compositions comprising vectors containing antisense molecules or inhibitors of  $\alpha_1H$  SHR which can be used in the prevention or treatment of conditions or diseases including, but not limited to, epilepsy, pain, cardiac arrhythmia, sleep disorders etc that are mediated by a deficient or dysfunctional T-type calcium channel subunit. Thus, for example, specific  $\alpha_1H$  SHR inhibitors can be used to prevent aberrant calcium currents.

"Nucleic acid sequence" as used herein refers to an oligonucleotide, nucleotide or polynucleotide sequence, and fragments or biologically equivalent portions thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand. Similarly, amino acid sequence as used herein refers to an oligopeptide, peptide, polypeptide or protein sequence. "Peptide nucleic acid" as used herein refers to a molecule which comprises an antisense oligomer to which an amino acid residue, such as lysine, and an amino group have been added. These small molecules, also designated anti-gene agents, stop transcript elongation by binding to their complementary (template) strand of DNA (Nielsen P. E. et al (1993) Anticancer Drug Des 8:53-63). Thus, "nucleotide sequence of the present invention" and "amino acid sequence of the present invention" and grammatical equivalents thereof refer respectively to any one or more nucleotide sequences presented or discussed herein and to any one or more of the amino acid sequences presented or discussed herein. Also, and as used herein, "amino acid" refers to peptide or protein sequence and may refer to portions thereof. In addition, the term "amino acid sequence of the present invention" is synonymous with the phrase "polypeptide of the present invention". Also the term "nucleotide

sequence of the present invention" is synonymous with the phrase "poly-nucleotide sequence of the present invention".

As used herein,  $\alpha_1H$  refers to the amino acid sequence of  $\alpha_1H$  from a rat, in a naturally occurring form or from any source, whether natural, synthetic, semi-synthetic or recombinant. As used herein, "naturally occurring" refers to a molecule, nucleic acid or amino acid sequence, found in nature.

The present invention also encompasses  $\alpha_1H$  variants. A preferred  $\alpha_1H$  variant is one having at least 80% amino acid sequence similarity, a more preferred  $\alpha_1H$  variant is one having at least 90% amino acid sequence similarity and a most preferred  $\alpha_1H$  variant is one having at least 95% amino acid sequence similarity to the  $\alpha_1H$  amino acid sequence (SEQ ID NO:2). A "variant" of  $\alpha_1H$  SHR may have an amino acid sequence that is different by one or more amino acid "substitutions". The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, eg, replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, eg, replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which and how many amino acid residues may be substituted, inserted or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

The term "biologically active" refers to a  $\alpha_1H$  sequence having structural, regulatory or biochemical functions of the naturally occurring  $\alpha_1H$ . Likewise, "immunologically active" defines the capability of the natural, recombinant or synthetic  $\alpha_1H$  subunit, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies. The term "derivative" as used herein refers to the chemical modification of a  $\alpha_1H$  encoding sequence or the encoded  $\alpha_1H$  subunit.

Illustrative of such modifications would be replacement of hydrogen by an alkyl, acyl, or amino group. An  $\alpha_1H$  encoding nucleotide sequence derivative would encode a polypeptide which retains essential biological characteristics of a T-type calcium channel  $\alpha_1H$  protein g subunit such as, for example, to form a functional calcium channel.

As used herein, the term "purified" refers to molecules, either nucleic or amino acid sequences, that are removed from their natural environment and isolated or separated from at least one other component with which they are naturally associated.

#### The $\alpha_1H$ SHR Coding Sequences

The nucleic and deduced amino acid sequences of  $\alpha_1H$  subunit, e.g.,  $\alpha_1H$  SHR are shown in SEQ ID NOS:1 and 2 respectively. In accordance with the invention, any

nucleotide sequence which encodes the amino acid sequence of  $\alpha_1\text{H}$  SHR can be used to generate recombinant molecules which express  $\alpha_1\text{H}$  SHR .

Methods for DNA sequencing are well known to a skilled artisan and may employ such enzymes as the Klenow fragment of DNA polymerase I Sequenase.RTM. (US Biochemical Corp, Cleveland Ohio)), Taq polymerase (Perkin Elmer, Norwalk Conn.), thermostable T7 polymerase (Amersham, Chicago Ill.), or combinations of recombinant polymerases and proofreading exonucleases such as the ELONGASE Amplification System marketed by Gibco BRL (Gaithersburg Md.). As well, methods to extend the DNA from an oligonucleotide primer annealed to the DNA template of interest have been developed for both single-stranded and double-stranded templates. Chain termination reaction products were separated using electrophoresis and detected via their incorporated, labelled precursors. Recent improvements in mechanized reaction preparation, sequencing and analysis have permitted expansion in the number of sequences that can be determined per day. Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno Nev.), Peltier Thermal Cycler (PTC200; MJ Research, Watertown Mass.) and the ABI Catalyst 800 and 377 and 373 DNA sequencers (Perkin Elmer).

The quality of any particular cDNA library may be determined by performing a pilot scale analysis of the cDNAs and checking for percentages of clones containing vector, lambda or E. coli DNA, mitochondrial or repetitive DNA, and clones with exact or homologous matches to public databases.

#### Extending the Polynucleotide Sequence:

The polynucleotide sequence of  $\alpha_1\text{H}$  SHR (SEQ ID NO:1) may be extended utilizing partial nucleotide sequence and various methods known in the art to detect upstream sequences such as promoters and regulatory elements. Gobinda et al (1993; PCR Methods Applic 2:318-22) disclose "restriction-site polymerase chain reaction (PCR)" as a direct method which uses universal primers to retrieve unknown sequence adjacent to a known locus. According to the process, initially, a genomic DNA is amplified in the presence of primer to a linker sequence and a primer specific to the known region. Thereafter, the amplified sequences are subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR may also be used to amplify or extend the target sequences using divergent primers based on a known region (Triglia T. et al(1988) Nucleic Acids Res 16:8186). The primers may be designed using Oligo 4.0 (National Biosciences Inc, Plymouth Minn.), or

another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72°C. The method proposes using several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is thereafter circularized by intramolecular ligation and used as a PCR template.

Capture PCR (Lagerstrom M. et al (1991) PCR Methods Applic 1:111-19) is drawn to a method for PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome (YAC) DNA. Capture PCR also requires multiple restriction enzyme digestions and ligations to place an engineered double-stranded sequence into an unknown portion of the DNA molecule before PCR.

Likewise, Parker J. D. et al (1991; Nucleic Acids Res 19:3055-60), teach walking PCR, a method for targeted gene walking which permits retrieval of unknown sequence. PromoterFinder™ a new kit available from Clontech (Palo Alto Calif.) uses PCR, nested primers and PromoterFinder libraries to walk in genomic DNA. This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

Another PCR method, "Improved Method for Obtaining Full Length cDNA Sequences" by Guegler et al, patent application Ser. No. 08/487,112, filed Jun. 7, 1995 and hereby incorporated by reference, employs XL-PCR.TM. (Perkin-Elmer) to amplify and/or extend nucleotide sequences.

Preferred libraries for screening for full length cDNAs are ones that have been size-selected to include larger cDNAs. Also, random primed libraries are preferred in that they will contain more sequences which contain the 5' and upstream regions of genes. A randomly primed library may be particularly useful if an oligo d(T) library does not yield a full-length cDNA. Genomic libraries are useful for extension 5' of the promoter binding region.

A newer method for analyzing either the size or confirming the nucleotide sequence of sequencing or PCR products is commonly known as "capillary electrophoresis". Systems for rapid sequencing are available from Perkin Elmer, Beckman Instruments (Fullerton Calif.), and other companies. In general, capillary sequencing employs flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity is converted to electrical signal using appropriate software (eg. Genotyper™ and Sequence Navigator™ from Perkin Elmer) and the entire process from loading of samples to computer analysis and electronic data display is computer controlled. Capillary electrophoresis is particularly suited to the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample. The reproducible sequencing of up to 350 bp

of M13 phage DNA in 30 min has been reported (Ruiz-Martinez M. C. et al (1993) Anal Chem 65:2851-8).

#### Expression of the Nucleotide Sequence:

In accordance with the present invention,  $\alpha_1\text{H}$  SHR polynucleotide sequences which encode  $\alpha_1\text{H}$  SHR, fragments of the polypeptide, fusion proteins or functional equivalents thereof, may be used to generate recombinant DNA molecules that direct the expression of  $\alpha_1\text{H}$  SHR in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence, may be used to clone and express  $\alpha_1\text{H}$  SHR. As will be understood by those of skill in the art, it may be advantageous to produce  $\alpha_1\text{H}$  SHR-encoding nucleotide sequences possessing non-naturally occurring codons. Codons preferred by a particular prokaryotic or eukaryotic host (Murray E. et al (1989) Nuc Acids Res 17:477-508) can be selected, for example, to increase the rate of GPG expression or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, than transcripts produced from naturally occurring sequence.

Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridizing to the nucleotide sequence of SEQ ID NO:1 under conditions of intermediate to maximal stringency. Hybridization conditions are based on the melting temperature ( $T_m$ ) of the nucleic acid binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol 152, Academic Press, San Diego Calif.) incorporated herein by reference, and confer a defined "stringency" as explained below.

"Maximum stringency" typically occurs at about  $T_m - 5^\circ\text{C}$ . ( $5^\circ\text{C}$ . below the  $T_m$  of the probe); "high stringency" at about  $5^\circ\text{C}$ . to  $10^\circ\text{C}$ . below  $T_m$ ; "intermediate stringency" at about  $10^\circ\text{C}$ . to  $20^\circ\text{C}$ . below  $T_m$ ; and "low stringency" at about  $20^\circ\text{C}$ . to  $25^\circ\text{C}$ . below  $T_m$ . As will be understood by those of skill in the art, a maximum stringency hybridization can be used to identify or detect identical polynucleotide sequences while an intermediate (or low) stringency hybridization can be used to identify or detect similar or related polynucleotide sequences. The term "hybridization" as used herein shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" (Coombs J. (1994) Dictionary of Biotechnology, Stockton Press, New York N.Y.) as well as the process of amplification has carried out in polymerase chain reaction technologies as described in Dieffenbach C. W. and G. S. Dveksler (1995, PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview N.Y.) and incorporated herein by reference.

As used herein a "deletion" is defined as a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent. As used herein an "insertion" or "addition" is that change in a nucleotide or amino acid sequence which has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as compared to the naturally occurring  $\alpha 1H$  subunit. As used herein "substitution" results from the replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively.

Altered  $\alpha 1H$  SHR encoding polynucleotide sequences which may be used in accordance with the invention include deletions, insertions or substitutions of different nucleotide residues resulting in a polynucleotide that encodes the same or a functionally/biologically equivalent  $\alpha 1H$  subunit. The protein may also show deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent  $\alpha 1H$  SHR. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity of an  $\alpha 1H$  subunit is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine; glycine, alanine; asparagine, glutamine; serine, threonine, phenylalanine, and tyrosine.

Also included within the scope of the present invention are alleles of the  $\alpha 1H$  subunit. As used herein, an "allele" or "allelic sequence" is an alternative form of an  $\alpha 1H$  subunit, e.g. the  $\alpha 1H$  SHR isoform. Alleles result from a mutation, i.e., a change in the nucleic acid sequence, and generally produce altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given gene may have none, one or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to deletions, additions or substitutions of amino acids. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

The nucleotide sequences of the present invention may be engineered in order to alter a  $\alpha 1H$  SHR coding sequence for a variety of reasons, including but not limited to, alterations, which modify the cloning, processing and/or expression of the gene product. For example, mutations may be introduced using techniques which are well known in the art, eg., site-directed mutagenesis to insert new restriction sites, to alter glycosylation patterns, to change codon preference, etc.

Yet another embodiment of the invention proposes ligating a  $\alpha 1H$  natural, modified or recombinant sequence to a heterologous sequence to encode a fusion protein. For

example, for screening of peptide libraries for inhibitors of  $\alpha_1\text{H}$  activity, it may be useful to encode a chimeric  $\alpha_1\text{H}$  SHR protein expressing a heterologous epitope that is recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between a  $\alpha_1\text{H}$  sequence and the heterologous protein sequence, so that the  $\alpha_1\text{H}$  SHR may be cleaved and purified away from the heterologous moiety.

In an alternate embodiment of the invention, the coding sequence of  $\alpha_1\text{H}$  SHR (SEQ ID NO:1) could be synthesized, whole or in part, using chemical methods well known in the art (see Caruthers M. H. et al (1980) Nuc Acids Res Symp Ser 215-23, Horn T. et al (1980) Nuc Acids Res Symp Ser 225-32, etc). Alternatively, the protein itself could be produced using chemical methods to synthesize a  $\alpha_1\text{H}$  SHR amino acid sequence, whole or in part identical to that embodied in SEQ ID NO:2. For example, peptides can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., Creighton (1983) Proteins Structures And Molecular Principles, W. H. Freeman and Co, New York N.Y.). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (eg, the Edman degradation procedure; Creighton, supra).

Direct peptide synthesis can be performed using various solid-phase techniques (Roberge J. Y. et al (1995) Science 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer. Additionally the amino acid sequence of  $\alpha_1\text{H}$  SHR, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequence(s) from other calcium channel subunits, or any part thereof, to produce a variant polypeptide.

### Expression Systems:

In order to express a biologically active  $\alpha_1\text{H}$  SHR of SEQ ID NO:1 including fragments, and biologically equivalent fragments thereof, the nucleotide sequence coding for  $\alpha_1\text{H}$  SHR, or a functional equivalent, is inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

Conventional methods, e.g., which are well known to those skilled in the art can be used to construct expression vectors containing a  $\alpha_1\text{H}$  SHR coding sequence and appropriate transcriptional or translational controls. These methods include *in vitro* recombinant DNA techniques, synthetic techniques and *in vivo* recombination or genetic recombination. Such techniques are described in Maniatis et al (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview N.Y. and Ausubel F. M. et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York N.Y.

A variety of expression vector/host systems may be utilized to contain and express a  $\alpha_1\text{H}$  SHR coding sequence. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (eg, baculovirus); plant cell systems transfected with virus expression vectors (eg, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with bacterial expression vectors (eg, Ti or pBR322 plasmid); or animal cell systems.

The "control elements" or "regulatory sequences" of these systems vary in their strength and specificities and are those nontranslated regions of the vector, enhancers, promoters, and 3' untranslated regions, which interact with host cellular proteins to carry out transcription and translation. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript.RTM. phagemid (Stratagene, LaJolla Calif.) and ptrp-lac hybrids and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (eg, heat shock, RUBISCO; and storage protein genes) or from plant viruses (eg, viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from the mammalian genes or from mammalian viruses are most appropriate. If it is necessary to generate a cell line that contains multiple copies of  $\alpha_1\text{H}$  SHR, vectors based on SV40 or EBV may be used with an appropriate selectable marker.



In bacterial systems, a number of expression vectors may be selected depending upon the use intended for  $\alpha_1\text{H}$  SHR of SEQ ID NO:2 or variant or fragment thereof (collectively referred to as " $\alpha_1\text{H}$  SHR"). For example, when large quantities of  $\alpha_1\text{H}$  SHR are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be desirable. Such vectors include, but are not limited to, the *E. coli* cloning and expression vector Bluescript.RTM. (Stratagene), in which the  $\alpha_1\text{H}$  SHR coding sequence may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of  $\beta$ -galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke G. & S. M. Schuster (1989) *J Biol Chem* 264:5503-5509); and the like. pGEX vectors (Promega, Madison Wis.) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems are designed to include heparin, thrombin or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the  $\alpha_1\text{H}$  SHR moiety at will.

In the yeast *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH may be used. For a review of the vectors and promoters, see Ausubel et al (supra).

In cases where plant expression vectors are used, the expression of a  $\alpha_1\text{H}$  SHR coding sequence may be driven by any of a number of promoters. For example, viral promoters such as the 35S or 19S promoters of CaMV (Rhodes C. A. et al (1988) *Science* 240:204-207) may be used alone or in combination with the omega leader sequence from TMV (Takamatsu N. et al (1987) *EMBO J* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO (Coruzzi G. et al (1984) *EMBO J* 3:1671-79; Broglie R. et al (1984) *Science* 224:838-43); or heat shock promoters (Winter J. and Sinibaldi R. M. (1991) *Results Probl Cell Differ* 17:85-105) may be used. These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Refer to Hobbs S or Murry L E in McGraw Yearbook of Science and Technology (1992) McGraw Hill New York N.Y., pp 191-196 for reviews of such techniques.

An alternative expression system which could be used to express  $\alpha_1\text{H}$  SHR encoding sequence is an insect system. In one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. The  $\alpha_1\text{H}$  SHR coding sequence may be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of  $\alpha_1\text{H}$  SHR will render the polyhedrin gene inactive

and produce recombinant virus lacking coat protein coat. The recombinant viruses are then used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which  $\alpha_1\text{H}$  SHR is expressed (Smith G. et al (1983) *J Virol* 46:584; Engelhard E. K. et al (1994) *Proc Nat Acad Sci* 91:3224-7).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, a  $\alpha_1\text{H}$  SHR coding sequence may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a nonessential E1 or E3 region of the viral genome will result in a viable virus capable of expressing  $\alpha_1\text{H}$  SHR in infected host cells. (Logan and Shenk (1984) *Proc Natl Acad Sci* 81:3655-59). In addition, transcription enhancers, such as the rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be required for efficient translation of an inserted  $\alpha_1\text{H}$  SHR sequence. These signals include the ATG initiation codon and adjacent sequences. In cases where  $\alpha_1\text{H}$  SHR, its initiation codon and upstream sequences are inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous transcriptional control signals including the ATG initiation codon must be provided. As well, the initiation codon must be in the correct reading frame to ensure transcription of the entire insert. Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate to the cell system in use (Scharf D. et al (1994) *Results Probl Cell Differ* 20:125-62; Bittner M. et al (1987) *Methods in Enzymol* 153:516-544).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be important for correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, 293, WI38, etc have specific cellular machinery and characteristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of the introduced, foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express  $\alpha_1\text{H}$  SHR may be transformed using expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose

of the selectable marker is to confer resistance to selection and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clumps of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler M. et al (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase (Lowy I. et al (1980) *Cell* 22:817-23) genes which can be employed in tk<sup>-</sup> or aprt<sup>-</sup> cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler M. et al (1980) *Proc Natl Acad Sci* 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin F. et al (1981) *J Mol Biol* 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman S. C. and R. C. Mulligan (1988) *Proc Natl Acad Sci* 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins,  $\beta$  glucuronidase and its substrate, GUS, and luciferase and its substrate, luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes C. A. et al (1995) *Methods Mol Biol* 55:121-131).

Thus, an aspect of the invention provides recombinant eukaryotic cells that contain the heterologous DNA encoding the a calcium channel subunit of the invention. These are produced by transfection with DNA encoding one or more of the subunits or are injected with RNA transcripts of DNA encoding one or more of the calcium channel subunits. The DNA may be introduced as a linear DNA fragment or may be included in an expression vector for stable or transient expression of the subunit-encoding DNA. Vectors containing DNA encoding human calcium channel subunits of the invention are also provided.

Eukaryotic cells expressing heterologous calcium channels may be used in assays for calcium channel function or, in the case of cells transformed with fewer subunit-encoding nucleic acids than necessary to constitute a functional recombinant human calcium channel, such cells may be used to assess the effects of additional subunits on calcium channel activity. The additional subunits can be provided by subsequently transfecting such a cell with one or more DNA clones or RNA transcripts encoding human calcium channel subunits.

The recombinant eukaryotic cells that express membrane spanning heterologous calcium channels may be used in methods for identifying compounds that modulate calcium

channel activity. In particular, the cells are used in assays that identify agonists and antagonists of calcium channel activity in humans and/or assessing the contribution of the various calcium channel subunits to the transport and regulation of transport of calcium ions. Because the cells constitute homogeneous populations of calcium channels, they provide a means to identify agonists or antagonists of calcium channel activity that are specific for each such population.

The recombinant cells of the invention may be used to assess T-type channel function and tissue distribution and to identify compounds that modulate the activity of T-type channels. Because T-type channels are operative in neurons in the thalamus, hypothalamus, and brain stem, and may be involved in autonomic nervous functions, in regulation of cardiovascular activities such as heart rate, arterial and venous smooth muscle innervation and tone, pulmonary rate and other fundamental processes, assays designed to assess such activities and assays to identify modulators of these activities provides a means to understand fundamental physiological processes and also a means to identify new drug candidates for an array of disorders.

As such, the recombinant cells of the invention provide a means to obtain homogeneous populations of calcium channels. Typically, the cells contain the selected calcium channel as the only heterologous ion channel expressed by the cell. Preferably, the  $\alpha_1$  of the calcium channel is one of the disclosed subunits of the invention comprising the amino acid sequences as set forth in one of SEQ ID NOS:1, 3 or 5.

These cells of the invention, which have functional, foreign calcium channels (i.e., functional calcium channels wherein at least one of the  $\alpha_1$ -subunit is foreign to the cell) will be useful for, among other purposes, assaying a compound for calcium channel agonist or antagonist activity. First, such a cell can be employed to measure the affinity of such a compound for the functional calcium channel. Secondly, such a cell can be employed to measure electrophysiologically the calcium channel activity in the presence of the compound being tested as well as a ion or molecule, such as  $\text{Ca}^{++}$  or  $\text{Ba}^{++}$ , which is known to be capable of entering the cell through the functional channel. For similar studies which have been carried out with the acetylcholine receptor, see Claudio et al. Science 238 1688-1694 (1987). These methods for assaying a compound for calcium channel agonist or antagonist activity are also contemplated by the present invention.

In another aspect, the recombinant cells of the invention contain heterologous gene(s) (foreign to the cell) with a transcriptional control element, which is active in the cell and responsive to an ion or molecule capable of entering the cell through a functional calcium channel and linked operatively for expression to a structural gene for an indicator protein, can also be employed for assaying a compound for calcium channel agonist or antagonist activity.

The preferred method comprises exposing a culture of such recombinant cells to a solution of a compound being tested for such activity, together with an ion or molecule, which is capable of entering the cells through a functional calcium channel and affecting the activity of the transcriptional control element controlling transcription of the genes for the indicator protein, and comparing the level of expression, in the cells of the culture, of the genes for the indicator protein with the level of such expression in the cells of another, control culture of such cells.

A "control culture," as clearly understood by the skilled, will be a culture that is treated, in substantially the same manner as the culture exposed to the compound being assayed except that the control culture is not exposed to the compound being assayed. Alternatively, control culture may comprise cells expressing a dysfunctional calcium channel. Levels of expression of the genes for the indicator proteins are ascertained readily by the skilled by known methods, which involve measurements of the concentration of indicator protein via assays for detectable compounds produced in reactions catalyzed by the indicator protein.

As indicated above, indicator proteins are enzymes which are active in the cells of the invention and catalyze production of readily detectable compounds (e.g., chromogens, fluorescent compounds).

In another aspect, the invention provides methods for assaying a compound for calcium channel agonist or antagonist activity employing the recombinant cells of the invention, wherein said cells are exposed to a solution of the compound being tested for such activity. For similar methods applied with *Xenopus laevis* oocytes and acetylcholine receptors, see Misham et al., *Nature*, 313, 364 (1985) and, with such oocytes and sodium channels, see Noda et al., *Nature* 322, 826-828 (1986).

#### Identification of Transformants Containing the Polynucleotide Sequence:

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression should be confirmed. For example, if the  $\alpha_1H$  SHR encoding nucleotide sequence is inserted within a marker gene sequence, recombinant cells containing  $\alpha_1H$  SHR encoding sequences can be identified by the absence of marker gene function. In the alternative, a marker gene can be placed in tandem with a  $\alpha_1H$  SHR encoding sequence under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of  $\alpha_1H$  SHR as well.

Alternatively, host cells which contain the coding sequence for  $\alpha_1H$  SHR and express  $\alpha_1H$  SHR (SEQ ID NO:2) may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridization and protein bioassay or immunoassay techniques which include membrane,

solution, or chip based technologies for the detection and/or quantification of the nucleic acid or protein.

The presence of the  $\alpha_1H$  SHR encoding polynucleotide sequence can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes, portions or fragments of the  $\alpha_1H$  SHR nucleotide sequence. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the  $\alpha_1H$  SHR sequence to detect transformants containing  $\alpha_1H$  SHR DNA or RNA. As used herein "oligonucleotides" or "oligomers" refer to a nucleic acid sequence of at least about 10 nucleotides and as many as about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20-25 nucleotides which can be used as a probe or amplimer.

The role of  $\alpha_1H$  SHR in the mobilization of  $Ca^{++}$  as part of the signal transduction pathway can be assayed *in vitro*. It requires preloading calcium channel expressing cells with a fluorescent dye such as FURA-2 or BCECF (Universal Imaging Corp, Westchester Pa.) whose emission characteristics have been altered by  $Ca^{++}$  binding. When the cells are exposed to one or more activating stimuli artificially or physiologically,  $Ca^{++}$  flux takes place. This flux can be observed and quantified by assaying the cells in a fluorometer or fluorescent activated cell sorter. The measurement of  $Ca^{++}$  mobilization in mobilization assays is well known. Briefly, in a calcium mobilization assay, cells expressing the target receptor are loaded with a fluorescent dye that chelates calcium ions, such as FURA-2. Upon addition of a calcium channel modulator to the cells expressing a calcium channel, the target modulator binds to the calcium channel and calcium is released from the intracellular stores. The dye chelates these calcium ions. Spectrophotometric determination of the ratio for dye:calcium complexes to free dye determine the changes in intracellular calcium concentrations upon addition of the target modulator. Hits from screens and other test compounds can be similarly tested in this assay to functionally characterize them as agonists or antagonists. Increases in intracellular calcium concentrations are expected for compounds with agonist activity while compounds with antagonist activity are expected to block target modulator stimulated increases in intracellular calcium concentrations. See U.S. patent Number 6,420,137 and similar patents.

In preferred embodiments, the cells express such heterologous calcium channel subunits and include one or more of the subunits in membrane-spanning heterologous calcium channels. In more preferred embodiments, the eukaryotic cells express functional, heterologous calcium channels that are capable of gating the passage of calcium channel-selective ions and/or binding compounds that, at physiological concentrations, modulate the activity of the heterologous calcium channel. In certain embodiments, the heterologous calcium channels include at least one heterologous calcium channel subunit. In most preferred embodiments, the

calcium channels that are expressed on the surface of the eukaryotic cells are composed substantially or entirely of subunits encoded by the heterologous DNA or RNA. In preferred embodiments, the heterologous calcium channels of such cells are distinguishable from any endogenous calcium channels of the host cell.

A variety of protocols for detecting and measuring the expression of  $\alpha_1\text{H}$  SHR, using either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on  $\alpha_1\text{H}$  SHR is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton R. et al (1990, Serological Methods, a Laboratory Manual, APS Press, St. Paul Minn.) and Maddox D. E. et al (1983, J Exp Med 158:1211).

A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic and amino acid assays. Means for producing labelled hybridization or PCR probes for detecting sequences related to  $\alpha_1\text{H}$  SHR include oligolabelling, nick translation, end-labelling or PCR amplification using a labelled nucleotide. Alternatively, the  $\alpha_1\text{H}$  SHR sequence, or any portion of it, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labelled nucleotides.

A number of companies such as Pharmacia Biotech (Piscataway N.J.), Promega (Madison Wis.), and US Biochemical Corp (Cleveland Ohio) supply commercial kits and protocols for these procedures. Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241. Also, recombinant immunoglobulins may be produced as shown in U.S. Pat. No. 4,816,567 incorporated herein by reference.

#### Purified $\alpha_1\text{H}$ SHR polypeptides:

Host cells transformed with a  $\alpha_1\text{H}$  SHR encoding nucleotide sequence may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The protein produced by a recombinant cell may be secreted or may be contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing  $\alpha_1\text{H}$  SHR can be designed with signal sequences

which direct secretion of  $\alpha_1H$  SHR through a particular prokaryotic or eukaryotic cell membrane. Other recombinant constructions may join  $\alpha_1H$  SHR to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins (Kroll D. J. et al (1993) DNA Cell Biol 12:441-53; see also above discussion of vectors containing fusion proteins).

An  $\alpha_1H$  SHR subunit may also be expressed as a recombinant protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle Wash). The inclusion of a cleavable linker sequences such as Factor XA or enterokinase (Invitrogen, San Diego Calif.) between the purification domain and GPG is useful to facilitate purification.

#### Proposed Uses of the various $\alpha_1H$ subunits of the Invention:

The rationale for diagnostic and potential therapeutic uses of the herein disclosed  $\alpha_1H$  subunit sequences is based on the nucleotide and amino acid sequences, their homology to the human  $\alpha_1H$  protein, their tissue distribution in (Provide details) and the known associations and functions of said proteins. The nucleic acid sequence presented in SEQ ID NO:1, its complement, fragments or oligomers, and anti- $\alpha_1H$  antibodies may be used as diagnostic compositions in assays of cells, tissues or their extracts. Purified  $\alpha_1H$  SHR encoding nucleic acid molecule or polypeptide can be used as the positive controls in their respective nucleic acid or protein based assays for conditions or diseases characterized by the excess expression or aberrant expression or activity of native T-type calcium channel  $\alpha_1H$  subunit. Antisense molecules, antagonists or inhibitors capable of specifically binding the  $\alpha_1H$  encoding nucleic acid molecule or the encoded polypeptide can be used as pharmaceutical compositions for conditions or diseases characterized by the aberrant expression of a T-type  $\alpha_1H$  calcium channel subunit.

Furthermore, calcium influx via low-voltage-gated calcium channels and intracellular calcium signaling plays a role in hormone secretion, cardiac pacing and disorders of the CNS. Thus, it is contemplated that the present invention will find use in investigations regarding the inactivation of low-voltage gated calcium channel subunits such as the  $\alpha_1H$  subunit by any of several means (e.g., in investigations pertaining to such areas as cancer pathogenesis, cardiac arrhythmias etc.)



The prior art is replete with teachings suggesting that the T-type calcium channel  $\alpha_1H$  subunit may be involved in the origin of cancers (e.g., lung cancer, breast cancer, etc). Indeed, interest in the physiological roles of  $Ca^{++}$  channels has increased, due to finding that mutations in these genes can lead to human diseases. In addition to potential role(s) in cardiac and CNS pathogenesis and pathologies involving the circadian rhythm, defects in the auxiliary subunits of  $Ca^{++}$  channels have been described in non-human models of absence epilepsy. These include mouse strains that have lost the expression of the beta auxiliary and the recently discovered gamma subunit. See Letts et al., Nat. Genet., 19:340-347, 1998; and Burgess et al., Cell 88:385-392, 1997. Thus, it is contemplated that the present invention will find use in the development of methods to identify and test for the presence of inherited defects in T-type calcium channel subunits in other species, including humans. It is also contemplated that the present invention will find use in assessing calcium channel defects associated with epileptic and other pathological phenotypes.

#### Clinical applications

In relation to therapeutic treatment of various disease states, the availability of DNA encoding a murine calcium channel subunits permits identification of any alterations in such genes (e.g., mutations) which may correlate with the occurrence of certain disease states. Thus, in one aspect, the herein disclosed sequences may be used as a probe to identify substantially similar genes in other species, preferably human. In addition, the creation of animal models of such disease states becomes possible, by specifically introducing such mutations into synthetic DNA fragments that can then be introduced into laboratory animals or *in vitro* assay systems to determine the effects thereof.

In another broad aspect, genetic screening can be carried out using the nucleotide sequences as probes. Thus, nucleic acid samples from subjects having pathological conditions suspected of involving alteration/modification of any one or more of the calcium channel subunits can be screened with appropriate probes to determine if any abnormalities exist with respect to any of the endogenous calcium channels. Similarly, subjects having a family history of disease states related to calcium channel dysfunction can be screened to determine if they are also predisposed to such disease states.

It is well known that mutations that lead to over expression, e.g., enhanced expression of channels or that reduce inactivation might help tip the balance to overexcitability. Indeed, enhanced expression of T-type channels have been detected in various animal models of for example, epilepsy, cardiac hypertrophy and heart failure. As well, enhanced expression has also been observed in neuronal injury. See Edward Perez-Reyes, Molecular Physiology of Low-

Voltage-Activated T-type Calcium Channels, *Physiol. Rev.*, 83:117-161, 2003, incorporated in its entirety by reference herein. Consequently, the sequences of the invention may be used to probe a biological specimen and identify a variant sequence whose expression may be correlated to a diseased phenotype. For example, antibodies specific for a sequence of the invention may be used to identify a T-type  $\alpha_1H$  calcium channel variant in a biological sample, and the sequence of the so identified variant may thereafter be compared to a reference sequence and mutations, if any identified. The mutated sequence, in turn, may then be used to correlate a disease status with its expression.

The regulation of the T-type calcium channel  $\alpha_1H$  subunit expression provides an opportunity for early intervention in conditions based on aberrant expression or a dysfunctional  $\alpha_1H$  subunit relative to normal.

In an analogous manner, appropriate delivery of vectors expressing antisense sequences, peptide nucleic acids (PNA), or inhibitors of  $\alpha_1H$  subunit can be used to prevent or treat excessive or inadequate calcium mobilization resulting from a dysfunctional  $\alpha_1H$  subunit resulting in damage to neuronal or cardiac tissue. Delivery of these therapies, as noted below, will necessarily be tissue/cell specific and depend on the diagnosis, size and status of the disease/damage.

The regulation of calcium flux or  $\alpha_1H$  subunit expression provides an opportunity to intervene in various disorders involving a dysfunctional T-type calcium channel. Inappropriate activation or aberrant expression or activation of a T-type calcium channel may result in the tissue damage and destruction seen in cardiac or neuronal disease states. For example, transfection of the cardiac cells expressing a dysfunctional T-type calcium channel subunit, for example, with vectors expressing antisense sequences or with liposomes bearing PNAs or inhibitors of human  $\alpha_1H$  subunit can be used to treat or correct a dysfunctional calcium channel and subsequent correction of the underlying disease state resulting from the dysfunctional calcium channel or excessive or inadequate calcium flux.

#### GPG Antibodies:

The prior art is replete with information pertaining to the the production of antibodies. Such information can be used to produce antibodies to the  $\alpha_1H$  subunit of SEQ ID NO:2. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments and fragments produced by a Fab expression library. Neutralizing antibodies, ie, those which inhibit dimer formation, are especially preferred for diagnostics and therapeutics.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, etc may be immunized by injection with the sequence encoded by SEQ ID NO:1 or the encoded protein of SEQ ID NO:2, or any portion, fragment or oligopeptide which retains immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include but are not limited to Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. BCG (bacilli Calmette-Guerin) and *Corynebacterium parvum* are potentially useful human adjuvants.

Monoclonal antibodies to SEQ ID NO:2 or a variant, biologically active fragment or derivative thereof may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Koehler and Milstein (1975 *Nature* 25 256:495-497), the human B-cell hybridoma technique (Kosbor et al (1983) *Immunol Today* 4:72; Cote et al (1983) *Proc Natl Acad Sci* 80:2026-2030) and the EBV-hybridoma technique (Cole et al (1985) *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss Inc, New York N.Y., pp 77-96). As well, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison et al (1984) *Proc Natl Acad Sci* 81:6851-6855; Neuberger et al (1984) *Nature* 312:604-608; Takeda et al (1985) *Nature* 314:452-454). Alternative techniques for the production of single chain antibodies (U.S. Pat. No. 4,946,778) may also be adapted to produce anti- $\alpha_1\text{H}$  SHR (SEQ ID NO:2 ) specific single chain antibodies.

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in Orlandi et al (1989, *Proc Natl Acad Sci* 86: 3833-3837), and Winter G and Milstein C. (1991; *Nature* 349:293-299).

Antibody fragments which contain specific binding sites for an  $\alpha_1\text{H}$  subunit may also be generated. For example, such fragments include, but are not limited to, the  $\text{F(ab')}_2$  fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the  $\text{F(ab')}_2$  fragments. On the other hand, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse W. D. et al (1989) *Science* 256:1275-1281).

$\alpha$ 1H subunit -specific antibodies are useful for the diagnosis of conditions and diseases associated with excessive expression of  $\alpha$ 1H subunit. A variety of protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically propose forming complexes between  $\alpha$ 1H polypeptide and its specific antibody and the measurement of complex formation. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two noninterfering epitopes on a specific  $\alpha$ 1H protein is preferred, but a competitive binding assay may also be employed. These assays are well known to one skilled in the art. See, for example, Maddox D. E. et al (1983, J Exp Med 158:1211).

#### Diagnostic Assays Using $\alpha$ 1H subunit Specific Antibodies of the Invention:

Particular  $\alpha$ 1H subunit-specific antibodies will find use in the diagnosis of conditions or diseases characterized by excessive or inadequate, e.g., aberrant expression of an  $\alpha$ 1H subunit. Diagnostic assays for aberrant  $\alpha$ 1H subunit expression or activity include methods utilizing the antibody and a label to detect  $\alpha$ 1H subunit in a subject's body fluids, cells, tissues or extracts of such tissues. The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, the polypeptides and antibodies will be labeled by joining them, either covalently or noncovalently, with a reporter molecule. A wide variety of reporter molecules are known, several of which were described above.

A variety of protocols for measuring  $\alpha$ 1H subunit expression or activity level using either polyclonal or monoclonal antibodies specific for the respective protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on an  $\alpha$ 1H subunit is preferred, but a competitive binding assay may be employed. These assays are described, among other places, in Maddox, D. E. et al (1983, J Exp Med 158:1211).

To be accurate and in order to provide a basis for the diagnosis of disease, normal or standard values for the respective  $\alpha$ 1H subunit expression or activity level must be established. This is accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with antibody to the respective  $\alpha$ 1H subunit under conditions suitable for complex formation which are well known in the art. The amount of standard complex formation may be quantified by comparing it with a dilution series of positive controls where a known amount of antibody is combined with known concentrations of purified  $\alpha$ 1H subunit. Thereafter, standard values obtained from normal samples may be compared with values obtained from samples from subjects potentially affected by a disorder or disease related

to aberrant  $\alpha_1H$  subunit expression. Deviation between standard and subject values, in turn, establishes the presence of disease state.

#### Uses of the Nucleic Acid Molecule Encoding an $\alpha_1H$ subunit :

A nucleic acid,  $\alpha_1H$  subunit encoding sequence, or any part thereof, may be used for diagnostic and/or therapeutic purposes. For diagnostic purposes, the nucleic acid molecules of the invention, e.g., SEQ ID NO:1 or its variant or fragment thereof, may be used to detect and quantitate gene expression in conditions or diseases characterized or mediated by a dysfunctional T-type calcium channel  $\alpha_1H$  subunit. These specifically include, but are not limited to cardiovascular pathologies such as angina, vascular, such as hypertension, and urologic, hepatic, reproductive, adjunctive therapies for reestablishing normal heart rate and cardiac output following traumatic injury, heart attack and other cardiac injuries; treatments of myocardial infarct (MI), post-MI and in an acute setting, neuronal pathologies of the central nervous system etc. Included in the scope of the invention are oligonucleotide sequences, antisense RNA and DNA molecules, PNAs and ribozymes, which function to inhibit translation of an  $\alpha_1H$  subunit.

Another aspect of the subject invention is to provide for hybridization or PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding  $\alpha_1H$  subunit or closely related molecules. The specificity of the probe, whether it is made from a highly conserved region, eg, 10 unique nucleotides in the 5' regulatory region, or a less conserved region, e.g., between cysteine residues especially in the 3' region, and the stringency of the hybridization or amplification (high, intermediate or low) will determine whether the probe identifies only naturally occurring  $\alpha_1H$  subunit or related sequences. Mutated sequences may also be detected in like manner.

#### Therapeutics

An antisense sequence based on the  $\alpha_1H$  subunit sequence of this application may be useful in the treatment of various conditions or diseases. By introducing antisense sequence into cells, gene therapy can be used to treat conditions or diseases characterized by a dysfunctional T-type calcium channel  $\alpha_1H$  subunit. In such instances, the antisense sequence binds with the complementary DNA strand and either prevents transcription or stops transcript elongation (Hardman J. G. et al. (1996) Goodman and Gilson's The Pharmacological Basis of Therapeutics. McGraw Hill, New York N.Y.).

Expression vectors derived retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of antisense sequences to the targeted cell population. Methods which are well known to those skilled in the art can be used to

construct recombinant vectors which will express the antisense sequence. See, for example, the techniques described in Maniatis et al (supra) and Ausubel et al (supra). Alternatively, antisense molecules such as PNAs can be produced and delivered to target cells or tissues in liposomes.

Alternatively, the full length cDNA sequence and/or its regulatory elements of the  $\alpha_1\text{H}$  subunit, e.g., SEQ ID NO:2 will enable researchers to use  $\alpha_1\text{H}$  subunit as a tool in sense (Yousoufian H. and H. F. Lodish 1993 Mol Cell Biol 13:98-104) or antisense (Eguchi et al (1991) Annu Rev Biochem 60:631-652) investigations or regulation of gene function. Such technology is now well known in the art, and sense or antisense oligomers, or larger fragments, can be designed from various locations along the coding or control regions.

#### Detection and Mapping of Related Polynucleotide Sequences:

The nucleic acid sequences of the invention can also be used to generate hybridization probes for mapping the naturally occurring genomic sequence corresponding to the  $\alpha_1\text{H}$  subunit in other species such as humans. The sequence may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. These include *in situ* hybridization to chromosomal spreads, flow-sorted chromosomal preparations, or artificial chromosome constructions such as YACs, bacterial artificial chromosomes (BACs), bacterial P1 constructions or single chromosome cDNA libraries (reviewed in Price C. M. (1993) Blood Rev 7:127-34 and Trask B. J. (1991) Trends Genet 7:149-54).

*In situ* hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers are invaluable in extending genetic maps. Examples of genetic maps can be found in Science (1995; 270:410f and 1994; 265:1981f). Often the placement of a gene on the chromosome of another mammalian species may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This will provide valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once a disease or syndrome is crudely localized by genetic linkage to a particular genomic region, any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. between normal, carrier or affected individuals.

### Pharmaceutical Compositions:

The present invention comprises pharmaceutical compositions which may comprise antibodies, antagonists, or inhibitors of a  $\alpha 1H$  subunit, alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water.

Antagonists, or inhibitors of  $\alpha 1H$  subunit can be administered to a patient alone, or in combination with other agents, drugs or hormones, in pharmaceutical compositions where it is mixed with excipient(s) or pharmaceutically acceptable carriers. In one embodiment of the present invention, the pharmaceutically acceptable carrier is pharmaceutically inert.

Further details on techniques for formulation and administration may be found in the latest edition of "Remington's Pharmaceutical Sciences" (Mack Publishing Co, Easton Pa.). Although local delivery is desirable, there are other means, for example, oral; parenteral delivery, including intra-arterial (directly to the tumor), intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration.

The examples below are provided to illustrate the subject invention. These examples are provided by way of illustration and are not included for the purpose of limiting the invention.

### EXAMPLE 1

#### Cloning of Rat alpha 1H T-type channels

Sprague-Dawley rat adrenal total RNA was purchased from Clontech. Adrenal glands were dissected from SHR and WKY rats and RNA isolated by Trizol (Invitrogen) extraction method. Complimentary DNA was synthesized and used as template in PCR reactions. Primary and nested PCR reactions used various combinations of the following forward and reverse oligonucleotide primers and amplified either full- or partial length fragments of alpha 1h cDNA:

#### Forward:

GCTCCGaagcttactagtCCCAGTGACAGCGCCGCCGGACTATG  
GCGCCGaagcttactagtCCACGGGGACGCCGCTAGCCACC  
CTAGCCAagcttactagtTGCTGCCCTCCGCCACCATGACCG

AGCGAGaagcttactagtGCCACCATGACCGAGGGCACGCTGG  
 AACAGGaagcttactagtTGTGCGCCACCCTCGCCGCCATCC  
 ACTCTGaagcttactagtGTATCTACCATGCTGACTGCCACGTGGAGGGGC

**Reverse:**

GGCTGCctcgagCCTCTAGGTGCCCCGTTAGGGGTCACTGCCA  
 GGGGTTctcgagCTGCACGGGCTGCTGGTCGATGCCCCAC  
 GCGAATctcgagAGCGGCGAGTGTGTGAATAGTCTGCGTAGTAGGGCC  
 GTCATGctcgagAGACGGGATGTCTGCTGCCTCTCCTGGGAT  
 AGGAATctcgagTCCTTCCCAGGACACAGCCTCTCCTCCTGA

Amplified cDNA fragments were subcloned into either pBluescript or pCR-XL-TOPO plasmids. DNA was prepared from transformed bacteria and sequenced by standard methods. Nucleotide and predicted amino acid sequences were compared to each other and available rat alpha 1H GenBank entries.

Cloned fragments encoding the consensus amino acid sequence were assembled by standard restriction enzyme digestion and ligation. This assembled clone was then transferred to pcDNA3.1 for transient expression in mammalian cells. Functional data is shown in Figure 1 for the SHR channel..

#### SUMMARY OF SEQUENCES

SEQ ID NO:1 Nucleotide sequence of the  $\alpha_1$ H subunit designated herein as  $\alpha_1$ H SHR subunit.

SEQ ID NO:2 Deduced amino acid sequence of the  $\alpha_1$ H SHR subunit

SEQ ID NO:3 Nucleotide sequence of the  $\alpha_1$ H subunit designated herein as  $\alpha_1$ H WKY subunit.

SEQ ID NO:4 Deduced amino acid sequence of the  $\alpha_1$ H WKY subunit.

SEQ ID NO:5 Nucleotide sequence of the  $\alpha_1$ H subunit designated herein as  $\alpha_1$ H S-D subunit.

SEQ ID NO:6 Deduced amino acid sequence of the  $\alpha_1$ H S-D subunit



## WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising a sequence of nucleotides encoding a murine T-type calcium channel  $\alpha_1H$  subunit selected from the group consisting of:
  - (a) a sequence of nucleotides that encodes a murine T-type calcium channel  $\alpha_1H$  subunit and comprises the sequence of nucleotides set forth in one of SEQ ID NOS:1 or 5;
  - (b) a sequence of nucleotides having at least 95% sequence identity or is exactly complementary to the nucleotide sequence set forth in SEQ ID NO:1 or 5, and
  - (c) a nucleotide sequence varying from the nucleotide sequence specified in (a) or (b) as a result of degeneracy of the genetic code.
2. A substantially pure polypeptide comprising an amino acid sequence selected from the group consisting of: (i) an amino acid sequence coded by the isolated nucleic acid molecule of claim 1; (ii) homologues of the amino acid sequences of (i) in which one or more amino acids has been added, deleted, replaced or chemically modified in the region, or adjacent to the region, where the amino acid sequences differs from the original amino acid sequence, coded SEQ ID NOS: 1 or 5.
3. A substantially pure polypeptide comprising an amino acid sequence encoded by the nucleotide sequence as set forth in one of SEQ ID NOS:1 or 5.
4. A substantially pure polypeptide comprising an amino acid sequence as set forth in one of SEQ ID NOS: 2 or 6.
5. An expression vector comprising the nucleic acid molecule of claim 1 operably linked to a regulatory nucleotide sequence that controls expression of the nucleic acid molecule in a suitable host cell.
6. A recombinant host cell transfected by the expression vector of claim 5.
7. A method for detecting the presence of a nucleic acid sequence of  $\alpha_1H$  in a biological sample, comprising the steps of: (a) hybridizing to nucleic acid material in said biological sample the nucleic acid molecule of claim 1 under conditions favoring the formation of a hybridization complex; and (b) detecting said hybridization complex; wherein the presence

of said hybridization complex correlates with the presence of an variant nucleic acid sequence in the said biological sample.

8. A method for determining the level of a nucleic acid sequences of  $\alpha 1H$  subunit or a variant thereof in a biological sample comprising the steps of: (a) hybridizing to nucleic acid material of said biological sample the nucleic acid sequences of claim 1; and (b) determining the amount of hybridization complexes and normalizing said amount to provide the level of the  $\alpha 1H$  subunit or variant thereof encoding nucleic acid sequences in the sample.

9. A method for detecting the level of the polypeptide variant of SEQ ID NO:2 or 6 or a biologically active fragment or variant thereof in a biological sample, comprising the steps of: (a) contacting said biological sample with a detectable antibody having binding specificity for a polypeptide of SEQ ID NO: 2 or 6, thereby forming an antibody-polypeptide complex; and (b) detecting the amount of said antibody-polypeptide complex and normalizing said amount to provide the level of said amino acid sequence in the sample.

10. A method for identifying lead compounds for a pharmacological agent useful in the treatment of disease associated with increased or decreased voltage regulated calcium influx mediated by a rat T-type calcium channel comprising:

(i) providing a cell expressing a rat T-type calcium channel subunit polypeptide designated herein as  $\alpha 1H$ ; said calcium channel subunit comprising the amino acid sequence as set forth in one of SEQ ID NOS: 2, 4 or 6;

(ii) contacting the cell with a candidate pharmacological agent under conditions which, in the absence of the candidate pharmacological agent, to thereby cause a first amount of voltage regulated calcium influx into the cell; and

(iii) determining a test amount of voltage regulated calcium influx as a measure of the effect of the lead compounds for a pharmacological agent on the voltage regulated calcium influx mediated by a human T-type calcium channel, wherein (a) the test amount of voltage regulated calcium influx which is less than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which reduces voltage regulated calcium influx and (b) wherein a test amount of voltage regulated calcium influx which is greater than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which increases voltage regulated calcium influx.

11. The method of claim 10, further comprising loading said cell with a calcium-sensitive dye which is detectable in the presence of calcium, wherein the calcium-sensitive dye is detected as a measure of the voltage regulated calcium influx.

12. A method for identifying compounds which selectively bind a T-type calcium channel  $\alpha_1H$  subunit comprising, (i) providing a test cell preparation, wherein said cell expresses a rat T-type calcium channel  $\alpha_1H$  subunit, (ii) providing a control cell preparation, wherein said cell expresses a rat T-type calcium channel non- $\alpha_1H$  subunit, with the proviso that the cell in the control cell preparation is identical to the test cell except for the expression of a non- $\alpha_1H$  being expressed, (iii) contacting the test cell preparation and the control cell preparation with a compound, and (iv) determining the binding of the compound to the test cell preparation and the control cell preparation, wherein a compound which binds the test cell preparation but does not bind the control cell preparation is a compound which selectively binds the a mammalian T-type calcium channel  $\alpha_1H$  subunit.

13. A diagnostic method for predicting an oncogenic potential of a sample of cells, comprising:

(a) determining, in the sample levels of expression of a target gene sequence as claimed in claim 8 and comparing said sequence with the sequence as set forth in GenBank Accession No. AF290213 to determine mutations in the target sequences or its complement, wherein excessive or insufficient levels of expression of said target sequence relative to normal is predictive of the oncogenic potential of said cells.

14. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is cDNA.

15. A method of producing the recombinant protein according to claim 3 or 4, comprising:

(a) inserting the nucleic acid sequence as set forth in SEQ ID NO: 1, 3 or 5 or a fragment or variant thereof into an expression vector;

(b) transferring the expression vector into a host cell; or transfecting or transforming a host cell with the expression vector of step (a) above;

(c) culturing the host organism under conditions appropriate for amplification of the vector and expression of the protein; and

(d) harvesting the recombinant protein from the culture.

16. A method for identifying compounds that modulate the activity of a T-type calcium channel  $\alpha_1H$  subunit, the method comprising:

comparing the difference in the amount of transcription of a reporter gene in a cell in the presence of the compound with the amount of transcription in the absence of the compound, or with the amount of transcription in the absence of a heterologous T-type calcium channel  $\alpha_1H$  subunit, whereby compounds that modulate the activity of the heterologous calcium channel subunit in the cell are identified, wherein the cell comprises a nucleic acid molecule that encodes a reporter gene construct containing a reporter gene in operative linkage with one or more transcription control elements that is regulated by a calcium channel and furthermore the cell is a eukaryotic cell transfected with a nucleic acid molecule comprising the coding portion of the sequence of nucleotides set forth in one of SEQ ID NO: 1 or 5.

17. A method for identifying a test compound capable of modulating the activity of T-type calcium channel  $\alpha_1H$  subunit, the method comprising :

(i) suspending a eukaryotic cell in a solution containing the compound and a calcium channel selective ion;

(ii) depolarizing the cell membrane of the cell, and

(iii) detecting the current or ions flowing into the cell,

wherein the eukaryotic cell comprises a functional calcium channel that contains at least one subunit encoded by a heterologous nucleic acid comprising the coding portion of the sequence of nucleotides set forth in SEQ ID NOs: 1 or 5, and

wherein the current that is detected is different from that produced by depolarizing the same or a substantially identical cell in the presence of the same calcium channel selective ion but in the absence of the test compound.

18. The method of claim 17, wherein prior to the depolarization step the cell is maintained at a holding potential which substantially inactivates calcium channels that are endogenous to the cell.

19. A method for determining whether a test compound inhibits calcium channel activity in cells, said method comprising:

(a) culturing recombinant cells expressing a functional calcium channel including as a component a functional T-type calcium channel  $\alpha_1H$  subunit under conditions where intracellular calcium concentrations depend on calcium channel activity; and

(b) measuring intracellular calcium concentrations in the cultured recombinant cells in the presence and absence of the test compound to determine whether the intracellular calcium concentration in the recombinant cells in the presence of the test compound is lower than the intracellular calcium concentration in the cells cultured in the absence of the test compound, wherein a test compound which lowers said calcium concentration is considered to be a calcium channel inhibitor.

20. A method as in claim 19, wherein intracellular calcium concentration is measured by observing a change in fluorescence of a calcium sensitive dye which is introduced to the cultured recombinant cells prior to the test compound.

#### ABSTRACT OF THE DISCLOSURE

Disclosed herein are novel nucleic acid molecules encoding murine low-voltage activated calcium channel proteins, designated -  $\alpha 1H$ , encoded proteins, vectors, host cells transformed therewith, as well as pharmaceutical compositions. Methods of using any of the foregoing, e.g., methods for screening for candidate agonists or antagonists utilizing the novel protein isoforms are also disclosed.


**FIGURE 1**

Figure 1. (A) Voltage-clamp protocol used to elicit T-type  $\text{Ca}^{2+}$  Currents. Every 10 sec a successively larger 20 msec depolarization from a holding potential of -110 mV was followed by a 75 msec step to -80 mV during which the exponentially decaying tail current could be observed. (B) Typical whole-cell  $\text{Ca}^{2+}$  currents elicited from the  $\alpha_1\text{H}$  channel cloned from Spontaneously Hypertensive Rat and transiently expressed in HEK293 cells. The electrophysiological bathing solution contained, in mM: 2  $\text{CaCl}_2$ , 140  $\text{NaCl}$ , 4  $\text{KCl}$ , 1.2  $\text{MgCl}_2$ , 20 Glucose, 10 HEPES, pH 7.4 with  $\text{NaOH}$ . The internal (pipette solution) contained, in mM: 140  $\text{CsCl}$ , 5 EGTA, 1  $\text{MgCl}_2$ , 4  $\text{MgATP}$ , 1  $\text{Na}_2\text{GTP}$ , 1  $\text{Na}_2\text{ATP}$ , 10 HEPES, pH 7.4 with  $\text{CsOH}$ .

## SEQUENCE LISTING

<110> Uebele, Victor N.  
Connolly, Thomas M.

<120> NUCLEIC ACID MOLECULES ENCODING NOVEL  
MURINE LOW-VOLTAGE ACTIVATED CALCIUM CHANNEL PROTEINS  
DESIGNATED - alH, ENCODED PROTEINS AND METHODS OF USED  
THEREOF

<130> 21314PV

<140> To Be Assigned

<141> 2004-02-18

<160> 6

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 7426

<212> DNA

<213> Rat

<400> 1

```

ccacgggggac gccgctagcc accggagcga ggtgctgccc tccgccacca tgaccgaggg 60
cacgctggca gccgacgaag tccgggtgcc cctgggcgct tcgccgccgg cccctgcagc 120
gccggtgagg gcttccccag cgagccctgg ggcgccgggg cgcgaggagc agggaggatc 180
cgggtcgggc gtgttggttc ccgagagccc agggaccgag tgtggtgagg acctgggcgc 240
cgacgaggaa cagccgggtcc catacccagc tctggctgcc acagtcttct tctgcctcgg 300
gcaaaccacg cggccgcgca gctggtgcc ccgactgggt tgtaaccctg ggttcgagca 360
catcagcatg ctggtcatca tgcgaactg cgtgacactg ggcatgttca ggccctgtga 420
ggatgttgag tgcgctccg aacgttgca catcttgagg gccttcgacg acttcatctt 480
tgcttcttc gccgtggaga tggatgcaa gatgggtggc ttggggctgt ttgggcaaaa 540
atgtactctg ggtgacacct ggaacaggct ggacttcttc attgtcatgg cgggcatgat 600
ggagtactct ctggacggac acaacgtgag cctctctgcc atccgaaccg tgcgtgtgct 660
gcggcccttc cgcgccatca accgagtccc cagtatgcgg atccctggta ctctgctgct 720
ggacacgctg cccatgcttg ggaatgtcct cctcctctgc ttcttcgtct tcttcatctt 780
cggcattgtt ggggtccagc tctgggctgg cctgcttcgg aaccgatgct tccctggacag 840
cgcttcgtc aggaacaaca acctgacctt ctgcccga tactaccaga cggaggaggg 900
tgaggagaac cctttcatct gctcctcccg ccgtgacaac ggcatgcaga agtgctcgca 960
catccccagc cgcctgtagc ttccagtgca gtgcacactc ggctgggagg cctatgggca 1020
gccacaggct gaggatgggg gtgctggccc caacgcctgt atcaactgga accagtatta 1080
caacgtgtgc cgctcggggg aattcaacct tcacaacggg gccatcaact tcgacaacat 1140
tggctacgct tggattgcca tcttccaggt catcacactg gagggctggg tggacatcat 1200
gtactacgtc atggatgccc actcgttcta caacttcac tacttcatcc tctcatcat 1260
tgtgggctcc ttcttcatga tcaacctgtg cctgggtggg atagccacac agttctcaga 1320
gacaaagcaa agggaaaacc agctgatgag agaacagcgg gcccgctatc tgtccaacga 1380
cagcactctg gccagcttct cagagcccg cagctgctac gaggagctcc tcaagtatgt 1440
aggccacatc ttccggaagg ttaaacgcgg tagcctgcgt ctttatgccc gctggcagag 1500
ccgctggcgt aagaagggtg atcccagcag taccgtgcat ggccaaggcc ctgggcggcg 1560
gccacgacgg gcaggcaggc gtacagcttc agtgacccat ctggtctacc accaccacca 1620
ccacctcac caccattacc acttttagcca cgggtggcca cgcaggccca gccagagcc 1680
agggtgctgg gacaacagg tggtcagggc ctgtgcgcca cctcgcgcgc catccccagg 1740
ccatgggcca ccagactctg agtctgtgca cagtatctac catgctgact gccacgtgga 1800
ggggccgcag gaacgagccc gagtggcaca ctccatagcc actgctgcta gcctcaagct 1860
ggcctcaggt ttgggtacca tgaactaccc caccatccta ccttcaggaa cagtcaacag 1920
caaaggtggc accagctcac gacccaagg gctacagagt gctggcgccc caggggctgc 1980
agtacacagc cctctagacc tgggaagccc cagaccctat gagaagatcc agcatgtggt 2040
gggagaacaa ggactaggcc gagcctctag ccacctgtca ggcttgagtg tgccttgccc 2100
cctgcccagc ccccaggctg gcacgctgac ctgtgagctg aagagctgcc catattgtgc 2160
cagcgccttg gaggacccc agtttgaatt cagtggctca gagagcgggg actcggatgc 2220
ccacggagtc tatgagttta cccaggatgt acggcaggg gattgtcggg accctgtgca 2280

```



gcagcccat	gaagtgggca	caccaggcca	cagcaatgag	cggcggcgga	caccactgcy	2340
gaaggcctca	caaccaggag	ggataggcca	cctctgggca	tccttcagtg	gcaagctacg	2400
tcgcattgta	gacagcaagt	acttcaaccg	aggcatcatg	gcagccatcc	tcgtcaatac	2460
tctgagcatg	ggcgttgagt	atcatgaaca	gcctgaggag	ctgaccaacg	ccctggagat	2520
aagcaacatc	gtgttcacca	gcatgtttgc	cttgagatg	ctactgaagc	tgctggcctg	2580
cggcccatcg	ggatacatcc	ggaaccccta	caacatcttc	gatggcattg	ttgtcgtcat	2640
aagtgtctgg	gagatcgtgg	ggcaggcgga	cgggtggcctg	tctgtgctgc	gcaccttcag	2700
gctgctgcgg	gtgctgaagc	tgggtgcgctt	cctgccggcc	ctgcggcgcc	agctcgtggt	2760
gctcatgagg	accatggaca	acgtggccac	cttctgcatg	ctcctcatgc	tggtcatctt	2820
catcttcagc	atcctgggca	tgcacctgtt	cggctgtaag	ttcagcctga	agacagactc	2880
tggagacacc	gtccctgaca	ggaagaactt	cgactcccta	ctgtgggcca	tcgtcaccgt	2940
gtttcagatc	ttgacacagg	aagactggaa	cgtggttctg	tacaacggca	tggcctccac	3000
ttcgtcctgg	gccgcccttt	actttgtggc	cctcatgacc	tttgggaact	atgtgctctt	3060
caacctgctg	gtagccatcc	tgggtggaagg	tttccaggca	gaggggtgacg	ccaccagatc	3120
tgacaccgac	gaggataaga	cgtctaccca	gctagaggga	gatttcgata	agctcagaga	3180
tcttcgagcc	acagagatga	agatgtattc	actggcagtg	acccctaacg	ggcacctaga	3240
gggcgagggc	agcctgccgc	cgccccctcat	cactcacacg	gcagctacgc	ctatgcctac	3300
tcccaaaaagc	tcccaaaacc	tggacgtggc	ccatgctctc	ctggactctc	ggcgagcag	3360
cagcggctct	gtggaccccc	agctggggga	ccagaagtct	ctggccagcc	tcgcagctc	3420
cccttgcaacc	ccatggggcc	ccaacagcgc	tgggagcagc	aggcgctcca	gttggaaacg	3480
cctggggccgc	gcacccagcc	tcaaacgccg	cagccagtg	ggggagcgcg	agtccttctg	3540
ctctggagag	gggaaggcca	gcaccgatga	cgaggccgag	gacagcagac	caagcacggg	3600
aaccacccca	ggggcctcgc	cagggccccg	agccacgccca	ctgcggcgctg	ccgagtcatt	3660
ggaccacccgc	agcacgctgg	acctgtgtcc	accacggcct	gcggccctcc	tgccgaccaa	3720
gttccatgac	tgcaacgggc	agatggtggc	cctgccacgc	gagttctttc	tgccgcatcga	3780
cagccacaag	gaggatgcag	cggagtttga	tgatgacata	gaggatagct	gctgcttccg	3840
tctacacaaa	gtgctggaac	cctatgcacc	ccagtggctg	cgtagccggg	agtcctgggc	3900
cctgtatctc	ttcccaccgc	agaacaggct	acgcgtctcc	tgccagaaag	tcatcgca	3960
caagatgttt	gaccacgtgg	tccttgtctt	catcttcttc	aactgtatca	ccattgctct	4020
ggagagggcca	gacattgacc	caggcagcac	tgagcgggcc	ttcctcagcg	tctccaacta	4080
catcttcaca	gccatcttcg	tgggtggagat	gatgggtgaag	gtggtagccc	tgggactgct	4140
gtggggtgaa	catgcctacc	tacagagcag	ttggaaatgtg	ctggacgggc	tgcttgcct	4200
ggtatccctg	gttgacatca	tcgtggccat	ggcctcagct	ggcgggtgcca	agatcctagg	4260
cgtcctgcgt	gtgctgcgcc	tgctgcggac	cctgaggcct	ctgagggtca	tcagccgagc	4320
tccaggcctc	aagctggttg	tagagactct	gatatcatcg	ctcaggccca	ttgggaacat	4380
cgtcctcctc	tgtctgcctt	tcctcatcat	ctttgcatc	ctcggggtgc	agcttttcaa	4440
gggcaaatc	tactactgcg	agggcacaga	taccaggaat	atcaccacca	aggccagtg	4500
ccatgctgcc	cactaccgct	gggtgaggcg	caaatacaac	tttgacaacc	tgggtcaggc	4560
gctgatgtct	ctgttcgtgc	tgctcatctaa	ggatggctgg	gtaaacatca	tgtatgacgt	4620
gctggatgcc	gtgggcatcg	accagcagcc	cgtgcagaac	cacaaccctt	ggatgctgct	4680
ctacttcctc	tccttcctgc	tcctctcgag	cttcttcgtg	ctcaacatgt	ttgtgggctg	4740
ggtggtggag	aacttccaca	agtgcgggca	gcaccaggag	gctgaggagg	ctcggcgccg	4800
ggaggagaaa	cggctgcggc	gcctggagag	gaggcgagc	aaggccagc	gccggcccta	4860
ctacgcagac	tattcacaca	ctcgcgcctc	catccattcg	ctgtgcacca	gccactacct	4920
ggacctcttc	atcaccttca	tcactgcctt	accatgtcca	accatgtcca	tggagcacta	4980
caaccagccc	aagtccctgg	atgaggccct	caagtactgc	aactacgtct	ttaccatcgt	5040
cttcgtcttt	gaggctgcac	tgaagctggt	ggcctttggg	ttccggaggt	tcttcaaggga	5100
cagggtggaac	cagctggact	tggccatcgt	cctcctatcc	atcatgggca	ttgcgctgga	5160
ggagattgag	atgaacgccg	ccctgcccct	caatccacc	atcatccgca	tcatgcgtgt	5220
gcttogaatc	gcccgtgtgc	tgaagctact	gaagatggcc	acaggcatgc	gcgccttgct	5280
ggatactgtg	gttcaagctc	tgccctcagg	agggaacctt	ggtcttcttt	tcattgctcct	5340
gttttttatc	tatgctgcc	tgggagtggga	gctgtttggg	aggctagagt	gcagcgagga	5400
taacccctgc	gagggcctga	gcaggcacgc	taccttcacc	aacttcggca	tggccttctc	5460
cacactgttt	cgagtgtcca	ctggggacaa	ctggaatggg	attatgaagg	ataccctccg	5520
tgagtgtacc	cgtgaggaca	agcactgcct	cagctacctg	cccgcgtctt	caccogtcta	5580
cttcgtcacc	ttcgtgctgg	tggctcagtt	cgtgctggtc	aatgtgggtg	tggcctgctc	5640
catgaagcac	ctggaggaga	gcaacaagga	ggcccgcgag	gatgcagaga	tggacgccga	5700
gatcgagctg	gagatggcac	aggggtccac	agcccagccc	ccacctacag	cacaggaaa	5760
ccaaggtacc	cagccaagca	ccccgaacct	cctggctcgtg	cgaaaagtat	ctgtgtccag	5820
gatgctctcg	ctgcccattg	acagctacat	gttcaggccg	gtggctccc	cggctgcccc	5880
acattcccac	ccactgcagg	aagtggagat	ggagacctac	acaggcccgg	tcacctctgc	5940
tcactcgcca	cccctggagc	cccgcgcctc	tttccaggtc	ccatcagccg	cgtcctcccc	6000
agccagggtc	agtgaacccc	tttgtgcctt	ttcaccgccg	ggtacacccc	gctctctgag	6060
tctctcacgg	atactctgca	gacaggaggc	catgcactct	gagtcctggt	aagggaaggt	6120

```

tgatgatgtt ggaggagaca gcatcccaga ctacacagag cctgctgaaa atatgtccac 6180
gagccaggca tcaacagggtg ccccgagggtc ccctccgtgc tccccgcgac ctgccagcgt 6240
ccgtacccgc aagcacacgt ttgggcaacg ctgcatctcc agccgcctc ccaccctggg 6300
aggagatgag gctgaagcag cagacccagc agatgaggag gtcagccaca tcaccagctc 6360
agcccccccc tggccggcta cagagcccca cagccctgag gcctcccca cagcctctcc 6420
tgtgaaaggc acaatgggca gtggggcgga cccacgcagg ttctgcagtg tagatgctca 6480
gagcttcctg gacaaaccag gtggggcaga tgcacaacgg tggtcctcag tggaaactgga 6540
taacggagaa agccacctag agtccgggga agtgaggggc cgggcctcag agctcgaacc 6600
agctcttggg gcacgaagga agaagaagat gagccctccc tgcattctca ttgaacctcc 6660
cactgaggat gagggctctt cccggccccc tgcagccgaa ggaggcaaca ctaccctgag 6720
gcgccgaacc ccattcctgtg aggtctgcct ccatagggac tgcccagagc ctacagaagg 6780
cccaggcacc ggaggggacc ctgtagccaa gggtagcgcg tggggccagg cctcttgccg 6840
agcagagcat ctgactgtcc ccaactttgc ctttgagcct ctggacatgg gcggacctgg 6900
tggagactgt ttcttggaac gtgaccaaag tgtgacccca gaaccagag tttcctcttt 6960
gggggctata gtgcctctga tactagaaac tgaactttct atgccctctg gtgactgcc 7020
agagaaggaa caaggactgt acctcactgt gccccagacc cccttgaaga aaccagggtc 7080
taccacagcc actcctgccc cagatgacag tggagatgag cctgtgtaga tggggctgtg 7140
tgtccacagg gctttggcat tgaggttggt ggctccctgc aggggtgtag ggccatgagt 7200
ggaccctggc ttaggcccca ctaaggcaga gggaccggga gataaccatc ccaggagagg 7260
cagcagacat cccgtctctg caccatgaca caggagcagc ctcgggcccc acgagcctcc 7320
ctcgtggtga ttcagggttg ggttttcctg agttttaacc accaccagaa gctgtaccag 7380
gaccaggtca tcagtctcag gaggagaggc tgtgtcctgg gaagga 7426

```

<210> 2  
 <211> 2359  
 <212> PRT  
 <213> Rat

```

<400> 2
Met Thr Glu Gly Thr Leu Ala Ala Asp Glu Val Arg Val Pro Leu Gly
 1      5      10      15
Ala Ser Pro Pro Ala Pro Ala Ala Pro Val Arg Ala Ser Pro Ala Ser
 20      25      30
Pro Gly Ala Pro Gly Arg Glu Glu Gln Gly Gly Ser Gly Ser Gly Val
 35      40      45
Leu Ala Pro Glu Ser Pro Gly Thr Glu Cys Gly Ala Asp Leu Gly Ala
 50      55      60
Asp Glu Glu Gln Pro Val Pro Tyr Pro Ala Leu Ala Ala Thr Val Phe
 65      70      75      80
Phe Cys Leu Gly Gln Thr Thr Arg Pro Arg Ser Trp Cys Leu Arg Leu
 85      90      95
Val Cys Asn Pro Trp Phe Glu His Ile Ser Met Leu Val Ile Met Leu
100     105     110
Asn Cys Val Thr Leu Gly Met Phe Arg Pro Cys Glu Asp Val Glu Cys
115     120     125
Arg Ser Glu Arg Cys Ser Ile Leu Glu Ala Phe Asp Asp Phe Ile Phe
130     135     140
Ala Phe Phe Ala Val Glu Met Val Ile Lys Met Val Ala Leu Gly Leu
145     150     155     160
Phe Gly Gln Lys Cys Tyr Leu Gly Asp Thr Trp Asn Arg Leu Asp Phe
165     170     175
Phe Ile Val Met Ala Gly Met Met Glu Tyr Ser Leu Asp Gly His Asn
180     185     190
Val Ser Leu Ser Ala Ile Arg Thr Val Arg Val Leu Arg Pro Leu Arg
195     200     205
Ala Ile Asn Arg Val Pro Ser Met Arg Ile Leu Val Thr Leu Leu Leu
210     215     220
Asp Thr Leu Pro Met Leu Gly Asn Val Leu Leu Leu Cys Phe Phe Val
225     230     235     240
Phe Phe Ile Phe Gly Ile Val Gly Val Gln Leu Trp Ala Gly Leu Leu
245     250     255
Arg Asn Arg Cys Phe Leu Asp Ser Ala Phe Val Arg Asn Asn Asn Leu

```



770	775	780
Arg Ile Val Asp Ser Lys Tyr Phe Asn Arg Gly Ile Met Ala Ala Ile		
785	790	800
Leu Val Asn Thr Leu Ser Met Gly Val Glu Tyr His Glu Gln Pro Glu		
805	810	815
Glu Leu Thr Asn Ala Leu Glu Ile Ser Asn Ile Val Phe Thr Ser Met		
820	825	830
Phe Ala Leu Glu Met Leu Leu Lys Leu Leu Ala Cys Gly Pro Leu Gly		
835	840	845
Tyr Ile Arg Asn Pro Tyr Asn Ile Phe Asp Gly Ile Val Val Val Ile		
850	855	860
Ser Val Trp Glu Ile Val Gly Gln Ala Asp Gly Gly Leu Ser Val Leu		
865	870	875
Arg Thr Phe Arg Leu Leu Arg Val Leu Lys Leu Val Arg Phe Leu Pro		
885	890	895
Ala Leu Arg Arg Gln Leu Val Val Leu Met Arg Thr Met Asp Asn Val		
900	905	910
Ala Thr Phe Cys Met Leu Leu Met Leu Phe Ile Phe Ile Phe Ser Ile		
915	920	925
Leu Gly Met His Leu Phe Gly Cys Lys Phe Ser Leu Lys Thr Asp Ser		
930	935	940
Gly Asp Thr Val Pro Asp Arg Lys Asn Phe Asp Ser Leu Leu Trp Ala		
945	950	955
Ile Val Thr Val Phe Gln Ile Leu Thr Gln Glu Asp Trp Asn Val Val		
965	970	975
Leu Tyr Asn Gly Met Ala Ser Thr Ser Ser Trp Ala Ala Leu Tyr Phe		
980	985	990
Val Ala Leu Met Thr Phe Gly Asn Tyr Val Leu Phe Asn Leu Leu Val		
995	1000	1005
Ala Ile Leu Val Glu Gly Phe Gln Ala Glu Gly Asp Ala Thr Arg Ser		
1010	1015	1020
Asp Thr Asp Glu Asp Lys Thr Ser Thr Gln Leu Glu Gly Asp Phe Asp		
1025	1030	1035
Lys Leu Arg Asp Leu Arg Ala Thr Glu Met Lys Met Tyr Ser Leu Ala		
1045	1050	1055
Val Thr Pro Asn Gly His Leu Glu Gly Arg Gly Ser Leu Pro Pro Pro		
1060	1065	1070
Leu Ile Thr His Thr Ala Ala Thr Pro Met Pro Thr Pro Lys Ser Ser		
1075	1080	1085
Pro Asn Leu Asp Val Ala His Ala Leu Leu Asp Ser Arg Arg Ser Ser		
1090	1095	1100
Ser Gly Ser Val Asp Pro Gln Leu Gly Asp Gln Lys Ser Leu Ala Ser		
1105	1110	1115
Leu Arg Ser Ser Pro Cys Thr Pro Trp Gly Pro Asn Ser Ala Gly Ser		
1125	1130	1135
Ser Arg Arg Ser Ser Trp Asn Ser Leu Gly Arg Ala Pro Ser Leu Lys		
1140	1145	1150
Arg Arg Ser Gln Cys Gly Glu Arg Glu Ser Leu Leu Ser Gly Glu Gly		
1155	1160	1165
Lys Gly Ser Thr Asp Asp Glu Ala Glu Asp Ser Arg Pro Ser Thr Gly		
1170	1175	1180
Thr His Pro Gly Ala Ser Pro Gly Pro Arg Ala Thr Pro Leu Arg Arg		
1185	1190	1195
Ala Glu Ser Leu Asp His Arg Ser Thr Leu Asp Leu Cys Pro Pro Arg		
1205	1210	1215
Pro Ala Ala Leu Leu Pro Thr Lys Phe His Asp Cys Asn Gly Gln Met		
1220	1225	1230
Val Ala Leu Pro Ser Glu Phe Phe Leu Arg Ile Asp Ser His Lys Glu		
1235	1240	1245
Asp Ala Ala Glu Phe Asp Asp Asp Ile Glu Asp Ser Cys Cys Phe Arg		
1250	1255	1260
Leu His Lys Val Leu Glu Pro Tyr Ala Pro Gln Trp Cys Arg Ser Arg		
1265	1270	1275
Glu Ser Trp Ala Leu Tyr Leu Phe Pro Pro Gln Asn Arg Leu Arg Val		

				1285					1290				1295
Ser	Cys	Gln	Lys	Val	Ile	Ala	His	Lys	Met	Phe	Asp	His	Val
			1300					1305					1310
Val	Phe	Ile	Phe	Leu	Asn	Cys	Ile	Thr	Ile	Ala	Leu	Glu	Arg
		1315					1320					1325	
Ile	Asp	Pro	Gly	Ser	Thr	Glu	Arg	Ala	Phe	Leu	Ser	Val	Ser
	1330					1335					1340		
Ile	Phe	Thr	Ala	Ile	Phe	Val	Val	Glu	Met	Met	Val	Lys	Val
1345				1350					1355				1360
Leu	Gly	Leu	Leu	Trp	Gly	Glu	His	Ala	Tyr	Leu	Gln	Ser	Ser
			1365					1370					1375
Val	Leu	Asp	Gly	Leu	Leu	Val	Leu	Val	Ser	Leu	Val	Asp	Ile
		1380						1385				1390	
Ala	Met	Ala	Ser	Ala	Gly	Gly	Ala	Lys	Ile	Leu	Gly	Val	Leu
	1395						1400					1405	
Leu	Arg	Leu	Leu	Arg	Thr	Leu	Arg	Pro	Leu	Arg	Val	Ile	Ser
	1410					1415					1420		
Pro	Gly	Leu	Lys	Leu	Val	Val	Glu	Thr	Leu	Ile	Ser	Ser	Leu
1425				1430						1435			1440
Ile	Gly	Asn	Ile	Val	Leu	Ile	Cys	Cys	Ala	Phe	Phe	Ile	Ile
		1445							1450				1455
Ile	Leu	Gly	Val	Gln	Leu	Phe	Lys	Gly	Lys	Phe	Tyr	Tyr	Cys
		1460						1465					1470
Thr	Asp	Thr	Arg	Asn	Ile	Thr	Thr	Lys	Ala	Glu	Cys	His	Ala
	1475						1480					1485	
Tyr	Arg	Trp	Val	Arg	Arg	Lys	Tyr	Asn	Phe	Asp	Asn	Leu	Gly
	1490					1495				1500			
Leu	Met	Ser	Leu	Phe	Val	Leu	Ser	Ser	Lys	Asp	Gly	Trp	Val
1505			1510						1515				1520
Met	Tyr	Asp	Gly	Leu	Asp	Ala	Val	Gly	Ile	Asp	Gln	Gln	Pro
		1525						1530					1535
Asn	His	Asn	Pro	Trp	Met	Leu	Leu	Tyr	Phe	Ile	Ser	Phe	Leu
		1540						1545				1550	
Val	Ser	Phe	Phe	Val	Leu	Asn	Met	Phe	Val	Gly	Val	Val	Val
	1555						1560				1565		
Phe	His	Lys	Cys	Arg	Gln	His	Gln	Glu	Ala	Glu	Glu	Ala	Arg
	1570					1575				1580			
Glu	Glu	Lys	Arg	Leu	Arg	Arg	Leu	Glu	Arg	Arg	Arg	Arg	Lys
1585			1590						1595				1600
Arg	Arg	Pro	Tyr	Tyr	Ala	Asp	Tyr	Ser	His	Thr	Arg	Arg	Ser
		1605						1610					1615
Ser	Leu	Cys	Thr	Ser	His	Tyr	Leu	Asp	Leu	Phe	Ile	Thr	Phe
		1620						1625				1630	
Cys	Leu	Asn	Val	Ile	Thr	Met	Ser	Met	Glu	His	Tyr	Asn	Gln
	1635					1640				1645			1650
Ser	Leu	Asp	Glu	Ala	Leu	Lys	Tyr	Cys	Asn	Tyr	Val	Phe	Thr
	1650					1655				1660			
Phe	Val	Phe	Glu	Ala	Ala	Leu	Lys	Leu	Val	Ala	Phe	Gly	Phe
1665			1670						1675				1680
Phe	Phe	Lys	Asp	Arg	Trp	Asn	Gln	Leu	Asp	Leu	Ala	Ile	Val
		1685						1690					1695
Ser	Ile	Met	Gly	Ile	Ala	Leu	Glu	Glu	Ile	Glu	Met	Asn	Ala
	1700							1705				1710	
Pro	Ile	Asn	Pro	Thr	Ile	Ile	Arg	Ile	Met	Arg	Val	Leu	Arg
	1715						1720				1725		
Arg	Val	Leu	Lys	Leu	Leu	Lys	Met	Ala	Thr	Gly	Met	Arg	Ala
	1730					1735				1740			
Asp	Thr	Val	Val	Gln	Ala	Leu	Pro	Gln	Val	Gly	Asn	Leu	Gly
1745				1750					1755				1760
Phe	Met	Leu	Leu	Phe	Phe	Ile	Tyr	Ala	Ala	Leu	Gly	Val	Glu
		1765						1770					1775
Gly	Arg	Leu	Glu	Cys	Ser	Glu	Asp	Asn	Pro	Cys	Glu	Gly	Leu
		1780						1785				1790	
His	Ala	Thr	Phe	Thr	Asn	Phe	Gly	Met	Ala	Phe	Leu	Thr	Leu

Val	Ser	Thr	Gly	Asp	Asn	Trp	Asn	Gly	Ile	Met	Lys	Asp	Thr	Leu	Arg	
	1810						1815				1820					
Glu	Cys	Thr	Arg	Glu	Asp	Lys	His	Cys	Leu	Ser	Tyr	Leu	Pro	Ala	Leu	
1825					1830					1835					1840	
Ser	Pro	Val	Tyr	Phe	Val	Thr	Phe	Val	Leu	Val	Ala	Gln	Phe	Val	Leu	
				1845					1850					1855		
Val	Asn	Val	Val	Val	Ala	Val	Leu	Met	Lys	His	Leu	Glu	Glu	Ser	Asn	
			1860					1865					1870			
Lys	Glu	Ala	Arg	Glu	Asp	Ala	Glu	Met	Asp	Ala	Glu	Ile	Glu	Leu	Glu	
	1875					1880					1885					
Met	Ala	Gln	Gly	Ser	Thr	Ala	Gln	Pro	Pro	Pro	Thr	Ala	Gln	Glu	Ser	
	1890					1895				1900						
Gln	Gly	Thr	Gln	Pro	Asp	Thr	Pro	Asn	Leu	Leu	Val	Val	Arg	Lys	Val	
1905					1910				1915						1920	
Ser	Val	Ser	Arg	Met	Leu	Ser	Leu	Pro	Asn	Asp	Ser	Tyr	Met	Phe	Arg	
				1925					1930					1935		
Pro	Val	Ala	Pro	Ala	Ala	Ala	Pro	His	Ser	His	Pro	Leu	Gln	Glu	Val	
			1940					1945					1950			
Glu	Met	Glu	Thr	Tyr	Thr	Gly	Pro	Val	Thr	Ser	Ala	His	Ser	Pro	Pro	
	1955					1960					1965					
Leu	Glu	Pro	Arg	Ala	Ser	Phe	Gln	Val	Pro	Ser	Ala	Ala	Ser	Ser	Pro	
	1970					1975					1980					
Ala	Arg	Val	Ser	Asp	Pro	Leu	Cys	Ala	Leu	Ser	Pro	Arg	Gly	Thr	Pro	
1985					1990					1995					2000	
Arg	Ser	Leu	Ser	Leu	Ser	Arg	Ile	Leu	Cys	Arg	Gln	Glu	Ala	Met	His	
				2005					2010					2015		
Ser	Glu	Ser	Leu	Glu	Gly	Lys	Val	Asp	Asp	Val	Gly	Gly	Asp	Ser	Ile	
			2020					2025					2030			
Pro	Asp	Tyr	Thr	Glu	Pro	Ala	Glu	Asn	Met	Ser	Thr	Ser	Gln	Ala	Ser	
	2035						2040					2045				
Thr	Gly	Ala	Pro	Arg	Ser	Pro	Pro	Cys	Ser	Pro	Arg	Pro	Ala	Ser	Val	
	2050					2055					2060					
Arg	Thr	Arg	Lys	His	Thr	Phe	Gly	Gln	Arg	Cys	Ile	Ser	Ser	Arg	Pro	
2065					2070					2075					2080	
Pro	Thr	Leu	Gly	Gly	Asp	Glu	Ala	Glu	Ala	Ala	Asp	Pro	Ala	Asp	Glu	
				2085					2090					2095		
Glu	Val	Ser	His	Ile	Thr	Ser	Ser	Ala	His	Pro	Trp	Pro	Ala	Thr	Glu	
			2100					2105					2110			
Pro	His	Ser	Pro	Glu	Ala	Ser	Pro	Thr	Ala	Ser	Pro	Val	Lys	Gly	Thr	
	2115						2120					2125				
Met	Gly	Ser	Gly	Arg	Asp	Pro	Arg	Arg	Phe	Cys	Ser	Val	Asp	Ala	Gln	

2305                      2310                      2315                      2320  
 Gly Asp Cys Pro Glu Lys Glu Gln Gly Leu Tyr Leu Thr Val Pro Gln  
                                  2325                      2330                      2335  
 Thr Pro Leu Lys Lys Pro Gly Ser Thr Pro Ala Thr Pro Ala Pro Asp  
                                  2340                      2345                      2350  
 Asp Ser Gly Asp Glu Pro Val  
                                  2355

<210> 3  
 <211> 7432  
 <212> DNA  
 <213> Rat

<400> 3  
 ccacggccac ggggacgccg ctagccaccg gagcgagggtg ctgccctccg ccaccatgac 60  
 cgagggcacg ctggcagcgg acgaagtccg ggtgcccttg ggcgttcgc cgcggcccc 120  
 tgcagcgccg gtgagggctt ccccagcgag ccctggggcg cggggcgcg aggagcagg 180  
 aggatccggg tcgggcgtgt tggctcccg gagcccagg accgagtgt gtgcggacct 240  
 gggcgccgac gaggaacagc cggctccata ccagctctg gctgccacag tcttcttctg 300  
 cctcgggcaa accacgcggc cgcgcagctg gtgcctccga ctggtttgta acccgtggt 360  
 cgagcacatc agcatgctgg tcatcatgct gaactgcgtg acactgggca tgttcaggcc 420  
 ctgtgaggat gttgagtgc gctccgaacg ttgcagcatc ttggaggcct tcgacgactt 480  
 catctttgcc ttcttcgccc tggagatggt gatcaagatg gtggcttttg ggctgtttgg 540  
 gcaaaaatgc tacctgggtg acacctggaa caggctggac ttcttcattg tcatggcggg 600  
 catgatggag tactctctgg acggacacaa cgtgagcctc tctgccatcc gaaccgtgcg 660  
 tgtgctgcgg cccctccgcg ccatcaaccg agtcccagt atgcggatcc tggtcactct 720  
 gctgctggac acgctgccc a t gcttgggaa t gctcctcct ctctgcttct tctgttctt 780  
 catcttcggc attgttgggg tccagctctg ggctggcctg cttcggaacc gatgcttct 840  
 ggacagcgcc ttcgtcagga acaacaacct gaccttcttg cggccatact accagacgga 900  
 ggaggggtgag gagaacctt tcatctgctc ctccgcctg gacaacggca tgcagaagt 960  
 ctgcacatc cccagccgccc gtgagcttcg agtgacgtgc acactcggct gggaggccta 1020  
 tgggcagcca caggctgagg atgggggtgc tggccgcaac gcctgtatca actggaacca 1080  
 gtattacaac gtgtgccgt cgggggaatt caacctcac aacggtgcca tcaacttcga 1140  
 caacattggc tacgcttgga ttgccatctt ccaggtcatc acactggagg gctgggtgga 1200  
 catcatgtac tagctcatgg atgccactc gttctacaac ttcactact tcatctct 1260  
 catcattgtg ggctccttct tcatgatcaa cctgtgcctg gtggtgatag ccacacagtt 1320  
 ctgagagaca aagcaaagg gaaaaccagct gatgcgagaa cagcgggcc gctatctgtc 1380  
 caacgacagc actctggcca gcttctcaga gcccggcagc tgctacgagg agctcctcaa 1440  
 gtatgtaggc cacatcttc ggaagggttaa acgccgtagc ctgctcttct atgcccgtg 1500  
 gcagagccgc tggcgtaaag aggtggatcc cagcagtaac gtgcatggcc aaggccctgg 1560  
 gcggcgccca cgacgggcag gcaggcgtac agcttcagtg caccatctgg tctaccacca 1620  
 ccaccaccac catcaccacc attaccactt tagccacggt ggcccacgca ggcccagccc 1680  
 agagccaggt gctggtgaca acaggttggg cagggcctgt gcgccacct cgcgccatc 1740  
 cccaggccat gggccaccag actctgagtc tgtgcacagt atctaccatg ctgactgcca 1800  
 cgtggagggg ccgcaggaac gagcccgagt ggcacactcc atagccactg ctgctagcct 1860  
 caagctggcc tcaggttttg gtaccatgaa ctaccccacc atcctacctt caggaacagt 1920  
 caacagcaaa ggtggcacca gctcacgacc caaggggcta cgaggtgtg gcgccccagg 1980  
 ggctgcagta cacagccctc tgagcctggg aagccccaga ccctatgaga agatccagca 2040  
 tgtggtggga gaacaaggac taggcccagc ctctagccac ctgtcaggcc tgagtgtgct 2100  
 ttgccccctg cccagccccc aggctggcac gctgacctgt gagctgaaga gctgccata 2160  
 ttgtgccagc gccctggagg accccgagtt tgaattcagt ggctcagaga gcggggactc 2220  
 ggatgcccac ggagtctatg agtttaccce ggatgtacgg catggggatt gtcgggacct 2280  
 tgtgacgagc ccccatgaag tgggcacacc aggccacagc aatgagcggc ggcggacacc 2340  
 actgcggaag gcctcacaac caggagggat cccctacact tgggcatcct tcagtgga 2400  
 gctacgtcgc attgtagaca gcaagtactt caaccgaggc atcatggcag ccatacctcgt 2460  
 caatactctg agcatgggcg ttgagtatca tgaacagcct gaggagctga ccaacgcct 2520  
 ggagataaag aacatcgtgt tcaccagcat gtttgccctg gagatgctac tgaagctgtc 2580  
 ggcctgcggc ccactcggat acatccggaa cccctacaac atcttcgatg gcattgttgt 2640  
 cgtcataagt gtctgggaga tcgtggggca ggcggacggt ggctgtctg tctgctgcac 2700  
 cttcaggctg ctgcgggtgc tgaagctggt gcgcttcttg ccggccctgc ggcgccagct 2760  
 cgtggtgtc atgaggacca tggacaacgt ggccaccttc tgcattgtcc tcatgtgt 2820  
 catcttcac ttcagcatcc tgggcatgca cctgttcggc tgtaagtcca gcctgaagac 2880  
 agactctgga gacaccgtcc ctgacaggaa gaacttcgac tccctactgt gggccatcgt 2940

caccgtgttt	cagatcttga	cacaggaaga	ctggaacgtg	gttctgtaca	acggcatggc	3000
ctccacttcc	tcctgggccc	ccctttactt	tgtggccctc	atgacctttg	ggaactatgt	3060
gctcttcaac	ctgctggtag	ccatcctggt	ggaagggttc	caggcagagg	gtgacgccac	3120
cagatctgac	accgacgagg	ataagacgtc	taccagcta	gagggagatt	tcgataagct	3180
cagagatctt	cgagccacag	agatgaagat	gtattcactg	gcagtgaccc	ctaacgggca	3240
cctagagggc	cgaggcagcc	tgcgcgcccc	cctcatcact	cacacggcag	ctacgcctat	3300
gcctactccc	aaaagctccc	caaacctgga	cgtggcccat	gctctcctgg	actctcggcg	3360
cagcagcagc	ggctctgtgg	acccccagct	gggggaccag	aagtctctgg	ccagcctccg	3420
cagctccccc	tgcaccccat	ggggccccaa	cagcgctggg	agcagcaggc	gctccagttg	3480
gaacagcctg	ggccgcgcac	ccagcctcaa	acgcgcgagc	cagtgtgggg	agcgcgagtc	3540
cctgctctct	ggagagggga	agggcagcac	cgatgacgag	gccgaggaca	gcagaccaag	3600
cacgggaacc	cacccagggg	cctcgccagg	gccccgagcc	acgccactgc	ggcgtgccga	3660
gtcattggac	caccgcagca	cgtggacct	gtgtccacca	cggcctgcgg	ccctcctgcc	3720
gaccaagtct	catgactgca	acgggcagat	ggtggccctg	cccagcgagt	tctttctgcg	3780
catcgacagc	cacaaggagg	atgcagcgga	gtttgatgat	gacatagagg	atagctgctg	3840
cttccgtcta	cacaaagtgc	tggaaacctt	tgcacccag	tgggtgccgt	gccgggagtc	3900
ctgggcccct	tatctcttcc	caccgcagaa	caggctacgc	gtctcctgcc	agaaagtcat	3960
cgacacaaag	atgttttgacc	acgtgggtcct	tgtcttcac	ttcctcaact	gtatcaccat	4020
tgtcttgagg	aggccagaca	ttgacccagg	cagcactgag	cgggccttcc	tcagcgtctc	4080
caactacatc	ttcacagcca	tcttcgtggg	ggagatgatg	gtgaagggtg	tagccctggg	4140
actgctgtgg	ggtgaacatg	cctacctaca	gagcagttgg	aatgtgctgg	acgggctgct	4200
tgtcctggta	tccctgggtg	acatcatcgt	ggcctggccc	tcagctggcg	gtgccaagat	4260
cctaggcgtc	ctgcgtgtgc	tgcgcctgct	gcggaccctg	aggcctctga	gggtcatcag	4320
ccgagctcca	ggcctcaagc	tgggtgtaga	gactctgata	tcctcgtcca	ggcccatagg	4380
gaacatcgct	ctcatctgct	gcgccttctt	catcatcttt	ggcatcctcg	gggtgcagct	4440
tttcaagggc	aaattctact	actgcgaggg	cacagatacc	aggaatatca	ccaccaaggc	4500
cgagtgccat	gctgcccact	accgctgggt	gaggcgcaaa	tacaactttg	acaacctggg	4560
tcaggcgctg	atgtctctgt	tctgtctgtc	atctaaggat	ggctgggtaa	acatcatgta	4620
tgacgggctg	gatgccgtgg	gcacgcacca	gcagcccgtg	cagaaccaca	acccctggat	4680
gctgctctac	ttcatctcct	tctgtctcat	cgtcagcttc	ttcgtgctca	acatgtttgt	4740
gggcgtgggt	gtggagaact	tcacaaagt	ccggcagcac	caggaggctg	aggaggctcg	4800
gcgccgggag	gagaaacggc	tgcggcgcc	ggagaggagg	cgcaggaagg	cccagcgccg	4860
gccctactac	gcagactatt	cacacactcg	ccgctccatc	cattcgctgt	gcaccagcca	4920
ctaccctggac	ctcttcatca	ccttcatcat	ctgcctcaat	gtcatcacca	tgtccatgga	4980
gcactacaac	cagcccaagt	ccctggatga	ggccctcaag	tactgcaact	acgtctttac	5040
catcgtcttc	gtctttgagg	ctgcactgaa	gctggtggcc	tttgggttcc	ggaggttctt	5100
caaggacagg	tggaaaccagc	tggacttggc	catcgctcct	ctatccatca	tgggcattgc	5160
gctggaggag	attgagatga	acgcgcgcct	gcccatacat	cccaccatca	tccgcatcat	5220
gcgtgtgctt	cgaatcgccc	gtgtgctgaa	gctactgaag	atggccacag	gcattgcgcg	5280
cttgctggat	actgtgggtc	aaagctctgc	tcaggtaggg	aaccttggtc	ttcttttcat	5340
gctcctgttt	tttatctatg	ctgccctggg	agtggagctg	tttgggaggc	tagagtgcag	5400
cgaggataac	ccctgcgagg	gcctgagcag	gcacgctacc	ttcaccaact	tcggcatggc	5460
cttcctcaca	ctgtttcgag	tgtccactgg	ggacaactgg	aatgggatta	tgaaggatac	5520
cctccgtgag	tgtaccctgg	aggacaagca	ctgcctcagc	tacctgccc	cgctctcacc	5580
cgtctacttc	gtcaccttcc	tgtgtgtggc	tcagttcgtg	ctgggtcaatg	tgggtgggtg	5640
cgtgctcatg	aagcacctgg	aggagagcaa	caaggaggcc	cgcgaggatg	cagagatgga	5700
cgccgagatc	gagctggaga	tggcacaggg	gtccacagcc	cagcccccc	ctacagcaca	5760
ggaaaagccaa	ggtacccagc	cagacacccc	gaacctcctg	gtcgtgcgaa	aagtatctgt	5820
gtccaggatg	ctctcgctgc	ccaatgacag	ctacatgttc	aggccgggtg	ctcccgcggc	5880
tgcccccacat	tcccaccac	tgcaggaaat	ggagatggag	acctacacag	gcccgggtcac	5940
ctctgctcac	tcgccacccc	tggagccccg	ggcctctttc	cagggtcccat	cagccgcgtc	6000
ctcccagacc	agggtcagtg	accccttttg	tgccttttca	ccccggggta	caccccgctc	6060
tctgagctct	tcacggatac	tctgcagaca	ggaggccatg	cactctgagt	ccctgggaagg	6120
gaaggttgat	gatgttggag	gagacagcat	cccagactac	acagagcctg	ctgaaaatat	6180
gtccacgagc	caggtgcccc	cagggtcccc	cgtgtctccc	ccgtgctccc	cgcgacctgc	6240
cagcgtccgt	acccgcaagc	acacgtttgg	gcaacgctgc	atctccagcc	gccctcccac	6300
cctgggagga	gatgaggctg	aagcagcaga	ccaagcagat	gaggaggtca	gccacatcac	6360
cagctcagcc	cacccctggc	cggtacaga	gccccacagc	cctgaggcct	ccccaacagc	6420
ctctcctgtg	aaaggcacaa	tgggcagtgg	cgcggaccca	cgcaggttct	gcagtgtaga	6480
tgctcagagc	ttcctggaca	aaccaggtcg	gccagatgca	caacggtggt	cctcagtgga	6540
actggataac	ggagaaagcc	acctagagtc	cggggaagtg	aggggcccgg	cctcagagct	6600
cgaaccagct	cttggggcac	gaaggaagaa	gaagatgagc	cctccctgca	tctccattga	6660
acctcccat	gaggatgagg	gctcttcccc	gccccctgca	gccgaaggag	gcaacactac	6720
cctgaggcgc	cgaaccccat	cctgtgaggc	tgccttccat	agggactgcc	cagagcctac	6780



```

agaaggccca ggcaccggag gggaccctgt agccaagggg gagcgcctggg gccaggcctc 6840
ttgccgagca gagcatctga ctgtcccca ctttgccttt gagcctctggg acatgggcgg 6900
acctgggtga gactgtttct tggacagtga ccaaagtgtg accccagaac ccagagtctc 6960
ctctttgggg gctatagtgc ctctgatact agaaactgaa ctttctatgc cctctgggtg 7020
ctgcccagag aaggaacaag gactgtacct cactgtgccc cagacccctc tgaagaaacc 7080
agggctctacc ccagccactc ctgccccaga tgacagtggg gatgagcctg tgtagatggg 7140
gctgtgtgtc cacagggctt tggcattgag gttgttggct ccctgcaggg tggtagggcc 7200
atgagtggac cctggcttag gccccactaa ggcagagggg ccgggagata accatcccag 7260
gagaggcagc agacatcccg tctctgcacc atgacacagg agcagcctcg ggccccacga 7320
gcctccctcg tgggtgattca ggtttgggtt ttcctgagtt ttaaccacca ccagaagctg 7380
taccaggacc aggtcatcag tctcaggagg agaggctgtg tcctgggaag ga 7432

```

```

<210> 4
<211> 2359
<212> PRT
<213> Rat

```

```

<400> 4
Met Thr Glu Gly Thr Leu Ala Ala Asp Glu Val Arg Val Pro Leu Gly
1      5      10      15
Ala Ser Pro Pro Ala Pro Ala Ala Pro Val Arg Ala Ser Pro Ala Ser
20      25      30
Pro Gly Ala Pro Gly Arg Glu Glu Gln Gly Gly Ser Gly Ser Gly Val
35      40      45
Leu Ala Pro Glu Ser Pro Gly Thr Glu Cys Gly Ala Asp Leu Gly Ala
50      55      60
Asp Glu Glu Gln Pro Val Pro Tyr Pro Ala Leu Ala Ala Thr Val Phe
65      70      75      80
Phe Cys Leu Gly Gln Thr Thr Arg Pro Arg Ser Trp Cys Leu Arg Leu
85      90      95
Val Cys Asn Pro Trp Phe Glu His Ile Ser Met Leu Val Ile Met Leu
100     105     110
Asn Cys Val Thr Leu Gly Met Phe Arg Pro Cys Glu Asp Val Glu Cys
115     120     125
Arg Ser Glu Arg Cys Ser Ile Leu Glu Ala Phe Asp Asp Phe Ile Phe
130     135     140
Ala Phe Phe Ala Val Glu Met Val Ile Lys Met Val Ala Leu Gly Leu
145     150     155     160
Phe Gly Gln Lys Cys Tyr Leu Gly Asp Thr Trp Asn Arg Leu Asp Phe
165     170     175
Phe Ile Val Met Ala Gly Met Met Glu Tyr Ser Leu Asp Gly His Asn
180     185     190
Val Ser Leu Ser Ala Ile Arg Thr Val Arg Val Leu Arg Pro Leu Arg
195     200     205
Ala Ile Asn Arg Val Pro Ser Met Arg Ile Leu Val Thr Leu Leu Leu
210     215     220
Asp Thr Leu Pro Met Leu Gly Asn Val Leu Leu Cys Phe Phe Val
225     230     235     240
Phe Phe Ile Phe Gly Ile Val Gly Val Gln Leu Trp Ala Gly Leu Leu
245     250     255
Arg Asn Arg Cys Phe Leu Asp Ser Ala Phe Val Arg Asn Asn Asn Leu
260     265     270
Thr Phe Leu Arg Pro Tyr Tyr Gln Thr Glu Glu Gly Glu Glu Asn Pro
275     280     285
Phe Ile Cys Ser Ser Arg Arg Asp Asn Gly Met Gln Lys Cys Ser His
290     295     300
Ile Pro Ser Arg Arg Glu Leu Arg Val Gln Cys Thr Leu Gly Trp Glu
305     310     315     320
Ala Tyr Gly Gln Pro Gln Ala Glu Asp Gly Gly Ala Gly Arg Asn Ala
325     330     335
Cys Ile Asn Trp Asn Gln Tyr Tyr Asn Val Cys Arg Ser Gly Glu Phe
340     345     350

```

Asn	Pro	His	Asn	Gly	Ala	Ile	Asn	Phe	Asp	Asn	Ile	Gly	Tyr	Ala	Trp
		355					360					365			
Ile	Ala	Ile	Phe	Gln	Val	Ile	Thr	Leu	Glu	Gly	Trp	Val	Asp	Ile	Met
	370					375					380				
Tyr	Tyr	Val	Met	Asp	Ala	His	Ser	Phe	Tyr	Asn	Phe	Ile	Tyr	Phe	Ile
385				390						395					400
Leu	Leu	Ile	Ile	Val	Gly	Ser	Phe	Phe	Met	Ile	Asn	Leu	Cys	Leu	Val
				405					410					415	
Val	Ile	Ala	Thr	Gln	Phe	Ser	Glu	Thr	Lys	Gln	Arg	Glu	Asn	Gln	Leu
		420						425					430		
Met	Arg	Glu	Gln	Arg	Ala	Arg	Tyr	Leu	Ser	Asn	Asp	Ser	Thr	Leu	Ala
		435					440					445			
Ser	Phe	Ser	Glu	Pro	Gly	Ser	Cys	Tyr	Glu	Glu	Leu	Leu	Lys	Tyr	Val
	450					455					460				
Gly	His	Ile	Phe	Arg	Lys	Val	Lys	Arg	Arg	Ser	Leu	Arg	Leu	Tyr	Ala
465				470						475					480
Arg	Trp	Gln	Ser	Arg	Trp	Arg	Lys	Lys	Val	Asp	Pro	Ser	Ser	Thr	Val
				485					490					495	
His	Gly	Gln	Gly	Pro	Gly	Arg	Arg	Pro	Arg	Arg	Ala	Gly	Arg	Arg	Thr
		500						505					510		
Ala	Ser	Val	His	His	Leu	Val	Tyr	His	His	His	His	His	His	His	His
		515					520					525			
His	Tyr	His	Phe	Ser	His	Gly	Gly	Pro	Arg	Arg	Pro	Ser	Pro	Glu	Pro
	530					535					540				
Gly	Ala	Gly	Asp	Asn	Arg	Leu	Val	Arg	Ala	Cys	Ala	Pro	Pro	Ser	Pro
545				550						555					560
Pro	Ser	Pro	Gly	His	Gly	Pro	Pro	Asp	Ser	Glu	Ser	Val	His	Ser	Ile
				565					570					575	
Tyr	His	Ala	Asp	Cys	His	Val	Glu	Gly	Pro	Gln	Glu	Arg	Ala	Arg	Val
		580						585					590		
Ala	His	Ser	Ile	Ala	Thr	Ala	Ala	Ser	Leu	Lys	Leu	Ala	Ser	Gly	Leu
		595					600					605			
Gly	Thr	Met	Asn	Tyr	Pro	Thr	Ile	Leu	Pro	Ser	Gly	Thr	Val	Asn	Ser
	610					615					620				
Lys	Gly	Gly	Thr	Ser	Ser	Arg	Pro	Lys	Gly	Leu	Arg	Gly	Ala	Gly	Ala
625				630						635					640
Pro	Gly	Ala	Ala	Val	His	Ser	Pro	Leu	Ser	Leu	Gly	Ser	Pro	Arg	Pro
				645					650					655	
Tyr	Glu	Lys	Ile	Gln	His	Val	Val	Gly	Glu	Gln	Gly	Leu	Gly	Arg	Ala
			660					665				670			
Ser	Ser	His	Leu	Ser	Gly	Leu	Ser	Val	Pro	Cys	Pro	Leu	Pro	Ser	Pro
		675					680					685			
Gln	Ala	Gly	Thr	Leu	Thr	Cys	Glu	Leu	Lys	Ser	Cys	Pro	Tyr	Cys	Ala
	690					695					700				
Ser	Ala	Leu	Glu	Asp	Pro	Glu	Phe	Glu	Phe	Ser	Gly	Ser	Glu	Ser	Gly
705				710						715					720
Asp	Ser	Asp	Ala	His	Gly	Val	Tyr	Glu	Phe	Thr	Gln	Asp	Val	Arg	His
				725					730					735	
Gly	Asp	Cys	Arg	Asp	Pro	Val	Gln	Gln	Pro	His	Glu	Val	Gly	Thr	Pro
			740					745					750		
Gly	His	Ser	Asn	Glu	Arg	Arg	Arg	Thr	Pro	Leu	Arg	Lys	Ala	Ser	Gln
		755					760					765			
Pro	Gly	Gly	Ile	Gly	His	Leu	Trp	Ala	Ser	Phe	Ser	Gly	Lys	Leu	Arg
	770					775					780				
Arg	Ile	Val	Asp	Ser	Lys	Tyr	Phe	Asn	Arg	Gly	Ile	Met	Ala	Ala	Ile
785				790						795					800
Leu	Val	Asn	Thr	Leu	Ser	Met	Gly	Val	Glu	Tyr	His	Glu	Gln	Pro	Glu
			805						810					815	
Glu	Leu	Thr	Asn	Ala	Leu	Glu	Ile	Ser	Asn	Ile	Val	Phe	Thr	Ser	Met
			820					825					830		
Phe	Ala	Leu	Glu	Met	Leu	Leu	Lys	Leu	Leu	Ala	Cys	Gly	Pro	Leu	Gly
	835						840					845			
Tyr	Ile	Arg	Asn	Pro	Tyr	Asn	Ile	Phe	Asp	Gly	Ile	Val	Val	Val	Ile
	850					855					860				

Ser	Val	Trp	Glu	Ile	Val	Gly	Gln	Ala	Asp	Gly	Gly	Leu	Ser	Val	Leu
865					870					875					880
Arg	Thr	Phe	Arg	Leu	Leu	Arg	Val	Leu	Lys	Leu	Val	Arg	Phe	Leu	Pro
				885					890					895	
Ala	Leu	Arg	Arg	Gln	Leu	Val	Val	Leu	Met	Arg	Thr	Met	Asp	Asn	Val
				900					905					910	
Ala	Thr	Phe	Cys	Met	Leu	Leu	Met	Leu	Phe	Ile	Phe	Ile	Phe	Ser	Ile
				915					920					925	
Leu	Gly	Met	His	Leu	Phe	Gly	Cys	Lys	Phe	Ser	Leu	Lys	Thr	Asp	Ser
				930					935					940	
Gly	Asp	Thr	Val	Pro	Asp	Arg	Lys	Asn	Phe	Asp	Ser	Leu	Leu	Trp	Ala
945					950					955					960
Ile	Val	Thr	Val	Phe	Gln	Ile	Leu	Thr	Gln	Glu	Asp	Trp	Asn	Val	Val
				965					970					975	
Leu	Tyr	Asn	Gly	Met	Ala	Ser	Thr	Ser	Ser	Trp	Ala	Ala	Leu	Tyr	Phe
				980					985					990	
Val	Ala	Leu	Met	Thr	Phe	Gly	Asn	Tyr	Val	Leu	Phe	Asn	Leu	Leu	Val
				995					1000					1005	
Ala	Ile	Leu	Val	Glu	Gly	Phe	Gln	Ala	Glu	Gly	Asp	Ala	Thr	Arg	Ser
				1010					1015					1020	
Asp	Thr	Asp	Glu	Asp	Lys	Thr	Ser	Thr	Gln	Leu	Glu	Gly	Asp	Phe	Asp
1025					1030					1035					1040
Lys	Leu	Arg	Asp	Leu	Arg	Ala	Thr	Glu	Met	Lys	Met	Tyr	Ser	Leu	Ala
				1045						1050				1055	
Val	Thr	Pro	Asn	Gly	His	Leu	Glu	Gly	Arg	Gly	Ser	Leu	Pro	Pro	Pro
				1060					1065					1070	
Leu	Ile	Thr	His	Thr	Ala	Ala	Thr	Pro	Met	Pro	Thr	Pro	Lys	Ser	Ser
				1075					1080					1085	
Pro	Asn	Leu	Asp	Val	Ala	His	Ala	Leu	Leu	Asp	Ser	Arg	Arg	Ser	Ser
				1090					1095					1100	
Ser	Gly	Ser	Val	Asp	Pro	Gln	Leu	Gly	Asp	Gln	Lys	Ser	Leu	Ala	Ser
1105					1110					1115					1120
Leu	Arg	Ser	Ser	Pro	Cys	Thr	Pro	Trp	Gly	Pro	Asn	Ser	Ala	Gly	Ser
				1125						1130				1135	
Ser	Arg	Arg	Ser	Ser	Trp	Asn	Ser	Leu	Gly	Arg	Ala	Pro	Ser	Leu	Lys
				1140					1145					1150	
Arg	Arg	Ser	Gln	Cys	Gly	Glu	Arg	Glu	Ser	Leu	Leu	Ser	Gly	Glu	Gly
				1155					1160					1165	
Lys	Gly	Ser	Thr	Asp	Asp	Glu	Ala	Glu	Asp	Ser	Arg	Pro	Ser	Thr	Gly
				1170					1175					1180	
Thr	His	Pro	Gly	Ala	Ser	Pro	Gly	Pro	Arg	Ala	Thr	Pro	Leu	Arg	Arg
1185					1190					1195					1200
Ala	Glu	Ser	Leu	Asp	His	Arg	Ser	Thr	Leu	Asp	Leu	Cys	Pro	Pro	Arg
				1205						1210				1215	
Pro	Ala	Ala	Leu	Leu	Pro	Thr	Lys	Phe	His	Asp	Cys	Asn	Gly	Gln	Met
				1220					1225					1230	
Val	Ala	Leu	Pro	Ser	Glu	Phe	Phe	Leu	Arg	Ile	Asp	Ser	His	Lys	Glu
				1235					1240					1245	
Asp	Ala	Ala	Glu	Phe	Asp	Asp	Asp	Ile	Glu	Asp	Ser	Cys	Cys	Phe	Arg
				1250					1255					1260	
Leu	His	Lys	Val	Leu	Glu	Pro	Tyr	Ala	Pro	Gln	Trp	Cys	Arg	Ser	Arg
1265					1270					1275					1280
Glu	Ser	Trp	Ala	Leu	Tyr	Leu	Phe	Pro	Pro	Gln	Asn	Arg	Leu	Arg	Val
				1285						1290				1295	
Ser	Cys	Gln	Lys	Val	Ile	Ala	His	Lys	Met	Phe	Asp	His	Val	Val	Leu
				1300					1305					1310	
Val	Phe	Ile	Phe	Leu	Asn	Cys	Ile	Thr	Ile	Ala	Leu	Glu	Arg	Pro	Asp
				1315					1320					1325	
Ile	Asp	Pro	Gly	Ser	Thr	Glu	Arg	Ala	Phe	Leu	Ser	Val	Ser	Asn	Tyr
				1330					1335					1340	
Ile	Phe	Thr	Ala	Ile	Phe	Val	Val	Glu	Met	Met	Val	Lys	Val	Val	Ala
1345					1350					1355					1360
Leu	Gly	Leu	Leu	Trp	Gly	Glu	His	Ala	Tyr	Leu	Gln	Ser	Ser	Trp	Asn
				1365					1370					1375	

Val Leu Asp Gly Leu Leu Val Leu Val Ser Leu Val Asp Ile Ile Val  
 1380 1385 1390  
 Ala Met Ala Ser Ala Gly Gly Ala Lys Ile Leu Gly Val Leu Arg Val  
 1395 1400 1405  
 Leu Arg Leu Leu Arg Thr Leu Arg Pro Leu Arg Val Ile Ser Arg Ala  
 1410 1415 1420  
 Pro Gly Leu Lys Leu Val Glu Thr Leu Ile Ser Ser Leu Arg Pro  
 1425 1430 1435 1440  
 Ile Gly Asn Ile Val Leu Ile Cys Cys Ala Phe Phe Ile Ile Phe Gly  
 1445 1450 1455  
 Ile Leu Gly Val Gln Leu Phe Lys Gly Lys Phe Tyr Tyr Cys Glu Gly  
 1460 1465 1470  
 Thr Asp Thr Arg Asn Ile Thr Thr Lys Ala Glu Cys His Ala Ala His  
 1475 1480 1485  
 Tyr Arg Trp Val Arg Arg Lys Tyr Asn Phe Asp Asn Leu Gly Gln Ala  
 1490 1495 1500  
 Leu Met Ser Leu Phe Val Leu Ser Ser Lys Asp Gly Trp Val Asn Ile  
 1505 1510 1515 1520  
 Met Tyr Asp Gly Leu Asp Ala Val Gly Ile Asp Gln Gln Pro Val Gln  
 1525 1530 1535  
 Asn His Asn Pro Trp Met Leu Leu Tyr Phe Ile Ser Phe Leu Leu Ile  
 1540 1545 1550  
 Val Ser Phe Phe Val Leu Asn Met Phe Val Gly Val Val Val Glu Asn  
 1555 1560 1565  
 Phe His Lys Cys Arg Gln His Gln Glu Ala Glu Glu Ala Arg Arg Arg  
 1570 1575 1580  
 Glu Glu Lys Arg Leu Arg Arg Leu Glu Arg Arg Arg Lys Ala Gln  
 1585 1590 1595 1600  
 Arg Arg Pro Tyr Tyr Ala Asp Tyr Ser His Thr Arg Arg Ser Ile His  
 1605 1610 1615  
 Ser Leu Cys Thr Ser His Tyr Leu Asp Leu Phe Ile Thr Phe Ile Ile  
 1620 1625 1630  
 Cys Leu Asn Val Ile Thr Met Ser Met Glu His Tyr Asn Gln Pro Lys  
 1635 1640 1645  
 Ser Leu Asp Glu Ala Leu Lys Tyr Cys Asn Tyr Val Phe Thr Ile Val  
 1650 1655 1660  
 Phe Val Phe Glu Ala Ala Leu Lys Leu Val Ala Phe Gly Phe Arg Arg  
 1665 1670 1675 1680  
 Phe Phe Lys Asp Arg Trp Asn Gln Leu Asp Leu Ala Ile Val Leu Leu  
 1685 1690 1695  
 Ser Ile Met Gly Ile Ala Leu Glu Glu Ile Glu Met Asn Ala Ala Leu  
 1700 1705 1710  
 Pro Ile Asn Pro Thr Ile Ile Arg Ile Met Arg Val Leu Arg Ile Ala  
 1715 1720 1725  
 Arg Val Leu Lys Leu Leu Lys Met Ala Thr Gly Met Arg Ala Leu Leu  
 1730 1735 1740  
 Asp Thr Val Val Gln Ala Leu Pro Gln Val Gly Asn Leu Gly Leu Leu  
 1745 1750 1755 1760  
 Phe Met Leu Leu Phe Phe Ile Tyr Ala Ala Leu Gly Val Glu Leu Phe  
 1765 1770 1775  
 Gly Arg Leu Glu Cys Ser Glu Asp Asn Pro Cys Glu Gly Leu Ser Arg  
 1780 1785 1790  
 His Ala Thr Phe Thr Asn Phe Gly Met Ala Phe Leu Thr Leu Phe Arg  
 1795 1800 1805  
 Val Ser Thr Gly Asp Asn Trp Asn Gly Ile Met Lys Asp Thr Leu Arg  
 1810 1815 1820  
 Glu Cys Thr Arg Glu Asp Lys His Cys Leu Ser Tyr Leu Pro Ala Leu  
 1825 1830 1835 1840  
 Ser Pro Val Tyr Phe Val Thr Phe Val Leu Val Ala Gln Phe Val Leu  
 1845 1850 1855  
 Val Asn Val Val Val Ala Val Leu Met Lys His Leu Glu Glu Ser Asn  
 1860 1865 1870  
 Lys Glu Ala Arg Glu Asp Ala Glu Met Asp Ala Glu Ile Glu Leu Glu  
 1875 1880 1885

Met Ala Gln Gly Ser Thr Ala Gln Pro Pro Pro Thr Ala Gln Glu Ser  
 1890 1895 1900  
 Gln Gly Thr Gln Pro Asp Thr Pro Asn Leu Leu Val Val Arg Lys Val  
 1905 1910 1915 1920  
 Ser Val Ser Arg Met Leu Ser Leu Pro Asn Asp Ser Tyr Met Phe Arg  
 1925 1930 1935  
 Pro Val Ala Pro Ala Ala Ala Pro His Ser His Pro Leu Gln Glu Val  
 1940 1945 1950  
 Glu Met Glu Thr Tyr Thr Gly Pro Val Thr Ser Ala His Ser Pro Pro  
 1955 1960 1965  
 Leu Glu Pro Arg Ala Ser Phe Gln Val Pro Ser Ala Ala Ser Ser Pro  
 1970 1975 1980  
 Ala Arg Val Ser Asp Pro Leu Cys Ala Leu Ser Pro Arg Gly Thr Pro  
 1985 1990 1995 2000  
 Arg Ser Leu Ser Leu Ser Arg Ile Leu Cys Arg Gln Glu Ala Met His  
 2005 2010 2015  
 Ser Glu Ser Leu Glu Gly Lys Val Asp Asp Val Gly Gly Asp Ser Ile  
 2020 2025 2030  
 Pro Asp Tyr Thr Glu Pro Ala Glu Asn Met Ser Thr Ser Gln Ala Ser  
 2035 2040 2045  
 Thr Gly Ala Pro Arg Ser Pro Pro Cys Ser Pro Arg Pro Ala Ser Val  
 2050 2055 2060  
 Arg Thr Arg Lys His Thr Phe Gly Gln Arg Cys Ile Ser Ser Arg Pro  
 2065 2070 2075 2080  
 Pro Thr Leu Gly Gly Asp Glu Ala Glu Ala Ala Asp Pro Ala Asp Glu  
 2085 2090 2095  
 Glu Val Ser His Ile Thr Ser Ser Ala His Pro Trp Pro Ala Thr Glu  
 2100 2105 2110  
 Pro His Ser Pro Glu Ala Ser Pro Thr Ala Ser Pro Val Lys Gly Thr  
 2115 2120 2125  
 Met Gly Ser Gly Arg Asp Pro Arg Arg Phe Cys Ser Val Asp Ala Gln  
 2130 2135 2140  
 Ser Phe Leu Asp Lys Pro Gly Arg Pro Asp Ala Gln Arg Trp Ser Ser  
 2145 2150 2155 2160  
 Val Glu Leu Asp Asn Gly Glu Ser His Leu Glu Ser Gly Glu Val Arg  
 2165 2170 2175  
 Gly Arg Ala Ser Glu Leu Glu Pro Ala Leu Gly Ala Arg Arg Lys Lys  
 2180 2185 2190  
 Lys Met Ser Pro Pro Cys Ile Ser Ile Glu Pro Pro Thr Glu Asp Glu  
 2195 2200 2205  
 Gly Ser Ser Arg Pro Pro Ala Ala Glu Gly Gly Asn Thr Thr Leu Arg  
 2210 2215 2220  
 Arg Arg Thr Pro Ser Cys Glu Ala Ala Leu His Arg Asp Cys Pro Glu  
 2225 2230 2235 2240  
 Pro Thr Glu Gly Pro Gly Thr Gly Gly Asp Pro Val Ala Lys Gly Glu  
 2245 2250 2255  
 Arg Trp Gly Gln Ala Ser Cys Arg Ala Glu His Leu Thr Val Pro Asn  
 2260 2265 2270  
 Phe Ala Phe Glu Pro Leu Asp Met Gly Gly Pro Gly Gly Asp Cys Phe  
 2275 2280 2285  
 Leu Asp Ser Asp Gln Ser Val Thr Pro Glu Pro Arg Val Ser Ser Leu  
 2290 2295 2300  
 Gly Ala Ile Val Pro Leu Ile Leu Glu Thr Glu Leu Ser Met Pro Ser  
 2305 2310 2315 2320  
 Gly Asp Cys Pro Glu Lys Glu Gln Gly Leu Tyr Leu Thr Val Pro Gln  
 2325 2330 2335  
 Thr Pro Leu Lys Lys Pro Gly Ser Thr Pro Ala Thr Pro Ala Pro Asp  
 2340 2345 2350  
 Asp Ser Gly Asp Glu Pro Val  
 2355

&lt;210&gt; 5

&lt;211&gt; 7277

&lt;212&gt; DNA

&lt;213&gt; Rat

&lt;400&gt; 5

```

ccacgggggac gccgctagcc accggagcga ggtgctgccc tccgccacca tgaccgaggg 60
cacgctggca gccgacgaag tccgggtgcc cctgggcgct tcgccgccgg cccctgcagc 120
gccggtgagg gcttccccag cgagccctgg ggccgccggg cgcgaggagc agggaggatc 180
cgggtcgggc gtgttggctc ccgagagccc agggaccgag tgtggtgcgg acctgggcgc 240
cgacgaggaa cagccgggtc catacccagc tctggctgcc acagtcttct tctgcctcgg 300
gcaaaccacg cggccgcgca gctggtgcct ccgactgggt tghtaacctg ggttcgagca 360
catcagcatg ctggtcatca tgctgaactg cgtgacactg ggcatgttca ggccctgtga 420
ggatgttgag tgccgctccg aacgttgca gcatctggag gccttcgacg acttcatctt 480
tgcttcttc gccgtggaga tggatgatcaa gatggtggct ttggggctgt ttgggcaaaa 540
atgctacctg ggtgacacct ggaacaggct ggacttcttc attgtcatgg cgggcatgat 600
ggagtactct ctggacggac acaacgtgag cctctctgcc atccgaaccg tgcgtgtgct 660
gcccggccctc cgcgccatca accgagtcct cagtatgcgg atcctggtea ctctgctgct 720
ggacacgctg cccatgcttg ggaatgtcct cctcctctgc ttcttctgtt tcttcatctt 780
cggcattgtt ggggtccagc tctgggctgg cctgcttcgg aaccgatgct tctggagacg 840
cgcttctgtc aggaacaaca acctgacctt ctgcccga tactaccaga cggaggaggg 900
tgaggagaac cctttcatct gctcctcccg ccgtgacaac ggcatgcaga agtgctcgca 960
catccccagc cgccgtgagc ttcgagtga gtgcacactc ggctgggagg cctatgggca 1020
gccacaggct gaggatgggg gtgctggccg caacgcctgt atcaactgga accagtatta 1080
caacgtgtgc cgctcggggg aattcaacct tcacaacggt gccatcaact tcgacaacat 1140
tggctacgct tggattgcca tcttccaggc catcacactg gagggtcggg tggacatcat 1200
gtactacgtc atggatgccc actcgttcta caacttcatc tacttcatcc tctcatcat 1260
tgtgggctcc ttcttcatga tcaacctgtg cctgggtggg atagccacac agttctcaga 1320
gacaaagcaa agggaaaacc agctgatgcg agaacagcgg gcccgctatc tgtccaacga 1380
cagcactctg gccagcttct cagagcccgg cagctgctac gaggagctcc tcaagtatgt 1440
aggccacatc ttccggaagg taaacgccg tagcctgcgt ctttatgcc gctggcagag 1500
ccgctggcgt aagaagggtg atcccagcag taccgtgcat ggccaaggcc ctgggcggcg 1560
gccacgacgg gcaggcaggc gtacagcttc agtgaccat ctggtctacc accaccacca 1620
ccaccatcac caccattacc actttagcca cggtgcccga cgcaggccca gccagagacc 1680
aggtgctggt gacaacaggt tggtcagggc ctgtgcgcca ccctcgccgc catccccagg 1740
ccatgggcca ccagactctg agtctgtgca cagtatctac catgctgact gccacgtgga 1800
ggggccgcag gaacgagccc gagtggcaca ctccatagcc actgctgcta gcctcaaget 1860
ggcctcaggt ttgggtacca tgaactacc caccatccta ccttcaggaa cagtcaacag 1920
caaaagtggt accagctcac gacccaaggg gctacgaggt gctggcgccc caggggctgc 1980
agtacacagc cctctgagcc tgggaagccc cagaccctat gagaagatcc agcatgtggt 2040
gggagaacaa ggactaggcc gagcctctag ccacctgtca ggcctgagtg tgccctgccc 2100
cctgcccagc ccccaggctg gcacgctgac ctgtgagctg aagagctgcc catattgtgc 2160
cagcgccctg gaggacccc agtttgaatt cagtggctca gagagcgggg actcggatgc 2220
ccacggagtc tatgagttta cccaggatgt acggcatggg gattgtcggg accctgtgca 2280
gcagcccat gaagtgggca caccaggcca cagcaatgag cggcgccgga caccactgcg 2340
gaaggcctca caaccaggag ggataggcca cctctgggca cctctcagtg gcaagctaac 2400
tcgcatgtga gacagcaagt acttcaaccg aggcacatg gcagccatcc tegtcaatcc 2460
tctgagcatg ggcgttgagt atcatgaaca gcctgaggag ctgaccaacg cctggagat 2520
aagcaacatc gtgttcacca gcatgtttgc cttggagatg ctactgaagc tgctggcctg 2580
cggcccactg ggatacatcc ggaaccccta caacatcttc gatggcattg ttgtcgtcat 2640
aagtgtctgg gagatcgtgg ggcaggcaga cgggtggcct tctgtgctgc gcaccttcag 2700
gctgctgcgg gtgctgaagc tgggtgcgct cctgcgggcc ctgcggcgcc agctcgtggt 2760
gctcatgagg accatggaca acgtggccac cttctgcatg ctctcatgc tgttcatctt 2820
catcttcagc atcctgggca tgcacctgtt cggctgtaag ttcagcctga agacagactc 2880
tggagacacc gtccctgaca ggaagaactt cgactcccta ctgtgggcca tcgtcaccgt 2940
gtttcagatc ttgacacagg aagactggaa cgtggttctg tacaacggca tggcctccac 3000
ttcgtcctgg gcgcctttt actttgtggc cctcatgacc tttgggaact atgtgcctct 3060
caacctgctg gtagccatcc tggtggaagg ttccaggga gaggggtgac ccaccagatc 3120
tgacaccgac gaggataaga cgtctaccca gctagaggga gatttcgata agctcagaga 3180
tcttcgagcc acagagatga agatgtatcc actggcagtg acccctaacg ggcacctaga 3240
gggcccaggc agcctgccgc cgccccctat cactcacacg gcagctacgc ctatgcctac 3300
tcccaaaagc tcccaaaac tggacgtggc ccatgctctc ctggactctc ggcgcagcag 3360
cagcggctct gtggaccccc agctggggga ccagaagtct ctggccagcc tccgcagctc 3420
cccttgaccc ccattggggc ccaacagcgc tgggagcagc aggcgtcca gttggaacag 3480
cctgggccgc gcacccagcc tcaaacgccg cagccagtgt ggggagcgcg agtccctgct 3540
ctctggagag ggaaggga gcacccatga cgaggcgag gacagcagac caagcacggg 3600

```

aaccaccca	ggggcctcgc	cagggccccg	agccacgcc	ctgcccgtg	ccgagtcatt	3660
ggaccaccgc	agcacgctgg	acctgtgtcc	accacggcct	gcccgcctcc	tgccgaccaa	3720
gttccatgac	tgcaacgggc	agatggtggc	cctgccagc	gagttctttc	tgccgcatcga	3780
cagccacaag	gaggatgcag	cggagtttga	tgatgacata	gaggatagct	gctgcttccg	3840
tctacacaaa	gtgctggaac	cctatgcacc	ccagtgggtg	cgtagccggg	agtccctggg	3900
cctgtatctc	ttcccaccgc	agaacaggct	acgcgtctcc	tgccagaaaag	tcacgcgaca	3960
caagatgttt	gaccacgtgg	tccttgtctt	catcttcttc	aactgtatca	ccattgctct	4020
ggagaggcca	gacattgacc	caggcagcac	tgagcgggcc	ttcctcagcg	tctccaacta	4080
catcttcaca	gccatcttcg	tggtggagat	gatgggtgaag	gtggtagccc	tgggactgct	4140
gtggggtgaa	catgcctacc	tacagagcag	ttggaatgtg	ctggacgggc	tgcttgctct	4200
ggtatccctg	gttgacatca	tcgtggccat	ggcctcagct	ggcgggtgcca	agatccctagg	4260
cgtcctgcgt	gtgctgcgcg	tgctgcggac	cctgaggcct	ctgaggggtca	tcagccgagc	4320
ttcaggcctc	aagctgggtg	tagagactct	gatatcatcg	ctcaggccca	ttgggaacat	4380
cgtcctcatc	tgctgcgcct	tcttcatcat	ctttggcatc	ctcgggggtg	agcttttcaa	4440
gggcaaattc	tactactgeg	agggcacaga	taccaggaat	atcaccacca	aggccgagtg	4500
ccatgctgcc	cactaccgct	gggtgaggcg	caaatacaac	tttgacaacc	tggttcaggc	4560
gctgatgtct	ctgttcgtgc	tgctcatctaa	ggatggctgg	gtaaacatca	tgatgacgg	4620
gctggatgcc	gtgggcatcg	accagcagcc	cgtgcagaac	cacaaccctc	ggatgctgct	4680
ctacttcate	tccttctctg	tcctcgtcag	cttcttcgtg	ctcaacatgt	ttgtgggctg	4740
gggtggtggag	aacttccaca	agtgcgggca	gcaccaggag	gctgaggagg	ctcggcgccg	4800
ggaggagaaa	cggctgcggc	gcctggagag	gaggcgcagg	aaggcccagc	gccggcccta	4860
ctacgcagac	tattcacaca	ctcgcgcctc	catccattcg	ctgtgcacca	gccactacct	4920
ggacctcttc	atcaccttca	tcattctgct	caatgtcatc	accatgtcca	tgagactacta	4980
caaccagccc	aagtcctctg	atgaggccct	caagtactgc	aactacgtct	ttaccatcgt	5040
cttcgtcttt	gaggctgcac	tgaagctggt	ggcctttggg	ttccggaggt	tcttcaagga	5100
caggtggaac	catctggact	tgggccatcgt	cctcctatcc	atcatgggca	ttgcgctgga	5160
ggagattgag	atgaacgcgc	ccctgcccac	caatcccacc	atcatccgca	tcatgcgtgt	5220
gcttcgaatc	gcccgtgtgc	tgaagctact	gaagatggcc	acaggcatgc	gcgccttgct	5280
ggatactgtg	gttcaagctc	tgccctcagg	agggaaacct	gggtcttctt	tcattgctcct	5340
gtttttttatc	tatgctgccc	tgggagtgga	gctgtttggg	aggctagagt	gcagcgagga	5400
taaccctctg	gagggcctga	gcaggcacgc	taccttcacc	aacttcggca	tgcccttctc	5460
cacactgttc	cgagtgtcca	ctggggacaa	ctggaatggg	attatgaagg	ataccctccg	5520
tgagtgtacc	cgtgaggaca	agcactgcct	cagctacctg	cccgcgctct	caccctctca	5580
cttcgtcacc	ttcgtgctgg	tggtctcagtt	cgtgctggte	aatgtgggtg	tgccctgctc	5640
catgaagcac	ctggaggaga	gcaacaagga	ggcccgcgag	gatgcagaga	tggaacgcca	5700
gatcgagctg	gagatggcac	aggggtccac	agcccagccc	ccacctacag	cacaggaaag	5760
ccaaggtacc	cagccagaca	ccccgaacct	cctggctcgt	cgaaaagtat	ctgtgtccag	5820
gatgctctcg	ctgcccaatg	acagctacat	gttcaggccg	gtggctcccg	cggctgcccc	5880
acattcccac	ccactgcagg	aagtggagat	ggagacctac	acaggcccgg	tcacctctgc	5940
tcactcgcca	cccctggagc	cccgcgcctc	tttccaggte	ccatcagccg	cgtcctcccc	6000
agccagggtc	agtgcacccc	tttgtgcccc	ttcaccccgg	ggtacacccc	gctctctgag	6060
tctctcacgg	atactctgca	gacaggaggc	catgcactct	gagtcctctg	aaggggaagg	6120
tgatgatgtt	ggaggagaca	gcattcccaga	ctacacagag	cctgctgaaa	atatgtccac	6180
gagccaggca	tcaacagggt	ccccgagggt	ccctccgtgc	tccccgcgac	ctgccagcgt	6240
cgtaccgcgc	aagcacacgt	ttgggcaacg	ctgcatctcc	agccgccttc	ccacctctgg	6300
aggagatgag	gctgaagcag	cagaccccag	agatgaggag	gtcagccaca	tcaccagctc	6360
agcccacccc	tgcccggtca	cagagcccca	cagccctgag	gcctccccaa	cagcctctcc	6420
tgtgaaaggc	acaatgggca	gtggggcgga	cccacgcagg	ttctgcaagt	tagatgctca	6480
gagcttctctg	gacaaaccag	gtcggccaga	tgcaaacagg	tggtcctcag	tggaactgga	6540
taacggagaa	agccacctag	agtccgggga	agtgaagggc	cgggcctcag	agctcgaacc	6600
agctcttggg	tcacgaagga	agaagaagat	gagccctccc	tgcatctcca	ttgaacctcc	6660
cactgaggat	gagggtctct	cccggccccc	tgacagcgaa	ggaggcaaca	ctacctgag	6720
gcgcggaacc	ccatcctgtg	aggctgcccc	ccatagggac	tgcccagagc	ctacagaagg	6780
cccaggcacc	ggaggggacc	ctgtagccaa	gggtgagcgc	tggggcccagg	cctcttgccg	6840
agcagagcat	ctgactgtcc	ccaactttgc	ctttgagcct	ctggacatgg	gcgggacctg	6900
tggagactgt	ttcttggaca	gtgaccaaag	tgtgacccca	gaacccagag	tttctctctt	6960
gggggctata	gtgcctctga	tactagaaac	tgaactttct	atgcctctct	gtgactgccc	7020
agagaaggaa	caaggactgt	acctcactgt	gccccagacc	cccttgaaga	aaccagggtc	7080
taccccagcc	actcctgccc	cagatgcagc	tggagatgag	cctgtgtaga	tggggctgcg	7140
tgctccacag	ctcttggcat	tgaggttggt	ggctccctgc	aggggtggtg	ggccatgagt	7200
ggaccctggc	ttaggcccca	ctaaggcaga	gggaccggga	gataaccatc	ccaggagagg	7260
cagcagacat	cccgtct					7277

<210> 6  
 <211> 2359  
 <212> PRT  
 <213> Rat

<400> 6  
 Met Thr Glu Gly Thr Leu Ala Ala Asp Glu Val Arg Val Pro Leu Gly  
 1 5 10 15  
 Ala Ser Pro Pro Ala Pro Ala Ala Pro Val Arg Ala Ser Pro Ala Ser  
 20 25 30  
 Pro Gly Ala Pro Gly Arg Glu Glu Gln Gly Gly Ser Gly Val  
 35 40 45  
 Leu Ala Pro Glu Ser Pro Gly Thr Glu Cys Gly Ala Asp Leu Gly Ala  
 50 55 60  
 Asp Glu Glu Gln Pro Val Pro Tyr Pro Ala Leu Ala Ala Thr Val Phe  
 65 70 75 80  
 Phe Cys Leu Gly Gln Thr Thr Arg Pro Arg Ser Trp Cys Leu Arg Leu  
 85 90 95  
 Val Cys Asn Pro Trp Phe Glu His Ile Ser Met Leu Val Ile Met Leu  
 100 105 110  
 Asn Cys Val Thr Leu Gly Met Phe Arg Pro Cys Glu Asp Val Glu Cys  
 115 120 125  
 Arg Ser Glu Arg Cys Ser Ile Leu Glu Ala Phe Asp Asp Phe Ile Phe  
 130 135 140  
 Ala Phe Phe Ala Val Glu Met Val Ile Lys Met Val Ala Leu Gly Leu  
 145 150 155 160  
 Phe Gly Gln Lys Cys Tyr Leu Gly Asp Thr Trp Asn Arg Leu Asp Phe  
 165 170 175  
 Phe Ile Val Met Ala Gly Met Met Glu Tyr Ser Leu Asp Gly His Asn  
 180 185 190  
 Val Ser Leu Ser Ala Ile Arg Thr Val Arg Val Leu Arg Pro Leu Arg  
 195 200 205  
 Ala Ile Asn Arg Val Pro Ser Met Arg Ile Leu Val Thr Leu Leu Leu  
 210 215 220  
 Asp Thr Leu Pro Met Leu Gly Asn Val Leu Leu Leu Cys Phe Phe Val  
 225 230 235 240  
 Phe Phe Ile Phe Gly Ile Val Gly Val Gln Leu Trp Ala Gly Leu Leu  
 245 250 255  
 Arg Asn Arg Cys Phe Leu Asp Ser Ala Phe Val Arg Asn Asn Asn Leu  
 260 265 270  
 Thr Phe Leu Arg Pro Tyr Tyr Gln Thr Glu Glu Gly Glu Glu Asn Pro  
 275 280 285  
 Phe Ile Cys Ser Ser Arg Arg Asp Asn Gly Met Gln Lys Cys Ser His  
 290 295 300  
 Ile Pro Ser Arg Arg Glu Leu Arg Val Gln Cys Thr Leu Gly Trp Glu  
 305 310 315 320  
 Ala Tyr Gly Gln Pro Gln Ala Glu Asp Gly Gly Ala Gly Arg Asn Ala  
 325 330 335  
 Cys Ile Asn Trp Asn Gln Tyr Tyr Asn Val Cys Arg Ser Gly Glu Phe  
 340 345 350  
 Asn Pro His Asn Gly Ala Ile Asn Phe Asp Asn Ile Gly Tyr Ala Trp  
 355 360 365  
 Ile Ala Ile Phe Gln Val Ile Thr Leu Glu Gly Trp Val Asp Ile Met  
 370 375 380  
 Tyr Tyr Val Met Asp Ala His Ser Phe Tyr Asn Phe Ile Tyr Phe Ile  
 385 390 395 400  
 Leu Leu Ile Ile Val Gly Ser Phe Phe Met Ile Asn Leu Cys Leu Val  
 405 410 415  
 Val Ile Ala Thr Gln Phe Ser Glu Thr Lys Gln Arg Glu Asn Gln Leu  
 420 425 430  
 Met Arg Glu Gln Arg Ala Arg Tyr Leu Ser Asn Asp Ser Thr Leu Ala  
 435 440 445  
 Ser Phe Ser Glu Pro Gly Ser Cys Tyr Glu Glu Leu Leu Lys Tyr Val



450	455	460
Gly His Ile Phe Arg	Lys Val Lys Arg Arg	Ser Leu Arg Leu Tyr Ala
465	470	475
Arg Trp Gln Ser Arg	Trp Arg Lys Lys Val	Asp Pro Ser Ser Thr Val
	485	490
His Gly Gln Gly Pro	Gly Arg Arg Pro Arg	Arg Ala Gly Arg Arg Thr
	500	505
Ala Ser Val His His	Leu Val Tyr His His	His His His His His
	515	520
His Tyr His Phe Ser	His Gly Gly Pro Arg	Arg Pro Ser Pro Glu Pro
	530	535
Gly Ala Gly Asp Asn	Arg Leu Val Arg Ala	Cys Ala Pro Pro Ser Pro
545	550	555
Pro Ser Pro Gly His	Gly Pro Pro Asp Ser	Glu Ser Val His Ser Ile
	565	570
Tyr His Ala Asp Cys	His Val Glu Gly Pro	Gln Glu Arg Ala Arg Val
	580	585
Ala His Ser Ile Ala	Thr Ala Ala Ser	Leu Lys Leu Ala Ser Gly Leu
	595	600
Gly Thr Met Asn Tyr	Pro Thr Ile Leu Pro	Ser Gly Thr Val Asn Ser
	610	615
Lys Gly Gly Thr Ser	Ser Arg Pro Lys Gly	Leu Arg Gly Ala Gly Ala
625	630	635
Pro Gly Ala Ala Val	His Ser Pro Leu Ser	Leu Gly Ser Pro Arg Pro
	645	650
Tyr Glu Lys Ile Gln	His Val Val Gly Glu	Gln Gly Leu Gly Arg Ala
	660	665
Ser Ser His Leu Ser	Gly Leu Ser Val Pro	Cys Pro Leu Pro Ser Pro
	675	680
Gln Ala Gly Thr Leu	Thr Cys Glu Leu Lys	Ser Cys Pro Tyr Cys Ala
	690	695
Ser Ala Leu Glu Asp	Pro Glu Phe Glu Phe	Ser Gly Ser Glu Ser Gly
705	710	715
Asp Ser Asp Ala His	Gly Val Tyr Glu Phe	Thr Gln Asp Val Arg His
	725	730
Gly Asp Cys Arg Asp	Pro Val Gln Gln Pro	His Glu Val Gly Thr Pro
	740	745
Gly His Ser Asn Glu	Arg Arg Arg Thr Pro	Leu Arg Lys Ala Ser Gln
	755	760
Pro Gly Gly Ile Gly	His Leu Trp Ala Ser	Phe Ser Gly Lys Leu Arg
	770	775
Arg Ile Val Asp Ser	Lys Tyr Phe Asn Arg	Gly Ile Met Ala Ala Ile
785	790	795
Leu Val Asn Thr Leu	Ser Met Gly Val Glu	Tyr His Glu Gln Pro Glu
	805	810
Glu Leu Thr Asn Ala	Leu Glu Ile Ser Asn	Ile Val Phe Thr Ser Met
	820	825
Phe Ala Leu Glu Met	Leu Leu Lys Leu Leu	Ala Cys Gly Pro Leu Gly
	835	840
Tyr Ile Arg Asn Pro	Tyr Asn Ile Phe Asp	Gly Ile Val Val Val Ile
	850	855
Ser Val Trp Glu Ile	Val Gly Gln Ala Asp	Gly Gly Leu Ser Val Leu
865	870	875
Arg Thr Phe Arg Leu	Leu Arg Val Leu Lys	Leu Val Arg Phe Leu Pro
	885	890
Ala Leu Arg Arg Gln	Leu Val Val Leu Met	Arg Thr Met Asp Asn Val
	900	905
Ala Thr Phe Cys Met	Leu Leu Met Leu Phe	Ile Phe Ile Phe Ser Ile
	915	920
Leu Gly Met His Leu	Phe Gly Cys Lys Phe	Ser Leu Lys Thr Asp Ser
	930	935
Gly Asp Thr Val Pro	Asp Arg Lys Asn Phe	Asp Ser Leu Leu Trp Ala
945	950	955
Ile Val Thr Val Phe	Gln Ile Leu Thr Gln	Glu Asp Trp Asn Val Val

- 19 -

			1475					1480					1485			
Tyr	Arg	Trp	Val	Arg	Arg	Lys	Tyr	Asn	Phe	Asp	Asn	Leu	Gly	Gln	Ala	
	1490					1495					1500					
Leu	Met	Ser	Leu	Phe	Val	Leu	Ser	Ser	Lys	Asp	Gly	Trp	Val	Asn	Ile	
1505					1510					1515					1520	
Met	Tyr	Asp	Gly	Leu	Asp	Ala	Val	Gly	Ile	Asp	Gln	Gln	Pro	Val	Gln	
			1525					1530						1535		
Asn	His	Asn	Pro	Trp	Met	Leu	Leu	Tyr	Phe	Ile	Ser	Phe	Leu	Leu	Ile	
			1540					1545					1550			
Val	Ser	Phe	Phe	Val	Leu	Asn	Met	Phe	Val	Gly	Val	Val	Val	Glu	Asn	
		1555					1560					1565				
Phe	His	Lys	Cys	Arg	Gln	His	Gln	Glu	Ala	Glu	Glu	Ala	Arg	Arg	Arg	
	1570					1575					1580					
Glu	Glu	Lys	Arg	Leu	Arg	Arg	Leu	Glu	Arg	Arg	Arg	Arg	Lys	Ala	Gln	
1585					1590					1595					1600	
Arg	Arg	Pro	Tyr	Tyr	Ala	Asp	Tyr	Ser	His	Thr	Arg	Arg	Ser	Ile	His	
			1605					1610						1615		
Ser	Leu	Cys	Thr	Ser	His	Tyr	Leu	Asp	Leu	Phe	Ile	Thr	Phe	Ile	Ile	
			1620					1625					1630			
Cys	Leu	Asn	Val	Ile	Thr	Met	Ser	Met	Glu	His	Tyr	Asn	Gln	Pro	Lys	
		1635					1640				1645					
Ser	Leu	Asp	Glu	Ala	Leu	Lys	Tyr	Cys	Asn	Tyr	Val	Phe	Thr	Ile	Val	
	1650					1655					1660					
Phe	Val	Phe	Glu	Ala	Ala	Leu	Lys	Leu	Val	Ala	Phe	Gly	Phe	Arg	Arg	
1665				1670						1675					1680	
Phe	Phe	Lys	Asp	Arg	Trp	Asn	Gln	Leu	Asp	Leu	Ala	Ile	Val	Leu	Leu	
			1685					1690					1695			
Ser	Ile	Met	Gly	Ile	Ala	Leu	Glu	Glu	Ile	Glu	Met	Asn	Ala	Ala	Leu	
		1700						1705					1710			
Pro	Ile	Asn	Pro	Thr	Ile	Ile	Arg	Ile	Met	Arg	Val	Leu	Arg	Ile	Ala	
	1715						1720					1725				
Arg	Val	Leu	Lys	Leu	Leu	Lys	Met	Ala	Thr	Gly	Met	Arg	Ala	Leu	Leu	
	1730				1735						1740					
Asp	Thr	Val	Val	Gln	Ala	Leu	Pro	Gln	Val	Gly	Asn	Leu	Gly	Leu	Leu	
1745				1750						1755					1760	
Phe	Met	Leu	Leu	Phe	Phe	Ile	Tyr	Ala	Ala	Leu	Gly	Val	Glu	Leu	Phe	
			1765					1770					1775			
Gly	Arg	Leu	Glu	Cys	Ser	Glu	Asp	Asn	Pro	Cys	Glu	Gly	Leu	Ser	Arg	
		1780						1785					1790			
His	Ala	Thr	Phe	Thr	Asn	Phe	Gly	Met	Ala	Phe	Leu	Thr	Leu	Phe	Arg	
		1795					1800					1805				
Val	Ser	Thr	Gly	Asp	Asn	Trp	Asn	Gly	Ile	Met						

1985					1990					1995				2000
Arg	Ser	Leu	Ser	Leu	Ser	Arg	Ile	Leu	Cys	Arg	Gln	Glu	Ala	Met His
				2005					2010					2015
Ser	Glu	Ser	Leu	Glu	Gly	Lys	Val	Asp	Asp	Val	Gly	Gly	Asp	Ser Ile
			2020					2025					2030	
Pro	Asp	Tyr	Thr	Glu	Pro	Ala	Glu	Asn	Met	Ser	Thr	Ser	Gln	Ala Ser
		2035					2040					2045		
Thr	Gly	Ala	Pro	Arg	Ser	Pro	Pro	Cys	Ser	Pro	Arg	Pro	Ala	Ser Val
	2050					2055					2060			
Arg	Thr	Arg	Lys	His	Thr	Phe	Gly	Gln	Arg	Cys	Ile	Ser	Ser	Arg Pro
2065					2070					2075				2080
Pro	Thr	Leu	Gly	Gly	Asp	Glu	Ala	Glu	Ala	Ala	Asp	Pro	Ala	Asp Glu
			2085					2090						2095
Glu	Val	Ser	His	Ile	Thr	Ser	Ser	Ala	His	Pro	Trp	Pro	Ala	Thr Glu
			2100					2105					2110	
Pro	His	Ser	Pro	Glu	Ala	Ser	Pro	Thr	Ala	Ser	Pro	Val	Lys	Gly Thr
	2115						2120					2125		
Met	Gly	Ser	Gly	Arg	Asp	Pro	Arg	Arg	Phe	Cys	Ser	Val	Asp	Ala Gln
	2130				2135						2140			
Ser	Phe	Leu	Asp	Lys	Pro	Gly	Arg	Pro	Asp	Ala	Gln	Arg	Trp	Ser Ser
2145				2150					2155					2160
Val	Glu	Leu	Asp	Asn	Gly	Glu	Ser	His	Leu	Glu	Ser	Gly	Glu	Val Arg
			2165					2170						2175
Gly	Arg	Ala	Ser	Glu	Leu	Glu	Pro	Ala	Leu	Gly	Ser	Arg	Arg	Lys Lys
		2180					2185					2190		
Lys	Met	Ser	Pro	Pro	Cys	Ile	Ser	Ile	Glu	Pro	Pro	Thr	Glu	Asp Glu
	2195					2200						2205		
Gly	Ser	Ser	Arg	Pro	Pro	Ala	Ala	Glu	Gly	Gly	Asn	Thr	Thr	Leu Arg
	2210				2215						2220			
Arg	Arg	Thr	Pro	Ser	Cys	Glu	Ala	Ala	Leu	His	Arg	Asp	Cys	Pro Glu
2225				2230					2235					2240
Pro	Thr	Glu	Gly	Pro	Gly	Thr	Gly	Gly	Asp	Pro	Val	Ala	Lys	Gly Glu
			2245					2250						2255
Arg	Trp	Gly	Gln	Ala	Ser	Cys	Arg	Ala	Glu	His	Leu	Thr	Val	Pro Asn
		2260					2265						2270	
Phe	Ala	Phe	Glu	Pro	Leu	Asp	Met	Gly	Gly	Pro	Gly	Gly	Asp	Cys Phe
	2275					2280					2285			
Leu	Asp	Ser	Asp	Gln	Ser	Val	Thr	Pro	Glu	Pro	Arg	Val	Ser	Ser Leu
	2290				2295						2300			
Gly	Ala	Ile	Val	Pro	Leu	Ile	Leu	Glu	Thr	Glu	Leu	Ser	Met	Pro Ser
2305				2310					2315					2320
Gly	Asp	Cys	Pro	Glu	Lys	Glu	Gln	Gly	Leu	Tyr	Leu	Thr	Val	Pro Gln
			2325					2330					2335	
Thr	Pro	Leu	Lys	Lys	Pro	Gly	Ser	Thr	Pro	Ala	Thr	Pro	Ala	Pro Asp
		2340					2345						2350	
Asp	Ser	Gly	Asp	Glu	Pro	Val								
		2355												